<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2678037-A1" country="EP" doc-number="2678037" kind="A1" date="20140101" family-id="45771806" file-reference-id="315082" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146551434" ucid="EP-2678037-A1"><document-id><country>EP</country><doc-number>2678037</doc-number><kind>A1</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12706239-A" is-representative="NO"><document-id mxw-id="PAPP154825357" load-source="docdb" format="epo"><country>EP</country><doc-number>12706239</doc-number><kind>A</kind><date>20120223</date><lang>EN</lang></document-id><document-id mxw-id="PAPP220438401" load-source="docdb" format="original"><country>EP</country><doc-number>12706239.6</doc-number><date>20120223</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140447900" ucid="CN-2011071287-W" linkage-type="A" load-source="docdb"><document-id format="epo"><country>CN</country><doc-number>2011071287</doc-number><kind>W</kind><date>20110225</date></document-id></priority-claim><priority-claim mxw-id="PPC140454613" ucid="CN-2011077863-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>CN</country><doc-number>2011077863</doc-number><kind>W</kind><date>20110801</date></document-id></priority-claim><priority-claim mxw-id="PPC140446727" ucid="CN-2011081857-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>CN</country><doc-number>2011081857</doc-number><kind>W</kind><date>20111107</date></document-id></priority-claim><priority-claim mxw-id="PPC140453365" ucid="EP-2012053039-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>2012053039</doc-number><kind>W</kind><date>20120223</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1988137090" load-source="docdb">A61K  47/48        20060101AFI20120914BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1777723654" load-source="docdb" scheme="CPC">A61K  47/6809      20170801 LI20170802BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1777723655" load-source="docdb" scheme="CPC">A61K  47/6845      20170801 LI20170802BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1777723656" load-source="docdb" scheme="CPC">A61K  47/65        20170801 LI20170802BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1777723657" load-source="docdb" scheme="CPC">A61K  47/64        20170801 LI20170802BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1777723658" load-source="docdb" scheme="CPC">A61K  47/60        20170801 LI20170802BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988135657" load-source="docdb" scheme="CPC">C07K   5/06043     20130101 FI20131207BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132186787" lang="EN" load-source="patent-office">BRANCHED LINKER FOR PROTEIN DRUG CONJUGATES</invention-title><invention-title mxw-id="PT132186788" lang="FR" load-source="patent-office">LIEUR RAMIFIÉ POUR CONJUGUÉS PROTÉINE-MÉDICAMENT</invention-title><invention-title mxw-id="PT132357710" lang="DE" load-source="patent-office">VERZWEIGTE LINKER FÜR  PROTEIN-WIRKSTOFF-KONJUGATE</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR918167762" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>LONZA AG</last-name><address><country>CH</country></address></addressbook></applicant><applicant mxw-id="PPAR918150803" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>LONZA LTD</last-name></addressbook></applicant><applicant mxw-id="PPAR918981412" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Lonza Ltd</last-name><iid>100823334</iid><address><street>Lonzastrasse</street><city>3930 Visp</city><country>CH</country></address></addressbook></applicant><applicant mxw-id="PPAR918145542" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>LONZA GUANGZHOU RES &amp; DEV CT LTD</last-name><address><country>CN</country></address></addressbook></applicant><applicant mxw-id="PPAR918134479" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>LONZA GUANGZHOU RESEARCH &amp; DEVELOPMENT CENTER LTD</last-name></addressbook></applicant><applicant mxw-id="PPAR918985156" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>Lonza Guangzhou Research &amp; Development Center Ltd</last-name><iid>100988320</iid><address><street>68, Huangge Dadaobei Nansha District Guangzhou</street><city>Guangdong Province 511455</city><country>CN</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918169138" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>DUCRY LAURENT</last-name><address><country>CH</country></address></addressbook></inventor><inventor mxw-id="PPAR918137015" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>DUCRY, LAURENT</last-name></addressbook></inventor><inventor mxw-id="PPAR918987542" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>DUCRY, LAURENT</last-name><address><street>Chemin des Vendanges 20</street><city>CH-3960 Sierre</city><country>CH</country></address></addressbook></inventor><inventor mxw-id="PPAR918157957" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>STUMP BERNHARD</last-name><address><country>CH</country></address></addressbook></inventor><inventor mxw-id="PPAR918145142" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>STUMP, Bernhard</last-name></addressbook></inventor><inventor mxw-id="PPAR918980670" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>STUMP, Bernhard</last-name><address><street>Rhonesandstrasse 13</street><city>CH-3900 Brig</city><country>CH</country></address></addressbook></inventor><inventor mxw-id="PPAR918147943" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>WONG WANG HEILAM HARRY</last-name><address><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR918149726" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>WONG (WANG), Heilam (Harry)</last-name></addressbook></inventor><inventor mxw-id="PPAR918982760" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>WONG (WANG), Heilam (Harry)</last-name><address><street>A2-3205 Lanting Xiyuan Chantggang Road</street><city>Guangzhou 510250</city><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR918164716" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>SHE JIN JACKY</last-name><address><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR918138111" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>SHE, Jin (Jacky)</last-name></addressbook></inventor><inventor mxw-id="PPAR918985114" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>SHE, Jin (Jacky)</last-name><address><street>16-2203 Yiyue Street Nancun Town Panyu District</street><city>Guangzhou</city><country>CN</country></address></addressbook></inventor><inventor mxw-id="PPAR918139860" load-source="docdb" sequence="5" format="epo"><addressbook><last-name>PHILLIPS GAYLE</last-name><address><country>CH</country></address></addressbook></inventor><inventor mxw-id="PPAR918140771" load-source="docdb" sequence="5" format="intermediate"><addressbook><last-name>PHILLIPS, Gayle</last-name></addressbook></inventor><inventor mxw-id="PPAR918991337" load-source="patent-office" sequence="5" format="original"><addressbook><last-name>PHILLIPS, Gayle</last-name><address><street>Jesuitenweg 25</street><city>CH-3902 Brig-Glis</city><country>CH</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR918980906" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Weber, Joachim</last-name><iid>101203733</iid><address><street>Lonza AG Patentabteilung Muenchensteinerstrasse 38</street><city>4052 Basel</city><country>CH</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="EP-2012053039-W"><document-id><country>EP</country><doc-number>2012053039</doc-number><kind>W</kind><date>20120223</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012113847-A1"><document-id><country>WO</country><doc-number>2012113847</doc-number><kind>A1</kind><date>20120830</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS548938456" load-source="docdb">AL</country><country mxw-id="DS548933991" load-source="docdb">AT</country><country mxw-id="DS548938457" load-source="docdb">BE</country><country mxw-id="DS548816853" load-source="docdb">BG</country><country mxw-id="DS548936018" load-source="docdb">CH</country><country mxw-id="DS548867060" load-source="docdb">CY</country><country mxw-id="DS548933992" load-source="docdb">CZ</country><country mxw-id="DS548938582" load-source="docdb">DE</country><country mxw-id="DS548867061" load-source="docdb">DK</country><country mxw-id="DS548867062" load-source="docdb">EE</country><country mxw-id="DS548929630" load-source="docdb">ES</country><country mxw-id="DS548816854" load-source="docdb">FI</country><country mxw-id="DS548816855" load-source="docdb">FR</country><country mxw-id="DS548938583" load-source="docdb">GB</country><country mxw-id="DS548867063" load-source="docdb">GR</country><country mxw-id="DS548938584" load-source="docdb">HR</country><country mxw-id="DS548933993" load-source="docdb">HU</country><country mxw-id="DS548936019" load-source="docdb">IE</country><country mxw-id="DS548938585" load-source="docdb">IS</country><country mxw-id="DS548816856" load-source="docdb">IT</country><country mxw-id="DS548867064" load-source="docdb">LI</country><country mxw-id="DS548918178" load-source="docdb">LT</country><country mxw-id="DS548933994" load-source="docdb">LU</country><country mxw-id="DS548918179" load-source="docdb">LV</country><country mxw-id="DS548918180" load-source="docdb">MC</country><country mxw-id="DS548838273" load-source="docdb">MK</country><country mxw-id="DS548838274" load-source="docdb">MT</country><country mxw-id="DS548938586" load-source="docdb">NL</country><country mxw-id="DS548816857" load-source="docdb">NO</country><country mxw-id="DS548918181" load-source="docdb">PL</country><country mxw-id="DS548936020" load-source="docdb">PT</country><country mxw-id="DS548938587" load-source="docdb">RO</country><country mxw-id="DS548936021" load-source="docdb">RS</country><country mxw-id="DS548918182" load-source="docdb">SE</country><country mxw-id="DS548936022" load-source="docdb">SI</country><country mxw-id="DS548816858" load-source="docdb">SK</country><country mxw-id="DS548918183" load-source="docdb">SM</country><country mxw-id="DS548867065" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA99625534" ref-ucid="WO-2012113847-A1" lang="EN" load-source="patent-office"><p num="0000">The present invention relates to method for connecting a protein and a drug to a protein drug conjugate, wherein the drug is linked to the protein through a specific branched linker, said branched linker comprises a peptide chain and is derived from o-hydroxy p-amino benzylic alcohol, wherein the peptide chain is connected to the phenyl ring via the p-amino group, the drug is connected to the phenyl ring via the benzylic alcohol moiety, and the protein is connected to the phenyl ring via the o-hydroxy group; further to a process for the preparation of said protein-drug-conjugates via various intermediates, to the pharmaceutical use of such protein drug conjugates, such as methods of controlling the growth of undesirable cells, to pharmaceutical compositions comprising such protein drug conjugates, and to intermediates of the preparation of the protein drug conjugates.</p></abstract><abstract mxw-id="PA99824053" ref-ucid="WO-2012113847-A1" lang="EN" source="national office" load-source="docdb"><p>The present invention relates to method for connecting a protein and a drug to a protein drug conjugate, wherein the drug is linked to the protein through a specific branched linker, said branched linker comprises a peptide chain and is derived from o-hydroxy p-amino benzylic alcohol, wherein the peptide chain is connected to the phenyl ring via the p-amino group, the drug is connected to the phenyl ring via the benzylic alcohol moiety, and the protein is connected to the phenyl ring via the o-hydroxy group; further to a process for the preparation of said protein-drug-conjugates via various intermediates, to the pharmaceutical use of such protein drug conjugates, such as methods of controlling the growth of undesirable cells, to pharmaceutical compositions comprising such protein drug conjugates, and to intermediates of the preparation of the protein drug conjugates.</p></abstract><abstract mxw-id="PA99625535" ref-ucid="WO-2012113847-A1" lang="FR" load-source="patent-office"><p num="0000">La présente invention concerne un procédé pour relier une protéine et un médicament dans un conjugué protéine-médicament, dans lequel le médicament est lié à la protéine par l'intermédiaire d'un lieur ramifié spécifique, ledit lieur ramifié comprend une chaîne peptidique et est dérivé d'alcool o-hydroxy-p-amino-benzylique, la chaîne peptidique étant liée au cycle phényle via le groupe p-amino, le médicament est lié au cycle phényle via le fragment alcool benzylique, et la protéine est liée au cycle phényle via le groupe o-hydroxy ; en outre un procédé pour la préparation de conjugués protéine-médicament via différents intermédiaires, l'utilisation pharmaceutique de tels conjugués protéine-médicament, tels que des procédés de contrôle de la croissance de cellules indésirables, des compositions pharmaceutiques comprenant de tels conjugués protéine-médicament, et des intermédiaires de la préparation des conjugués protéine-médicament.</p></abstract><abstract mxw-id="PA99824054" ref-ucid="WO-2012113847-A1" lang="FR" source="national office" load-source="docdb"><p>La présente invention concerne un procédé pour relier une protéine et un médicament dans un conjugué protéine-médicament, dans lequel le médicament est lié à la protéine par l'intermédiaire d'un lieur ramifié spécifique, ledit lieur ramifié comprend une chaîne peptidique et est dérivé d'alcool o-hydroxy-p-amino-benzylique, la chaîne peptidique étant liée au cycle phényle via le groupe p-amino, le médicament est lié au cycle phényle via le fragment alcool benzylique, et la protéine est liée au cycle phényle via le groupe o-hydroxy ; en outre un procédé pour la préparation de conjugués protéine-médicament via différents intermédiaires, l'utilisation pharmaceutique de tels conjugués protéine-médicament, tels que des procédés de contrôle de la croissance de cellules indésirables, des compositions pharmaceutiques comprenant de tels conjugués protéine-médicament, et des intermédiaires de la préparation des conjugués protéine-médicament.</p></abstract><description mxw-id="PDES50931287" ref-ucid="WO-2012113847-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> Branched linker for protein drug conjugates </p><p id="p0002" num="0002">The present invention relates to method for connecting a protein and a drug to a protein drug conjugate, wherein the drug is linked to the protein through a specific branched linker, said branched linker comprises a peptide chain and is derived from o-hydroxy p-amino benzylic alcohol, wherein the peptide chain is connected to the phenyl ring via the p-amino group, the drug is connected to the phenyl ring via the benzylic alcohol moiety, and the protein is connected to the phenyl ring via the o-hydroxy group; </p><p id="p0003" num="0003">further to a process for the preparation of said protein-drug-conjugates via various </p><p id="p0004" num="0004">intermediates, to the pharmaceutical use of such protein drug conjugates, such as methods of controlling the growth of undesirable cells, to pharmaceutical compositions comprising such protein drug conjugates, and to intermediates of the preparation of the protein drug </p><p id="p0005" num="0005">conjugates. Most drugs used for chemotherapy have severe side-effects which limit their efficacy and use. Linking such payloads, i.e. pharmaceutically active compounds, such as drugs, to targeting agents, in particular monoclonal antibodies, affords novel antibody drug conjugates (ADC) for e.g. cancer therapy. Tissue-specificity is typically governed by the monoclonal antibody (mAb) component, while the drug provides the therapeutic effect. The efficiency and tolerability of ADCs is dependent on the interplay between the target antigen, drug potency and conjugation technology. In particular, linker chemistry strongly influences the ADC specificity and safety. </p><p id="p0006" num="0006">Instead of chemically labile linkers, which have limited stability in physiological extracellular conditions, such as hydrazone- and disulfide-based linkers, linkers, which are stable in physiological extracellular conditions, especially which have high plasma stability, are desired for improving the therapeutic applicability, because the drug should be released only within the cell, which is targeted by the protein, to which the drug is linked, and not outside of the cell. </p><p id="p0007" num="0007">Non cleavable linkers have disadvantages: ADC internalization followed by complete hydrolysis of the polypeptide backbone of the mAb is required for payload release, and reduced efficacy may be encountered when ADC internalization is poor. Thus, ADCs bearing non-cleavable linkers are highly dependent on the biology of the target cell. Also, not all 
<!-- EPO <DP n="3"/>-->
 payloads retain their biological activity when attached to the last amino acid of the mAb as is the case after mAb degradation. </p><p id="p0008" num="0008"> In order to allow the ADC to deliver the payload not only to tumor cells but also to adjacent antigen-negative cells, i.e. bystander effect, the released payload must readily diffuse through hydrophobic cell membranes, which is not the case, when ADCs with non-cleavable linkers release their payloads in form of an amino acid bearing drug with the amino acid being in a zwitterionic state, i.e. having a positively charged ammonium and a negatively charged carboxylate. </p><p id="p0009" num="0009"> Therefore it is desired to have a linker which shows high plasma stability, and which releases the drug without the drug being chemically modified after its release. </p><p id="p0010" num="0010">Furthermore it is desired to have protein drug conjugates, which show reduced agglomeration or aggregation, which would impair their performance. EP 624377 A discloses a drug ligand conjugate, wherein the linker comprises a linear peptide. </p><p id="p0011" num="0011">Fanny Guzman et al, Electronic Journal of Biotechnology, 2007, 10, 279-314; Yoshio Okada, Current Organic Chemistry, 2001, 5, 1-43; US 6897289 B and the text books "Houben-Weyl Synthesis of Peptides and Peptidomimetics (Methods in Organic Chemistry)", Murray Goodman et al, Thieme Publishing Group, 2001, in particular Volumes E22a and E22b; disclose protecting groups, peptide bond formation, the synthesis of peptides and proteins detailing general and specific methods, and analytical techniques used to determine the structure and composition of peptides. Known linkers comprising linear peptide chains still show deficiencies. There was a need for linkers and for protein drug conjugates based on such linkers, which show improved performance. Surprisingly, specific branched linkers derived from o-hydroxy p-amino benzylic alcohol show the desired performance. In the following text, the following abbreviations are used, if not otherwise stated: </p><p id="p0012" num="0012">DCC N,N'-dicyclohexylcarbodiimide </p><p id="p0013" num="0013">EDC N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide </p><p id="p0014" num="0014">Fmoc 9-fluorenylmethoxycarbonyl </p><p id="p0015" num="0015">Boc tert-butoxycarbonyl 
<!-- EPO <DP n="4"/>-->
 Boc20 di-tert-butyl di carbonate </p><p id="p0016" num="0016"> Cit citrulline</p><p id="p0017" num="0017"> BS N-bromosuccinimide </p><p id="p0018" num="0018"> NHS compound of formula (HOSu), N-hydroxysuccinimide </p><p id="p0019" num="0019"> NIS N-iodosuccinimide </p><p id="p0020" num="0020"> -OTs tosylate </p><p id="p0021" num="0021"> -OMs mesylate </p><p id="p0022" num="0022"> -OTf triflate </p><p id="p0023" num="0023"> PBS phosphate buffered saline </p><p id="p0024" num="0024"> Red-Al sodium bis(2-methoxyethoxy)aluminium hydride </p><p id="p0025" num="0025"> TCEP tris(2-carboxyethyl)phosphine hydrochloride </p><p id="p0026" num="0026"> Tos or Ts Tosyl or p-toluenesulfonyl </p><p id="p0027" num="0027"> TsCl Tosyl chloride or p-toluenesulfonyl chloride </p><p id="p0028" num="0028"> Z or Cbz benzyloxycarbonyl </p><p id="p0029" num="0029">Subject of the invention is a method (MI) for connecting a ligand LI with a drug DR, LI is selected from the group consisting of amino acids LI-AA, mono- or polyclonal antibodies LI-Ab, antibody fragments LI-AbFrag, proteins Ll-Prot and peptides LI-</p><p id="p0030" num="0030">Pep; </p><p id="p0031" num="0031"> DR is a pharmaceutically active drug; characterized that a linker LIN is used to covalently connect LI with DR; </p><p id="p0032" num="0032">LIN comprises a connecting group CG2; </p><p id="p0033" num="0033">CG2 is derived from o-hydroxy p-amino benzylic alcohol and is a connecting group of formula (CG2-1); 
<!-- EPO <DP n="5"/>-->
</p><p id="p0034" num="0034">(CG2-1) </p><p id="p0035" num="0035">denotes the connecting site which is used to connect LI; </p><p id="p0036" num="0036"> denotes the connecting site which is used to connect DR; </p><p id="p0037" num="0037"> ^****** denotes the connecting site to which a linear peptide is connected, said peptide has 2 to 8 amino acid residues; </p><p id="p0038" num="0038"> (4) denotes the p-amino group of the o-hydroxy p-amino benzylic alcohol from which CG2 is derived. </p><p id="p0039" num="0039">Further subject of the invention is a method (MI), with the method (MI) as defined herein, also with all its preferred embodiments, </p><p id="p0040" num="0040">wherein LI is covalently connected with DR in form of a compound of formula (I); </p><p id="p0041" num="0041">CGI hSG -CG2— HT4 -CG3 -T2 DRRes </p><p id="p0042" num="0042"> nl n2 n2 </p><p id="p0043" num="0043"> Tl </p><p id="p0044" num="0044">LIRes</p><p id="p0045" num="0045"><img id="imgf000005_0001" he="19" wi="79" file="imgf000005_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0046" num="0046"> Rl ^ 3) ^ R2 </p><p id="p0047" num="0047">CG2 is as defined herein, also with all its preferred embodiments; </p><p id="p0048" num="0048">CGI is a connecting group selected from the group consisting of connecting group of formula (CGI -I), connecting group of formula (CGI -II), connecting group of formula (CGI -III) and connecting group of formula (CGI -IV); 
<!-- EPO <DP n="6"/>-->
 
<img id="imgf000006_0001" he="16" wi="42" file="imgf000006_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/>
 CGI -I) O (CGI -II) </p><p id="p0049" num="0049"><img id="imgf000006_0002" he="34" wi="105" file="imgf000006_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0050" num="0050"> (CG1-III) (CG1-IV) m30 and m32 are identical or different and independently from each other 1, 2, 3, 4, 5, 6, 7, 8, </p><p id="p0051" num="0051"> 9 or 10; </p><p id="p0052" num="0052">(*) in the formulae of CGI denotes the bond between Tl and CGI, </p><p id="p0053" num="0053">the covalently connected LI forms in compound of formula (I) a ligand residue LIRes, which is covalently connected to CGI via Tl; </p><p id="p0054" num="0054">LI is as defined herein, also with all its preferred embodiments, and is a compound of formula (LIRes-Tl-H); </p><p id="p0055" num="0055">LIRes T 1 H (LIRes-H) </p><p id="p0056" num="0056">LIRes is selected from the group consisting of amino acid residue LIRes-AA, mono- or </p><p id="p0057" num="0057"> polyclonal antibody residue LIRes- Ab, antibody fragment residue LIRes- AbFrag, protein residue LIRes-Prot and peptide residue LIRes-Pep; </p><p id="p0058" num="0058"> LI has a functional group selected from the group consisting of SH, OH or H<sub>2</sub>, which forms in formula (I) the Tl, the Tl is bonded to CGI via the bond (*); </p><p id="p0059" num="0059"> Tl is -S-, -O- or - H-; nl is 0 or 1; 
<!-- EPO <DP n="7"/>-->
 is a spacer group selected from the group consisting of spacer group of formula (SG- II) and spacer group of formula (SG-III); </p><p id="p0060" num="0060"><img id="imgf000007_0001" he="19" wi="115" file="imgf000007_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0061" num="0061">\ </p><p id="p0062" num="0062"> HN— HCH- SGPEG CH -NH </p><p id="p0063" num="0063"> ml l ml m\2 (SG-III) o ml and m2 are identical or different and independently from each other 0 or 1; </p><p id="p0064" num="0064">mlO, ml 1 and ml2 are identical or different and independently from each other 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; with the proviso, that m2 and mlO are not simultaneously 0; </p><p id="p0065" num="0065">with the proviso, that ml, mi l and ml2 are not simultaneously 0; </p><p id="p0066" num="0066">SGPEG is a connecting group of formula (SGPEG-I); </p><p id="p0067" num="0067">CH<sub>2</sub> CH<sub>2</sub> O- "CH<sub>2</sub> H<sub>2</sub> (SGPEG-I) m20 m20 is 1, 2, 3, 4, 5 or 6, n2 is 0 or 1; </p><p id="p0068" num="0068">T4 is -0-; CG3 is selected from the group consisting of connecting group of formula (CG3-I) and connecting group of formula (CG3-II); 
<!-- EPO <DP n="8"/>-->
 
<img id="imgf000008_0001" he="17" wi="68" file="imgf000008_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0069" num="0069"><img id="imgf000008_0002" he="25" wi="112" file="imgf000008_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0070" num="0070">R5 and R6 are identical or different and independently from each other C<sub>1-4</sub> alkyl; nl being 1, the (**) in the formulae of CGI and in the formulae of SG denote the bond between to CGI and SG, and the (***) in the formula of SG and in the formula of CG2 denote the bond between SG and CG2; in case that CGI is a connecting group of formula (CGI -I), the nitrogen atom denoted with (**) in SG forms an endocyclic nitrogen atom, thereby replacing the hydrogen atom of said nitrogen atom by an endocyclic bond; nl being 0, the (**) in the formulae of CGI and the (***) in the formula of CG2 denote the bond between CGI and CG2; with the proviso, that in case that nl is 0, then CGI is not a connecting group of formula </p><p id="p0071" num="0071"> (CG1-I); for n2 being 1, the (****) in the formula of CG2 and in the formula of CG3 denote the bonds, with which CG2 and CG3 are bonded to T4; and the (*****) i<sub>n</sub> the formula of CG3 denotes the bond between CG3 and T2: for n2 being 0, the (****) in the formula of CG2 denotes the bond between CG2 and T2; the (******) in the formula of CG2 denotes the bond between CG2 and AA<sup>n4</sup>; 
<!-- EPO <DP n="9"/>-->
 the covalently connected DR forms in compound of formula (I) a drug residue DRRes, which is covalently connected to CG2 via T2; </p><p id="p0072" num="0072">DR is as defined herein, also with all its preferred embodiments, and is a compound of formula (DRRes-T2-H); </p><p id="p0073" num="0073">H T2 DRRes (DRRes-T2-H) </p><p id="p0074" num="0074">DRRes is a drug residue derived from DR; </p><p id="p0075" num="0075">DR has a functional group selected from the group consisting of -N(R4)H, -OH or -SH, which forms in formula (I) the T2; </p><p id="p0076" num="0076">T2 is -N(R4)-, -O- or -S-; </p><p id="p0077" num="0077">R4 is H or C alkyl; n3 is 2, 3, 4, 5, 6, 7 or 8; </p><p id="p0078" num="0078">n4 is an integer from 1 to n3; </p><p id="p0079" num="0079"> AA<sup>n4</sup> is an amino acid residue, with n4 being the index of said amino acid residue, and </p><p id="p0080" num="0080"> (AA<sup>n4</sup>)<sub>n3</sub> is a linear peptide with n3 amino acid residues AA<sup>n4</sup> and with n4 denoting the position of the amino acid residue AA<sup>n4</sup> in the peptide starting from CG2, in which peptide the individual amino acid residues are connected to each other via a peptide bond, with AA<sup>1</sup> being the first amino acid residue in the chain and being connected to CG2 via the bond (******)<sub>^</sub> with the bond (******) being an amid bond of the carboxylic acid group of AA<sup>1</sup> with the amino group denoted with (4) of CG2, and with AA<sup>n3</sup> being the last amino acid residue in the chain, and with the individual AA<sup>n4</sup> being independently from each other identical or different; </p><p id="p0081" num="0081"> (3) denotes the N-terminal amino group of AA<sup>n3</sup>; </p><p id="p0082" num="0082">Rl and R2 are identical or different and independently from each other selected from the group consisting of hydrogen, C<sub>1-4</sub> alkyl, C(0)-(CH<sub>2</sub>-0-)<sub>M5</sub>-(GRPEG)<sub>M4</sub>-R3 and PGN; R3 is Ci-<sub>4</sub> alkyl; </p><p id="p0083" num="0083">m4 is 0 or 1; </p><p id="p0084" num="0084">m5 is 0 or 1; 
<!-- EPO <DP n="10"/>-->
 PGN is a protecting group; </p><p id="p0085" num="0085"> GRPEG is a connecting group of formula (GRPEG-I); </p><p id="p0086" num="0086">(GRPEG-I)</p><p id="p0087" num="0087"><img id="imgf000010_0001" he="15" wi="65" file="imgf000010_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 m21 is 1, 2, 3, 4, 5 or 6; </p><p id="p0088" num="0088">LI, DR and CG2 are as defined herein, also with all their preferred embodiments. </p><p id="p0089" num="0089">Preferably, LIN is compound of formula (LIN). </p><p id="p0090" num="0090"><img id="imgf000010_0002" he="38" wi="128" file="imgf000010_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0091" num="0091"> Rl ^ ) ^ R2 </p><p id="p0092" num="0092">Preferably, the drug DR is selected from group consisting of cytotoxic agents, other </p><p id="p0093" num="0093"> chemotherapeutic and antimetastatic agents. </p><p id="p0094" num="0094">Preferably, the other chemotherapeutic and antimetastatic agents are selected from the group consisting of tyrosine kinase inhibitors and Racl inhibitors. </p><p id="p0095" num="0095">Preferably, tyrosine kinase inhibitors are selected from the group of active pharmaceutical ingredients (API) consisting of Imatinib, Lapatimib, Sunitimib, Nilotimib and Dasatimib. </p><p id="p0096" num="0096">Preferably, Racl inhibitors is NSC 23766. </p><p id="p0097" num="0097">Preferable cytotoxic agents are those used for cancer therapy. </p><p id="p0098" num="0098"> Preferable classes of cytotoxic agents include, for example, the enzyme inhibitors such anthracycline family of drugs, the bleomycins, the cytotoxic nucleosides, 
<!-- EPO <DP n="11"/>-->
 dihydrofolate reductase inhibitors, differentiation inducers, DNA cleavers, DNA intercalators, diynenes, the mitomycins, the podophyllotoxins, the pteridine family of drugs, taxols, thymidylate synthase inhibitors, topoisomerase inhibitors, and the vinca drugs. </p><p id="p0099" num="0099"> Preferable useful members of various classes of cytotoxic agents are selected from the group consisting of N8-acetyl spermidine, actinomycin, 9-amino camptothecin, aminopterin, anguidine, anthracycline, auristatin, bleomycin, calicheamycin, camptothecin (lactone or ring-opened form of the lactone), carminomycin, CC-1065, clofaribine, l-(2- chloroethyl)-l,2-dimethanesulfonyl hydrazide, cyclopropabenzindol-4-one (CBI), cytarabine, cytosine arabinoside, daunorubicin, dichloromethotrexate, n-(5,5- diacetoxy-pentyl) doxorubicin, </p><p id="p0100" num="0100"> l,8-dihydroxy-bicyclo[7.3.1] trideca-4-9-diene-2,6-diyne-13-one, difluoronucleosides, doxorubicin, duocarmycin, epirubicin, esperamicin, etoposide, 5-fluorouracil, irinotecan, leurosideine, leurosine, maytansine, melphalan, 6-mercaptopurine, methopterin, methotrexate, mitomycin A, mitomycin C, morpholine-doxorubicin, nemorubicin, podophyllotoxin and podophyllotoxin derivatives such as etoposide or etoposide phosphate, retinoic acid, saporin, tallysomycin, vinblastine, vincristine, vindesine, taxane, such as taxol or paclitaxel, taxotere or docetaxel, and taxotere retinoic acid, and analogues and derivatives thereof. </p><p id="p0101" num="0101">More preferable cytotoxic agents are selected from the group consisting of anthracycline, auristatin, calicheamycin, cyclopropabenzindol-4-one (CBI), doxorubicin, </p><p id="p0102" num="0102"> duocarmycin, maytansine, mitomycin C, taxol, and analogues and derivatives of these substances. </p><p id="p0103" num="0103">Preferably, R4 is H. </p><p id="p0104" num="0104">Preferably, Tl is -NH- or -S-. </p><p id="p0105" num="0105"> Preferably, n2 is 1 and T2 is - H-, -O- or -S- and is connected via the bond (*****) with CG3; more preferably, T2 is -NH- or -S-. </p><p id="p0106" num="0106">Doxorubicin has the CAS number 23214-92-8 and is the compound of formula (DOXO). 
<!-- EPO <DP n="12"/>-->
 
<img id="imgf000012_0001" he="75" wi="100" file="imgf000012_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0107" num="0107"> OH </p><p id="p0108" num="0108"> (d2) </p><p id="p0109" num="0109">Compound of formula (DOXO) is also used in form of its hydrochloride salt. </p><p id="p0110" num="0110">Doxorubicin can be connected to CG3 or CG2 respectively via one of its functional groups, e.g. via one of the functional groups denoted with (dl), (d2), (d3) and (d4) in formula</p><p id="p0111" num="0111">(DOXO). </p><p id="p0112" num="0112"> The functional groups denoted with (dl), (d2), (d3) and (d4) function then as the T2 in </p><p id="p0113" num="0113"> formula (I). </p><p id="p0114" num="0114"> Preferably doxorubicin is connected via the amino group denoted with (dl) in formula </p><p id="p0115" num="0115"> (DOXO) with CG3 via the bond (*****). </p><p id="p0116" num="0116">Maytansine has the CAS number 35846-53-8 and the formula (MAYT). 
<!-- EPO <DP n="13"/>-->
</p><p id="p0117" num="0117"><img id="imgf000013_0001" he="80" wi="99" file="imgf000013_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0118" num="0118">Maytansine can be connected to CG3 or CG2 respectively via the -OH denoted with (m2) in formula (MAYT). </p><p id="p0119" num="0119"> Or the -C(0)-CH<sub>3</sub> group denoted with (ml) in the formula (MAYT) is exchanged against an acyl group, said acyl group has a nucleophilic group -SH, -NH<sub>2</sub> or -OH, which again is the connected to CG3 or CG2 respectively. </p><p id="p0120" num="0120"> The -OH denoted with (m2) or said nucleophilic group of the acyl group function then as the T2 in formula (I). </p><p id="p0121" num="0121">A preferred taxane is taxol with the CAS number 33069-62-4 and the formula (TAXO). </p><p id="p0122" num="0122"><img id="imgf000013_0002" he="78" wi="123" file="imgf000013_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="14"/>-->
 Taxol can be connected to CG3 or CG2 respectively via one of the -OH denoted with (tl), (t2) and (t3) in formula (TAXO). Said -OH functions then as the T2 in formula (I). </p><p id="p0123" num="0123">In one preferred embodiment, n2 is 0, T2 is -O- and is connected via the bond (****) with</p><p id="p0124" num="0124">CG2, and DRRes is derived from DR, with DR being compound of formula (TAXO).</p><p id="p0125" num="0125">In another preferred embodiment, n2 is 1, T2 is -O- and is connected via the bond (*****) with CG3, CG3 is the connecting group of formula (CG3-II) and DRRes is derived from DR, with DR being compound of formula (TAXO), one possible Taxol intermediate for this embodiment is the compound of formula (TAXO-tl-1). </p><p id="p0126" num="0126"><img id="imgf000014_0001" he="91" wi="122" file="imgf000014_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0127" num="0127">A Camptothecin is (S)-(+)-camptothecin, which has the CAS number 7689-03-4 and is the compound of formula (CAMPTO). 
<!-- EPO <DP n="15"/>-->
 (CAMPTO) 
<img id="imgf000015_0001" he="59" wi="41" file="imgf000015_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0128" num="0128">Camptothecin can be connected to CG3 or the CG2 respectively via the functional </p><p id="p0129" num="0129"> denoted with (cl) in formula (CAMPTO). </p><p id="p0130" num="0130">The functional group denoted with (cl) functions then as the T2 in formula (I). </p><p id="p0131" num="0131">In one preferred embodiment, n2 is 0, T2 is -O- and is connected via the bond (****) with CG2, and DRRes is derived from DR, with DR being compound of formula </p><p id="p0132" num="0132"> (CAMPTO). </p><p id="p0133" num="0133"> In another preferred embodiment, n2 is 1, T2 is -O- and is connected via the bond (*****) with CG3, CG3 is the connecting group of formula (CG3-II) and DRRes is derived from DR, with DR being compound of formula (CAMPTO). </p><p id="p0134" num="0134">In one preferred embodiment, CGI is the connecting group of formula (CGI -I), (CGI -III) or (CG1-IV) and the sulphur atom of the side chain of a Cys residue of LIRes is Tl and is connected via the bond (*) to CGI . </p><p id="p0135" num="0135">In another preferred embodiment, CGI is the connecting group of formula (CG1-II), and Tl is -N- or -O- of LIRes and is connected to CGI via the bond (*). This amino or hydroxyl group of LIRes connected to CGI is preferably the N-terminal amino group of LIRes or an amino or hydroxy group of a side chain of an amino acid residue of LIRes. </p><p id="p0136" num="0136"> Preferably, in case Tl is an amino group of a side chain of an amino acid residue of LIRes connected to CGI, said amino acid residue of LIRes is preferably a Lys; in case Tl is an hydroxyl group of a side chain of an amino acid residue of LIRes connected to CGI, said amino acid residue of LIRes is preferably a Tyr, Ser or Thr. 
<!-- EPO <DP n="16"/>-->
 Preferably, LI is selected from the group consisting of mono- or polyclonal antibodies LI-Ab, antibody fragments LI-AbFrag, proteins Ll-Prot and peptides Li-Pep; and </p><p id="p0137" num="0137">LIRes is selected from the group consisting of mono- or polyclonal antibody residue LIRes- Ab, antibody fragment residue LIRes- AbFrag, protein residue LIRes-Prot and peptide residue LIRes-Pep. </p><p id="p0138" num="0138">In the case that LIRes is LIRes-AA, LIRes is preferably an alpha amino acid residue. </p><p id="p0139" num="0139">LIRes can be preferably connected to CGI via one of two possible functional groups of LIRes: via a N-terminal amino group or via a functional group of a side chain of LIRes, if LIRes has such a side chain with a functional group. This functional group, which connects LIRes with CGI, is the Tl . In case that LIRes is connected via a functional group of a side chain of LIRes, said side chain is preferably a side chain of a Cys, Lys, Tyr, Ser or Thr residue of LIRes. </p><p id="p0140" num="0140">In case of LIRes being LIRes-AA, the remaining functional groups of LIAARes-AA, which are not connected to CGI, can be protected by a protecting group commonly used in peptide chemistry, e.g. a non-connected amino group can carry a acetate, a non-connected carboxy group can be esterified with a C<sub>1-4</sub> alkohol, a non-connected functional group of a side chain can carry a side chain protecting group conventionally used in peptide chmistry. </p><p id="p0141" num="0141"> More preferably, LIRes-AA is an alpha amino acid residue with a side chain having a functional group and is connected via this functional group with CGI, even more preferably LIRes-AA is derived from Cys, Lys, Tyr, Ser or Thr. Preferably, in the case, that LIRes is connected via the side chain of a Cys residue of LIRes, Tl is formed by the sulfur atom of the side chain of said Cys residue and is connected through the bond (*) with CGI, preferably with CGI being the connecting group of formula (CGI -I), (CGI -III) or (CGI -IV); or </p><p id="p0142" num="0142">in the case, that LIRes is connected via the side chain of a Lys, Tyr, Ser or Thr residue of LIRes, Tl is formed by the nitrogen or oxygen atom of the side chain of said Lys, Tyr,</p><p id="p0143" num="0143">Ser or Thr residue and is connected through the bond (*) with CGI, preferably with CGI being the connecting group of formula (CGI -II). </p><p id="p0144" num="0144">LIRes-Pep can be derived from a cell-penetrating peptide. 
<!-- EPO <DP n="17"/>-->
 LIRes-AB and LIRes-ABFrag are preferably derived from antibodies and antibody fragments used in treatment of dieases, preferably in cancer treatment. </p><p id="p0145" num="0145">Preferably, m30 and m32 are identical or different and independently from each other 2, 3, 4, </p><p id="p0146" num="0146"> 5 or 6. </p><p id="p0147" num="0147">Preferably, m30 is 2 when CGI is a connecting group of formula (CGl-IV). </p><p id="p0148" num="0148">Preferably, m32 is 2 when CGI is a connecting group of formula (CGI -II). Preferably, nl is 1. </p><p id="p0149" num="0149"> Preferably, ml and m2 are 0 or 1. </p><p id="p0150" num="0150"> Preferably, mlO, ml 1 and ml2 are identical or different and independently from each other 0,</p><p id="p0151" num="0151">1, 2, 3, 4, 5 or 6. </p><p id="p0152" num="0152">Preferably, m20 is 1, 2, 3 or 4. </p><p id="p0153" num="0153">More preferably, </p><p id="p0154" num="0154">mlO is 6 and m2 is 0; or </p><p id="p0155" num="0155">m2 is 1, mlO is 0 and m20 is 1; or </p><p id="p0156" num="0156">ml is 1, mi l is 1, ml2 is 1 and m20 is 3; or </p><p id="p0157" num="0157">ml is 0, mi l is 3, ml2 is 0. </p><p id="p0158" num="0158">Preferably, R5 and R6 are CH<sub>3</sub>. </p><p id="p0159" num="0159">In a particular embodiment, CGI is a connecting group of formula (CGI -I), SG is a spacer group of formula (SG-II), ml 0 is 6 and m2 is 0. </p><p id="p0160" num="0160"> In another particular embodiment, CGI is a connecting group of formula (CGI -II) with m32 being 2 or a connecting group of formula (CGI -III), or a connecting group of formula (CGl-IV) with m30 being 2, and SG is a spacer group of formula (SG-II), mlO is 0, m2 is 1 and m20 is 1. </p><p id="p0161" num="0161">In another particular embodiment, CGI is a connecting group of formula (CG1-II) with m32 being 2 or a connecting group of formula (CGI -III), or a connecting group of formula (CGl-IV) with m30 being 2, and SG is a spacer group of formula (SG-III) with ml being 1, mi l being 1, ml2 being 1 and m20 being 3, or SG is a spacer group of formula (SG-III) with ml being 0, ml 1 being 3 and ml2 being 0. 
<!-- EPO <DP n="18"/>-->
 Preferably, n3 is 2, 3, 4, 5 or 6; more preferably 2, 3 or 4; even more preferably, n3 is 2 or 3. </p><p id="p0162" num="0162">Preferably, AA<sup>n4</sup> is an alpha amino acid residue. </p><p id="p0163" num="0163">More preferably, AA<sup>n4</sup> is selected from the group consisting of alanine, valine, leucine, </p><p id="p0164" num="0164"> isoleucine, methionine, phenylalanine, tryptophan, proline, lysine, lysine side chain protected with acetyl or formyl, arginine, arginine side chain protected, preferably protected with tosyl or nitro groups, histidine, ornithine, ornithine side chain protected, preferably protected with acetyl or formyl, and citrulline. </p><p id="p0165" num="0165">Even more preferably, AA<sup>n4</sup> is alanine, glycine, phenylalanine, valine, lysine, leucine, </p><p id="p0166" num="0166"> tryptophan, arginine, side-chain protected arginine or citrulline, especially alanine, glycine, phenylalanine, valine, lysine or citrulline. </p><p id="p0167" num="0167">In case that AA<sup>n4</sup> has a side chain with a functional group, this functional group can be protected by a protecting group commonly used for protecting functional groups of side chains of amino acids. </p><p id="p0168" num="0168"> In case of Lys, the side chain is preferably protected with acetyl or formyl </p><p id="p0169" num="0169">Examples of peptides for the (AA<sup>n4</sup>)<sub>n3</sub> peptide chain are Phe-Lys, Val-Lys, Phe-Phe-Lys, D- Phe-Phe-Lys, Gly-Phe-Lys, Ala-Lys, Val-Cit, Phe-Cit, Leu-Cit, Trp-Cit, Phe-Ala, Gly-Phe- Leu-Gly, Ala-Leu- Ala-Leu, Phe-N9-tosyl-Arg and Phe-N9-Nitro-Arg, preferably Phe-Lys, Val-Lys, Val-Cit and D-Phe-L-Phe-Lys; any Lys side chain being optionally protected, preferably with acetyl . Especially preferably, n3 is 2 or 3, and AA<sup>n4</sup> is alanine, glycine, valine or citrulline; </p><p id="p0170" num="0170">more especially, </p><p id="p0171" num="0171">n3 is 2 and AA<sup>1</sup> is citrulline and AA<sup>2</sup> is valine or alanine; or </p><p id="p0172" num="0172">n3 is 3 and AA<sup>1</sup> is citrulline, AA<sup>2</sup> is valine and AA<sup>3</sup> is glycine. </p><p id="p0173" num="0173">Preferably, m4 is 1. </p><p id="p0174" num="0174">Preferably, R3 is methyl. </p><p id="p0175" num="0175"> Preferably, Rl and R2 are identical or different and independently from each other selected from the group consisting of hydrogen, methyl, C(0)-(CH<sub>2</sub>-0-)<sub>m</sub>5-(GRPEG)<sub>m</sub>4-CH<sub>3</sub> and PGN. 
<!-- EPO <DP n="19"/>-->
 Preferably, m21 is 2, 3 or 4. </p><p id="p0176" num="0176"> Preferably, PGN is a protecting group commonly used in peptide chemistry for protecting the N-terminus of a peptide or for protecting the alpha amino group of an alpha amino acid used as building block in peptide synthesis. </p><p id="p0177" num="0177">More preferably, PGN is selected from group consisting of Boc, Fmoc and Z. </p><p id="p0178" num="0178">Even more preferably, Rl is hydrogen, methyl, acetyl or C(0)-(CH<sub>2</sub>-0-)<sub>m</sub>5-(GRPEG)<sub>m</sub>4-CH<sub>3</sub> with m4 being 1 and m21 being 3, and R2 is hydrogen or methyl. </p><p id="p0179" num="0179"> Especially, </p><p id="p0180" num="0180"> Rl is acetyl and R2 is hydrogen; or </p><p id="p0181" num="0181"> Rl and R2 are methyl; or </p><p id="p0182" num="0182"> Rl is C(0)-(CH<sub>2</sub>-0-)<sub>m</sub>5-(GRPEG)<sub>m</sub>4-CH<sub>3</sub> with m5 being 0, m4 being 1 and m21 being</p><p id="p0183" num="0183">3, and R2 is hydrogen; or </p><p id="p0184" num="0184"> Rl is C(0)-(CH<sub>2</sub>-0-)<sub>m5</sub>-(GRPEG)<sub>m</sub>4-CH<sub>3</sub> with m5 being 1, m4 being 1 and m21 being</p><p id="p0185" num="0185">2, and R2 is hydrogen. </p><p id="p0186" num="0186">Further subject of the invention is a method (MI); </p><p id="p0187" num="0187">wherein compound of formula (I) is prepared in a step (MI); </p><p id="p0188" num="0188">step (MI) comprises a reaction (MI), wherein a compound of formula (II) is reacted with a compound of formula (LIRes-Tl-H); </p><p id="p0189" num="0189">DRRes </p><p id="p0190" num="0190"><img id="imgf000019_0001" he="38" wi="117" file="imgf000019_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0191" num="0191"> Rl ^ (3) ^ R2 </p><p id="p0192" num="0192">CG1M is a connecting group selected from the group consisting of connecting group of formula (CG1M-I), connecting group of formula (CG1M-II), connecting group of formula (CG1M-III) and connecting group of formula (CG1M-IV); 
<!-- EPO <DP n="20"/>-->
 
<img id="imgf000020_0001" he="76" wi="119" file="imgf000020_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0193" num="0193"> (CG1M-III) (CGIM-IV) </p><p id="p0194" num="0194">XI is CI, Br or I; </p><p id="p0195" num="0195">SG, nl, n4, n3, AA<sup>n4</sup>, (3), Rl, R2, T4, CG3, n2, T2, DRRes, m30 and m32 are as defined herein, also with all their preferred embodiments; </p><p id="p0196" num="0196">CG2 is as defined herein, also with all its preferred embodiments. </p><p id="p0197" num="0197">Preferably, XI is CI or Br, more preferably XI is Br. </p><p id="p0198" num="0198">Preferably, CG1M is a connecting group of formula (CGIM-IV). </p><p id="p0199" num="0199"> More preferably, CG1M is a connecting group of formula (CGIM-IV) and m30 is 2. </p><p id="p0200" num="0200">In a particular embodiment, CG1M is a connecting group of formula (CG1M-I), SG is a spacer group of formula (SG-II), mlO is 6 and m2 is 0. </p><p id="p0201" num="0201"> In another particular embodiment, CG1M is a connecting group of formula (CG1M-II) with m32 being 2 or a connecting group of formula (CG1M-III) or a connecting group of formula (CGIM-IV) with m30 being 2, and SG is a spacer group of formula (SG-II), mlO is 0, m2 is 1 and m20 is 1. </p><p id="p0202" num="0202">In another particular embodiment, CG1M is a connecting group of formula (CGI -II) with m32 being 2 or a connecting group of formula (CGI -III), or a connecting group of formula (CGIM-IV) with m30 being 2, and SG is a spacer group of formula (SG-III) with ml being 1, ml 1 being 1, ml2 being 1 and m20 being 3, or SG is a spacer group of formula (SG-III) with ml being 0, ml 1 being 3 and ml2 being 0. 
<!-- EPO <DP n="21"/>-->
 Preferably, the reaction temperature of reaction (MI) is from 0 to 150 °C, more preferably from 5 to 50 °C, even more preferably from 10 to 40 °C. Preferably, the reaction time of reaction (MI) is from 1 min to 168 h, more preferably from 10 min to 24 h, even more preferably from 15 min to 3 h. </p><p id="p0203" num="0203">Reaction (MI) is usually done in a solvent (MI). </p><p id="p0204" num="0204"> Preferably, solvent (MI) is selected from the group consisting of water, N,N- dimethylacetamide, N,N-dimethylformamide, Ν,Ν-dimethylsulfoxide and mixtures thereof. In case of water, the water can comprise a buffer (MI), preferably the buffer (MI) is a buffer conventionally used in protein chemistry, more preferably buffer (MI) is derived from a buffering substance selected from the group consisting of acetic acid, citric acid, dithiothreitol (DTT), ethylenediaminetetraacetic acid (EDTA), glycine, histidine, phosphoric acid (incl. phosphate buffered saline, PBS), polysorbate 20, polysorbate 80, saccharose, sodium chloride, succinic acid, trehalose, tris-(hydroxymethyl)-aminomethane, mixtures thereof and salts thereof. </p><p id="p0205" num="0205"> The salts of said buffering substance are preferably sodium salt, potassium salts or HC1 salts. Preferably, the amount of solvent (MI) is from 5 to 10000 fold, more preferably from 10 to 5000 fold, even more preferably from 50 to 500 fold, of the weight of compound of (LIRes- Tl-H). </p><p id="p0206" num="0206">Preferably, in reaction (MI), from 1 to 100 mol equivalents, more preferably from 2 to 20 mol equivalents, even more preferably from 3 to 10 mol equivalents, of compound of formula (II) are used, the mol equivalents being based the mol of compound of formula (LIRes-Tl-H). </p><p id="p0207" num="0207">Reaction (MI) can be done in the presence of TCEP. </p><p id="p0208" num="0208"> TCEP is preferably used, when LI is a mono- or polyclonal antibodies LI-Ab or an antibody fragments LI-AbFrag. </p><p id="p0209" num="0209"> Preferably, in reaction (MI), from 0.5 to 20 mol equivalents, more preferably from 1 to 10 mol equivalents, even more preferably from 1.5 to 5 mol equivalents, of TCEP are used, the mol equivalents being based the mol of compound of formula (LIRes-Tl-H) 
<!-- EPO <DP n="22"/>-->
 After the reaction (MI), compound of formula (I) can be isolated by standard methods such as washing, extraction, filtration, concentration and drying. The compound of formula (I) can be purified before or after isolation, preferably by chromatography or crystallization from an appropriate solvent. </p><p id="p0210" num="0210">Alternatively, compound of formula (I) can be purified by standard methods such as filtration, ultrafiltration, diafiltration and chromatography, and ca be stored or further used as a solution. </p><p id="p0211" num="0211">Further subject of the invention is a method (Mil) for the preparation of compound of formula (II), with the compound of formula (II) as defined herein, also with all its preferred embodiments, </p><p id="p0212" num="0212">wherein </p><p id="p0213" num="0213">in case that n2 is 1 and CG3 is a connecting group of formula (CG3-I), then method (Mil) comprises a step (Mlla) and a step (Mllb); </p><p id="p0214" num="0214">in case that n2 is 1 and CG3 is a connecting group of formula (CG3-II), then method (Mil) comprises the step (Mlla), a step (Mile), a step (Mild) and a step (Mile); in case that n2 is 0 and CG1M is a connecting group of formula (CG1M-IV) then method (Mil) comprises one step, a step (MIIO-IV), or two steps, a step (MII0-I-IVa) and a step (MII0-I-IVb); </p><p id="p0215" num="0215">in case that n2 is 0 and CG1M is a connecting group of formula (CG1M-III) then method (Mil) comprises a step (MIIO-III); </p><p id="p0216" num="0216">in case that n2 is 0 and CG1M is a connecting group of formula (CG1M-II) then method </p><p id="p0217" num="0217"> (Mil) comprises two steps, a step (MII0-IIa) and a step (MII0-IIb), or one step, a step (MIIO-IIc); </p><p id="p0218" num="0218">in case that n2 is 0 and CG1M is a connecting group of formula (CG1M-I) then method (Mil) comprises one step, a step (MIIO-I), or two steps, a step (MII0-I-IVa) and a step (MII0-I-IVb); step (Mlla) comprises a reaction (Mlla), wherein a compound of formula (III) is reacted with a compound (II-I); 
<!-- EPO <DP n="23"/>-->
 
<img id="imgf000023_0001" he="38" wi="118" file="imgf000023_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0219" num="0219"> Rl ^ ) ^ <sub>R2</sub> formula (III) is as defined herein, also with all its preferred embodiment; compound (II-I) is selected from the group consisting of compound of formula (II-l), 1,1 '- carbonyldiimidazole, 4-nitrophenylchloroformate, phosgene, diphosgene, triphosgene and mixtures thereof; </p><p id="p0220" num="0220"><img id="imgf000023_0002" he="26" wi="102" file="imgf000023_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 step (Mllb) comprises a reaction (Mllb), wherein the reaction product from the reaction (Mlla) is reacted with a compound of formula (DRRes-T2-H); step (MIIc) comprises a reaction (MIIc), wherein the reaction product from the reaction</p><p id="p0221" num="0221">(Mlla) is reacted with a compound of formula (CG3M-II) to provide a compound of formula (He); </p><p id="p0222" num="0222"><img id="imgf000023_0003" he="19" wi="75" file="imgf000023_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/><!-- EPO <DP n="24"/>--><img id="imgf000024_0001" he="47" wi="114" file="imgf000024_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0223" num="0223"> Rl ) R2 (lie) n2 in formula (lie) is as defined in claim 2; step (Mild) comprises a reaction (Mild), wherein compound of formula (He), prepared in reaction (Mile), is reacted with the compound (II-I); step (Mile) comprises a reaction (Mile), wherein the reaction product from the reaction (Mild) is reacted with a compound of formula (DRRes-T2-H); step (MII0-I-IVa) comprises a reaction (MllO-I-IVa), wherein a compound of formula (III) is reacted with a compound (II0-I-IVa) to provide a compound of formula (III0-I-IVa); </p><p id="p0224" num="0224"><img id="imgf000024_0002" he="20" wi="84" file="imgf000024_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0225" num="0225"> (AA<sup>n4</sup>) </p><p id="p0226" num="0226"> n3 (III0-I-IVa) </p><p id="p0227" num="0227">Rl ^ (3) ^ R2 n2 is 0 in formula (III0-I-IVa); compound (II0-I-IVa) is selected from the group consisting of p-toluenesulfonyl chloride, p- toluenesulfonic anhydride, methanesulfonyl chloride, methanesulfonic anhydride, trifluoromethanesulfonyl chloride and trifluoromethanesulfonic anhydride and mixtures thereof; 
<!-- EPO <DP n="25"/>-->
 X2 is selected from the group consisting of -OTs, -OMs and -OTf; step (MII0-I-IVb) comprises a reaction (MII0-I-IVb), wherein compound of formula </p><p id="p0228" num="0228"> (III0-I-IVa), prepared in reaction (MII0-I-IVa), is reacted with compound of formula (DRRes-T2-H); compound of formula (III) is prepared in a step (MIII-IV) for the case that CG1M is a connecting group of formula (CG1M-IV); or in a step (MIII-III) for the case that CG1M is a connecting group of formula (CG1M-III); or in two steps, a step (MIII-IIa) and a step (MIII-IIb), or in one step, a step (MIII-IIc), for the case that CG1M is a connecting group of formula (CG1M-II); or </p><p id="p0229" num="0229">a step (MIII-I) for the case that CG1M is a connecting group of formula (CG1M-I); step (MIII-IV) comprises a reaction (MIII-IV) of a compound of formula (IV), </p><p id="p0230" num="0230"><img id="imgf000025_0001" he="38" wi="111" file="imgf000025_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0231" num="0231"> Rl (3) R2 n2 in formula (IV) is as defined herein, also with all its preferred embodiments; with a compound of formula (CGIMR-IV); 
<!-- EPO <DP n="26"/>-->
 
<img id="imgf000026_0001" he="29" wi="55" file="imgf000026_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0232" num="0232">(CG1MR-IV) m30 is as defined herein, also with all its preferred embodiments; </p><p id="p0233" num="0233">R20 is a residue of formula (R20-1); </p><p id="p0234" num="0234"><img id="imgf000026_0002" he="28" wi="22" file="imgf000026_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0235" num="0235"> (R20-1) step (MIII-III) comprises a reaction (MIII-III) of a compound of formula (IV) with a compound of formula (CG1MR-III); </p><p id="p0236" num="0236"><img id="imgf000026_0003" he="15" wi="28" file="imgf000026_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0237" num="0237"> (CG1MR-III) with XI as defined herein, also with all its preferred embodiments; step (MIII-IIa) comprises a reaction (MIII-IIa) of the compound of formula (IV) with a compound of formula (CGlMR-IIa) to provide a compound of formula (IV-IIa); 
<!-- EPO <DP n="27"/>-->
 (CGlMR-IIa) 
<img id="imgf000027_0001" he="54" wi="31" file="imgf000027_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 
<img id="imgf000027_0002" he="42" wi="113" file="imgf000027_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0238" num="0238">Rl (<sup>3</sup>) R2 with m32 as defined herein, also with all its preferred embodiments; step (MIII-IIb) comprises a reaction (MIII-IIb) of compound of formula (IV-IIa) prepared in step (MIII-IIa) with a compound of formula (HOSu); </p><p id="p0239" num="0239"><img id="imgf000027_0003" he="28" wi="24" file="imgf000027_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0240" num="0240"> (HOSu) step (MIII-IIc) comprises a reaction (MIII-IIc) of the compound of formula (IV) with a compound of formula (CGlMR-IIc); 
<!-- EPO <DP n="28"/>-->
 (CGlMR-IIc) 
<img id="imgf000028_0001" he="26" wi="78" file="imgf000028_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 with m32 as defined herein, also with all its preferred embodiments; step (MIII-I) comprises a reaction (MIII-I) of a compound of formula (IV) with a compound of formula (MA); </p><p id="p0241" num="0241"><img id="imgf000028_0002" he="29" wi="14" file="imgf000028_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0242" num="0242">(MA) compound of formula (IV) is prepared in a step (MIV); </p><p id="p0243" num="0243">step (MIV) comprises a reaction (MIV), reaction (MIV) is a reduction of a compound of formula (V) with a compound (IV); </p><p id="p0244" num="0244"><img id="imgf000028_0003" he="78" wi="67" file="imgf000028_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="29"/>-->
 compound (IV) is selected from the group consisting of NaBH<sub>4</sub>, BH<sub>3</sub>, DIBAL-H, sodium bis(2-methoxyethoxy)aluminium hydride and mixtures thereof; </p><p id="p0245" num="0245">SG, nl, AA, n4, n3, (3), Rl and R2 have the same definition as above, also with all their preferred embodiments; compound of formula (V) is prepared in a step (MVb); </p><p id="p0246" num="0246">step (MVb) comprises a reaction (MVb), wherein R30 is cleaved off from compound of formula (Va) with HC1; </p><p id="p0247" num="0247"><img id="imgf000029_0001" he="84" wi="97" file="imgf000029_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0248" num="0248">R30 is connected to SG via the bond denoted with (**) in the formulae of SG and is Boc; step (MIIO-IV) comprises a reaction (MIIO-IV) of a compound of formula (IIIO) with a compound of formula (CG1MR-IV); 
<!-- EPO <DP n="30"/>-->
 H- SG -CG2— hT4 -CG3 -T2 DRRes </p><p id="p0249" num="0249"> nl n2 n2 </p><p id="p0250" num="0250">(AA<sup>n4</sup>) </p><p id="p0251" num="0251"> n3 </p><p id="p0252" num="0252"> (IIIO) </p><p id="p0253" num="0253"> Rl ^ ) ^ <sub>R2</sub> with </p><p id="p0254" num="0254"> SG, CG2, nl, AA, n4, n3, (3), Rl, R2, T2 and DRRes as defined herein, also with all their preferred embodiments, and n2 is 0 in formula (IIIO); step (MIIO-III) comprises a reaction (MIIO-III) of a compound of formula (IIIO) with a </p><p id="p0255" num="0255"> compound of formula (CGIMR-III); step (MII0-IIa) comprises a reaction (MII0-IIa) of the compound of formula (IIIO) with a compound of formula (CGlMR-IIa) to provide a compound of formula (III0-IIa); </p><p id="p0256" num="0256"><img id="imgf000030_0001" he="51" wi="143" file="imgf000030_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 with </p><p id="p0257" num="0257"> SG, CG2, nl, AA, n4, n3, (3), Rl, R2, T2 and DRRes and m32 as defined herein, also with all their preferred embodiments, and n2 is 0 in formula (III0-IIa); step (MII0-IIb) comprises a reaction (MII0-IIb) of compound of formula (III0-IIa) prepared step (MII0-IIa) with a compound of formula (HOSu); 
<!-- EPO <DP n="31"/>-->
 step (MIIO-IIc) comprises a reaction (MIIO-IIc) of the compound of formula (IIIO) with a compound of formula (CGlMR-IIc); step (MIIO-I) comprises a reaction (MIIO-I) of a compound of formula (IIIO) with a compound of formula (MA); compound of formula (IIIO) is prepared in a step (MIIIO), </p><p id="p0258" num="0258">step (MIIIO) comprises a reaction (MIIIO), wherein R30 is cleaved off from compound of formula (IVO) with HC1; </p><p id="p0259" num="0259">R30— t-SGH CG2 -CG3 -T2 DRRes nl i n2 n2 </p><p id="p0260" num="0260">(AA<sup>n4</sup>) </p><p id="p0261" num="0261"> n3 </p><p id="p0262" num="0262"> (IVO) </p><p id="p0263" num="0263">R1 ) ^ R2 n2 is 0 in formula (IVO); compound of formula (IVO) is prepared in a step (MlVOa) and a step (MlVOb), </p><p id="p0264" num="0264">step (MlVOa) comprises a reaction (MlVOa), wherein a compound of formula (VO) </p><p id="p0265" num="0265"> with a compound (RIVOa) to provide a compound of formula (IVOa); </p><p id="p0266" num="0266"><img id="imgf000031_0001" he="19" wi="55" file="imgf000031_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0267" num="0267"> (AA<sup>n4</sup>) (VO) </p><p id="p0268" num="0268"> n3 </p><p id="p0269" num="0269">R1 <sup>X</sup> (3) ^ R2 
<!-- EPO <DP n="32"/>-->
 
<img id="imgf000032_0001" he="19" wi="56" file="imgf000032_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0270" num="0270"> (AA<sup>n4</sup>) (IVOa) </p><p id="p0271" num="0271"> n3 </p><p id="p0272" num="0272">R 1 ) ^ R2 with </p><p id="p0273" num="0273"> R30, SG, CG2, nl, AA, n4, n3, (3), Rl and R2 as defined herein, also with all their preferred embodiments; compound (RIVOa) is selected from the group consisting of p-toluenesulfonyl chloride, p- toluenesulfonic anhydride, methanesulfonyl chloride, methanesulfonic anhydride, trifluoromethanesulfonyl chloride and trifluoromethanesulfonic anhydride, SOCl<sub>2</sub>, (COCl)<sub>2</sub>, POCl<sub>3</sub>, PCI3, PCI5, POBr<sub>3</sub>, PBr<sub>3</sub>, PBr<sub>5</sub>, N-bromosuccinimide, </p><p id="p0274" num="0274"> N-iodosuccinimide, HC1, HBr, HI and mixtures thereof; </p><p id="p0275" num="0275">X3 is selected from the group consisting of -OTs, -OMs, -OTf, -CI, -Br and -I; step (MlVOb) comprises a reaction (MlVOb), wherein compound of formula (IVOa), prepared in reaction (MIVO), is reacted with compound of formula (DRRes-T2-H); compound of formula (V0) is prepared in a step (MVO), </p><p id="p0276" num="0276">step (MVO) comprises a reaction (MVO), reaction (MVO) is a reduction of a compound of formula (Va) with a compound (IV); </p><p id="p0277" num="0277">CG1M and XI are as defined herein, also with all its preferred embodiments; </p><p id="p0278" num="0278">SG, nl, n4, n3, AA<sup>n4</sup>, (3), Rl, R2, T4, CG3, n2, T2, DRRes, compound of formula (DRRes- T2-H), m30, m32, R5 and R6 are as defined herein, also with all its preferred embodiments; CG2 is as defined herein, also with all its preferred embodiments. 
<!-- EPO <DP n="33"/>-->
 The compounds (II-I) and of formula (CG3M-II) are known compounds and can be prepared according to known methods, often they are even commercially available. </p><p id="p0279" num="0279">Reaction (Mlla) and reaction (Mild) are similar reactions and can be done under similar reaction parameters ranges as defined herein, with the individual reaction parameters for each of said two reactions being selected independently from each other. </p><p id="p0280" num="0280">Preferably, compound (II-I) is compound of formula (II-l). Reaction (Mlla) and reaction (Mild) are usually done in a solvent (Mlla). </p><p id="p0281" num="0281"> Preferably, solvent (Mlla) is selected from the group consisting of N,N-dimethylformamide, N,N-dimethylacetamide, Ν,Ν-dimethylsulfoxide, acetonitrile, acetone, 1,4-dioxane, THF and mixtures thereof. Preferably, the amount of solvent (Mlla) is from 1 to 500 fold, more preferably from 5 to 50 fold, even more preferably from 10 to 30 fold, of the weight of compound of formula (III). </p><p id="p0282" num="0282">Preferably, in the reaction (Mlla) and in the reaction (Mild), from 0.5 to 20 mol equivalents, more preferably from 1 to 10 mol equivalents, even more preferably from 1 to 2 mol equivalents, of compound (II-I) are used, the mol equivalents being based the mol of compound of formula (III). </p><p id="p0283" num="0283">Reaction (Mlla) and reaction (Mild) can be done in the presence of a base (Mlla). </p><p id="p0284" num="0284">Preferably, the base (Mlla) is selected from the group consisting of K<sub>2</sub>C0<sub>3</sub>, Na<sub>2</sub>C0<sub>3</sub>, diisopropylethylamine, triethylamine, pyridine, 4-dimethylaminopyridine and mixtures thereof. </p><p id="p0285" num="0285">Preferably, in the reaction (Mlla) and in the reaction (Mild), from 0.5 to 50 mol equivalents, more preferably from 1 to 20 mol equivalents, even more preferably from 2 to 10 mol equivalents, of base (Mlla) are used, the mol equivalents being based the mol of compound of formula (III). </p><p id="p0286" num="0286">Preferably, the reaction (Mlla) and the reaction (Mild) are done under inert atmosphere. 
<!-- EPO <DP n="34"/>-->
 After the reaction (Mlla) and the reaction (Mild), the reaction product of reaction (Mlla) and of reaction (Mild) can be isolated by standard methods such as washing, extraction, filtration, concentration and drying. Any of the compounds can be purified before or after isolation, preferably by chromatography or crystallization from an appropriate solvent. </p><p id="p0287" num="0287">The crude reaction mixture from reaction (Mlla) and from reaction (Mild) can also be directly used in reaction (Mllb) or reaction (Mile). </p><p id="p0288" num="0288">More preferably, reaction (Mlla) and reaction (Mllb) as well as reaction (Mild) and reaction (Mile) are done consecutively in the same solvent and in one pot. </p><p id="p0289" num="0289">Reaction (Mllb) and reaction (Mile) are similar reactions and can be done under similar reaction parameters ranges as defined herein, with the individual reaction parameters for each of said two reactions being selected independently from each other. </p><p id="p0290" num="0290">Reaction (Mllb) and reaction (Mile) are usually done in a solvent (Mllb). </p><p id="p0291" num="0291">Preferably, solvent (Mllb) is selected from the group consisting of N,N-dimethylformamide, N,N-dimethylacetamide, Ν,Ν-dimethylsulfoxide, acetonitrile, acetone, 1,4-dioxane, THF, water, methanol, ethanol and mixtures thereof. </p><p id="p0292" num="0292">Preferably, the amount of solvent (Mllb) is from 1 to 500 fold, more preferably from 5 to 50 fold, even more preferably from 10 to 30 fold, of the weight of the reaction product of reaction (Mlla) or of reaction product of reaction (Mild) respectively. Preferably, in reaction (Mllb) and in reaction (Mile), from 0.2 to 10 mol equivalents, more preferably from 0.5 to 5 mol equivalents, even more preferably from 0.8 to 2 mol equivalents, of compound of formula (DRRes-T2-H) are used, the mol equivalents being based the mol of the reaction product of reaction (Mlla) or of the reaction product of reaction (Mild) respectively. </p><p id="p0293" num="0293">Preferably, reaction (Mllb) and reaction (Mile) are done under inert atmosphere. 
<!-- EPO <DP n="35"/>-->
 Reaction (MII0-I-IVb) and reaction (MlVOb) are similar reactions and can be done under similar reaction parameters ranges as defined herein, with the individual reaction parameters for each of said two reactions being selected independently from each other. Reaction (MII0-I-IVb) and reaction (MlVOb) are usually done in a solvent (MlVOb). </p><p id="p0294" num="0294">Preferably, solvent (MlVOb) is selected from the group consisting of N,N- dimethylformamide, N,N-dimethylacetamide, Ν,Ν-dimethylsulfoxide, acetonitrile, acetone, 1,4-dioxane, THF and mixtures thereof. Preferably, the amount of solvent (MlVOb) is from 1 to 500 fold, more preferably from 5 to 50 fold, even more preferably from 10 to 30 fold, of the weight of compound of formula (III0- I-IVb) or of formula (IVOa) respectively. </p><p id="p0295" num="0295">Preferably, in reaction (MII0-I-IVb) and in reaction (MlVOb), from 0.2 to 10 mol equivalents, more preferably from 0.5 to 5 mol equivalents, even more preferably from 0.8 to 2 mol equivalents, of compound of formula (DRRes-T2-H) are used, the mol equivalents being based the mol of compound of formula (III0-I-IVb) or of formula (IVOa) respectively. </p><p id="p0296" num="0296">Preferably, reaction (MII0-I-IVb) and reaction (MlVOb) are done under inert atmosphere. </p><p id="p0297" num="0297">Reaction (Mile) is usually done in a solvent (Mile). </p><p id="p0298" num="0298"> Preferably, solvent (Mile) is selected from the group consisting of N,N-dimethylformamide, N,N-dimethylacetamide, Ν,Ν-dimethyl sulfoxide, acetonitrile, acetone, 1,4-dioxane, THF, water, methanol, ethanol and mixtures thereof. </p><p id="p0299" num="0299">Preferably, the amount of solvent (Mile) is from 1 to 500 fold, more preferably from 5 to 50 fold, even more preferably from 10 to 30 fold, of the weight of reaction product of reaction (Mlla). Preferably, in the reaction (Mile) from 0.2 to 20 mol equivalents, more preferably from 0.5 to 10 mol equivalents, even more preferably from 0.8 to 5 mol equivalents, of compound of formula (CG3M-II) are used, the mol equivalents being based the mol of the reaction product of reaction (Mlla). 
<!-- EPO <DP n="36"/>-->
 Preferably, the reaction (Mile) is done under inert atmosphere. </p><p id="p0300" num="0300">After the reaction (Mile), the reaction product of the reaction (Mile) can be isolated by standard methods such as washing, extraction, filtration, concentration and drying. Any of the compounds can be purified before or after isolation, preferably by chromatography or crystallization from an appropriate solvent. </p><p id="p0301" num="0301">After reaction (Mllb), reaction (Mile), reaction (MII0-I-IVb) and reaction (MlVOb), compound of formula (II) or compound of formula (IVO) respectively can be isolated by standard methods such as washing, extraction, filtration, concentration and drying. Any of the compounds can be purified before or after isolation, preferably by chromatography or crystallization from an appropriate solvent. </p><p id="p0302" num="0302">Preferably, CG1M is a connecting group of formula (CG1M-IV); </p><p id="p0303" num="0303">more preferably, CG1M is a connecting group of formula (CG1M-IV) and m30 is 2. </p><p id="p0304" num="0304">Compound of formula (V) and compound of formula (IIIO) can be used in unprotonated form or in protonated form as a salt in reaction (MIV), reaction (MIIO-I), reaction (MII0-IIa), reaction (MIIO-III) and reaction (MIIO-IV) </p><p id="p0305" num="0305">Reaction (MIII-IV) and reaction (MIIO-IV) are similar reactions and can be done under similar reaction parameters ranges as defined herein, with the individual reaction parameters for each of said two reactions being selected independently from each other. Reaction (MIII-IV) and reaction (MIIO-IV) are usually done in a solvent (MIII-IV). </p><p id="p0306" num="0306">Preferably, solvent (MIII-IV) is selected from the group consisting of N,N- dimethylformamide, N,N-dimethylacetamide, Ν,Ν-dimethylsulfoxide, acetonitrile, acetone, 1,4-dioxane, THF, water, methanol, ethanol and mixtures thereof. Preferably, the amount of solvent (MIII-IV) is from 1 to 500 fold, more preferably from 5 to 50 fold, even more preferably from 10 to 30 fold, of the weight of compound of formula (IV). </p><p id="p0307" num="0307">Preferably, in the reaction (MIII-IV) and in the reaction (MIIO-IV), from 1 to 20 mol equivalents, more preferably from 1 to 10 mol equivalents, even more preferably from 1 to 5 
<!-- EPO <DP n="37"/>-->
 mol equivalents, of compound (CG1MR-IV) are used, the mol equivalents being based the mol of compound of formula (IV) or of formula (IIIO) respectively. </p><p id="p0308" num="0308">Preferably, reaction (MIII-IV) and reaction (MIIO-IV) are done under inert atmosphere. </p><p id="p0309" num="0309">Reaction (MIII-IV) and reaction (MIIO-IV) is usually done in the presence of a base (Mill- IV). </p><p id="p0310" num="0310"> Preferably, the base (MIII-IV) is selected from the group consisting of K<sub>2</sub>C0<sub>3</sub>, Na<sub>2</sub>C0<sub>3</sub>, diisopropylethylamine, triethylamine, pyridine, 4-dimethylaminopyridine and mixtures thereof. </p><p id="p0311" num="0311">Preferably, in the reaction (MIII-IV) and in reaction (MIIO-IV), from 0.5 to 50 mol equivalents, more preferably from 1 to 20 mol equivalents, even more preferably from 2 to 10 mol equivalents, of base (MIII-IV) are used, the mol equivalents being based the mol of compound of formula (IV) or of formula (IIIO) respectively. </p><p id="p0312" num="0312">After reaction (MIII-IV) and reaction (MIIO-IV), the compound of formula (III) or of formula (II) respectively can be isolated by standard methods such as washing, extraction, filtration, concentration and drying. The compound of formula (III) or of formula (II) respectively can be purified before or after isolation, preferably by chromatography or crystallization from an appropriate solvent. </p><p id="p0313" num="0313">Reaction (MIII-III) and reaction (MIIO-III) are similar reactions and can be done under similar reaction parameters ranges as defined herein, with the individual reaction parameters for each of said two reactions being selected independently from each other. </p><p id="p0314" num="0314">Reaction (MIII-III) and reaction (MIIO-III) are usually done in a solvent (MIII-III). </p><p id="p0315" num="0315">Preferably, solvent (MIII-III) is selected from the group consisting of N,N- dimethylformamide, N,N-dimethylacetamide, Ν,Ν-dimethylsulfoxide, acetonitrile, acetone, 1,4-dioxane, THF, water, methanol, ethanol and mixtures thereof. </p><p id="p0316" num="0316">Preferably, the amount of solvent (MIII-III) is from 1 to 500 fold, more preferably from 5 to 50 fold, even more preferably from 10 to 30 fold, of the weight of compound of formula (IV). 
<!-- EPO <DP n="38"/>-->
 Preferably, in reaction (MIII-III) and in reaction (MIIO-III), from 1 to 20 mol equivalents, more preferably from 1 to 10 mol equivalents, even more preferably from 1 to 5 mol equivalents, of compound (CGIMR-III) are used, the mol equivalents being based the mol of compound of formula (IV) or of formula (IIIO) respectively. </p><p id="p0317" num="0317">Preferably, reaction (MIII-III) and reaction (MIIO-III) are done under inert atmosphere. </p><p id="p0318" num="0318">After reaction (MIII-III) and reaction (MIIO-III), the compound of formula (III) or of formula (II) respectively can be isolated by standard methods such as washing, extraction, filtration, concentration and drying. The compound of formula (III) or of formula (II) respectively can be purified before or after isolation, preferably by chromatography or crystallization from an appropriate solvent. </p><p id="p0319" num="0319">Reaction (MIII-IIa) and reaction (MII0-IIa) are similar reactions and can be done under similar reaction parameters ranges as defined herein, with the individual reaction parameters for each of said two reactions being selected independently from each other. </p><p id="p0320" num="0320">Reaction (MIII-IIa) and reaction (MII0-IIa) are usually done in a solvent (MIII-IIa). </p><p id="p0321" num="0321">Preferably, solvent (MIII-IIa) is selected from the group consisting of N,N- dimethylformamide, N,N-dimethylacetamide, Ν,Ν-dimethylsulfoxide, acetonitrile, acetone, 1,4-dioxane, THF, water, methanol, ethanol and mixtures thereof. </p><p id="p0322" num="0322">Preferably, the amount of solvent (MIII-IIa) is from 1 to 500 fold, more preferably from 5 to 50 fold, even more preferably from 10 to 30 fold, of the weight of compound of formula (IV). </p><p id="p0323" num="0323">Preferably, in reaction (MIII-IIa) and in reaction (MII0-IIa), from 1 to 20 mol equivalents, more preferably from 1 to 10 mol equivalents, even more preferably from 1 to 5 mol equivalents, of compound (CGlMR-IIa) are used, the mol equivalents being based the mol of compound of formula (IV) or of formula (IIIO). </p><p id="p0324" num="0324">Preferably, reaction (MIII-IIa) and reaction (MII0-IIa) done under inert atmosphere. </p><p id="p0325" num="0325">After reaction (MIII-IIa) and reaction (MII0-IIa), the compound of formula (IV-IIa) or formula (III0-IIa) respectively can be isolated by standard methods such as washing, 
<!-- EPO <DP n="39"/>-->
 extraction, filtration, concentration and drying. The compound of formula (IV-IIa) or of formula (III0-IIa) respectively can be purified before or after isolation, preferably by chromatography or crystallization from an appropriate solvent. Reaction (MIII-IIb) and reaction (MII0-IIb) are similar reactions and can be done under similar reaction parameters ranges as defined herein, with the individual reaction parameters for each of said two reactions being selected independently from each other. </p><p id="p0326" num="0326">Preferably, reaction (MIII-IIb) and reaction (MllO-IIb) are done in the presence of a compound (COUPADD). </p><p id="p0327" num="0327">Compound (COUPADD) is a coupling additive conventionally used in peptide chemistry for the coupling reaction of amino acid to peptides by amide bond formation. Preferably, compound (COUPADD) is selected from the group consisting of DCC, EDC and mixtures thereof. </p><p id="p0328" num="0328">Preferably, in reaction (MIII-IIb) and in reaction (MII0-IIb), from 1 to 20 mol equivalents, more preferably from 1 to 10 mol equivalents, even more preferably from 1 to 5 mol equivalents, of compound (COUPADD) are used, the mol equivalents being based the mol of compound of formula (IV-IIa) or of formula (III0-IIa) respectively. </p><p id="p0329" num="0329">Reaction (MIII-IIb) and reaction (MII0-IIb) are usually done in a solvent (MIII-IIb). </p><p id="p0330" num="0330">Preferably, solvent (MIII-IIb) is selected from the group consisting of N,N- dimethylformamide, N,N-dimethylacetamide, Ν,Ν-dimethylsulfoxide, acetonitrile, acetone, 1,4-dioxane, THF and mixtures thereof. </p><p id="p0331" num="0331">Preferably, the amount of solvent (MIII-IIb) is from 1 to 500 fold, more preferably from 5 to 50 fold, even more preferably from 10 to 30 fold, of the weight of compound of formula (IV- IIa). </p><p id="p0332" num="0332">Preferably, in reaction (MIII-IIb) and in reaction (MII0-IIb), from 1 to 20 mol equivalents, more preferably from 1 to 10 mol equivalents, even more preferably from 1 to 5 mol equivalents, of compound of formula (HOSu) are used, the mol equivalents being based the mol of compound of formula (IV-IIa) or of formula (III0-IIa) respectively. 
<!-- EPO <DP n="40"/>-->
 Preferably, reaction (MIII-IIb) and reaction (MII0-IIb) are done under inert atmosphere. </p><p id="p0333" num="0333">After reaction (MIII-IIb) and reaction (MllO-IIb), the compound of formula (III) or of formula (II) respectively can be isolated by standard methods such as washing, extraction, filtration, concentration and drying. The compound of formula (III) or of formula (II) respectively can be purified before or after isolation, preferably by chromatography or crystallization from an appropriate solvent. Reaction (MIII-IIc) and reaction (MIIO-IIc) are similar reactions and can be done under similar reaction parameters ranges as defined herein, with the individual reaction parameters for each of said two reactions being selected independently from each other. </p><p id="p0334" num="0334">Reaction (MIII-IIc) and reaction (MIIO-IIc) are usually done in a solvent (MIII-IIc). </p><p id="p0335" num="0335">Preferably, solvent (MIII-IIc) is selected from the group consisting of N,N- dimethylformamide, N,N-dimethylacetamide, Ν,Ν-dimethylsulfoxide, acetonitrile, acetone, 1,4-dioxane, THF, water, methanol, ethanol and mixtures thereof. </p><p id="p0336" num="0336">Preferably, the amount of solvent (MIII-IIc) is from 1 to 500 fold, more preferably from 5 to 50 fold, even more preferably from 10 to 30 fold, of the weight of compound of formula (IV). </p><p id="p0337" num="0337">Preferably, in reaction (MIII-IIc) and in reaction (MIIO-IIc), from 1 to 20 mol equivalents, more preferably from 1 to 10 mol equivalents, even more preferably from 1 to 5 mol equivalents, of compound (CGlMR-IIa) are used, the mol equivalents being based the mol of compound of formula (IV) or of formula (IIIO) respectively. </p><p id="p0338" num="0338">Preferably, reaction (MIII-IIc) and reaction (MIIO-IIc) are done under inert atmosphere. </p><p id="p0339" num="0339">Reaction (MIII-IIc) and reaction (MIIO-IIc) are usually done in the presence of a base (MIII- lie). </p><p id="p0340" num="0340"> Preferably, the base (MIII-IIc) is selected from the group consisting of K<sub>2</sub>C0<sub>3</sub>, Na<sub>2</sub>C0<sub>3</sub>, diisopropylethylamine, triethylamine, pyridine, 4-dimethylaminopyridine and mixtures thereof. 
<!-- EPO <DP n="41"/>-->
 Preferably, in the reaction (MIII-IIc) and reaction (MIIO-IIc), from 0.5 to 50 mol equivalents, more preferably from 1 to 20 mol equivalents, even more preferably from 2 to 10 mol equivalents, of base (MIII-IIc) are used, the mol equivalents being based the mol of compound of formula (IV) or of formula (IIIO) respectively. </p><p id="p0341" num="0341">After reaction (MIII-IIc) and reaction (MIIO-IIc), the compound of formula (III) or of formula (II) respectively can be isolated by standard methods such as washing, extraction, filtration, concentration and drying. The compound of formula (III) or of formula (II) respectively can be purified before or after isolation, preferably by chromatography or crystallization from an appropriate solvent. </p><p id="p0342" num="0342">Reaction (MIII-I) and reaction (MIIO-I) are similar reactions and can be done under similar reaction parameters ranges as defined herein, with the individual reaction parameters for each of said two reactions being selected independently from each other. </p><p id="p0343" num="0343">Preferably, the reaction time of reaction (MIII-I) and of reaction (MIIO-I) is from 1 min to 168 h, more preferably from 2 to 144 h, even more preferably from 12 to 120 h. </p><p id="p0344" num="0344">Reaction (MIII-I) and reaction (MIIO-I) are usually done in a solvent (MIII-I). </p><p id="p0345" num="0345">Preferably, solvent (MIII-I) is selected from the group consisting of N,N-dimethylformamide, N,N-dimethylacetamide, Ν,Ν-dimethylsulfoxide, acetonitrile, acetone, 1,4-dioxane, THF and mixtures thereof. </p><p id="p0346" num="0346">Preferably, the amount of solvent (MIII-I) is from 1 to 500 fold, more preferably from 5 to 50 fold, even more preferably from 10 to 30 fold, of the weight of compound of formula (IV) or of formula (IIIO) respectively. </p><p id="p0347" num="0347">Preferably, in reaction (MIII-I) and in reaction (MIIO-I), from 1 to 20 mol equivalents, more preferably from 1 to 10 mol equivalents, even more preferably from 1 to 5 mol equivalents, of compound of formula (MA) are used, the mol equivalents being based the mol of compound of formula (IV) or of formula (IIIO) respectively. </p><p id="p0348" num="0348">Preferably, reaction (MIII-I) and reaction (MIIO-I) are done under inert atmosphere. 
<!-- EPO <DP n="42"/>-->
 Preferably, reaction (MIII-I) and reaction (MIIO-I) are done in the presence of compound (COUP ADD). </p><p id="p0349" num="0349">Preferably, in reaction (MIII-I) and reaction (MIIO-I), from 1 to 20 mol equivalents, more preferably from 1 to 10 mol equivalents, even more preferably from 1 to 5 mol equivalents, of compound (COUP ADD) are used, the mol equivalents being based the mol of compound of formula (IV) or of formula (IIIO) respectively. </p><p id="p0350" num="0350">Preferably, reaction (MIII-I) and reaction (MIIO-I) are done in the presence of compound of formula (HOSu). </p><p id="p0351" num="0351">Preferably, reaction (MIII-I) and reaction (MIIO-I) are done in the presence of compound (COUP ADD) and compound of formula (HOSu). Preferably, in reaction (MIII-I) and reaction (MIIO-I), from 1 to 20 mol equivalents, more preferably from 1 to 10 mol equivalents, even more preferably from 1 to 5 mol equivalents, of compound of formula (HOSu) are used, the mol equivalents being based the mol of compound of formula (IV) or of formula (IIIO) respectively. After reaction (MIII-I) and reaction (MIIO-I), the compound of formula (III) or of formula (II) respectively can be isolated by standard methods such as washing, extraction, filtration, concentration and drying. The compound of formula (III) or of formula (II) respectively can be purified before or after isolation, preferably by chromatography or crystallization from an appropriate solvent. </p><p id="p0352" num="0352">Reaction (MIV) and reaction (MVO) are similar reactions and can be done under similar reaction parameters ranges as defined herein, with the individual reaction parameters for each of said two reactions being selected independently from each other. Preferably, the reaction time of reaction (MIV) and of reaction (MVO) is from 1 min to 168 h, more preferably from 1 to 120 h, even more preferably from 6 to 48 h. </p><p id="p0353" num="0353">Reaction (MIV) and reaction (MVO) are usually done in a solvent (MIV). 
<!-- EPO <DP n="43"/>-->
 Preferably, solvent (MIV) is selected from the group consisting of water, methanol, ethanol, Ν,Ν-dimethylformamide, N,N-dimethylacetamide, Ν,Ν-dimethylsulfoxide, acetonitrile, acetone, 1,4-dioxane, THF, water, methanol, ethanol and mixtures thereof. </p><p id="p0354" num="0354">Preferably, the amount of solvent (MIV) is from 1 to 500 fold, more preferably from 5 to 50 fold, even more preferably from 10 to 30 fold, of the weight of compound of formula (V) or of formula (Va) respectively. </p><p id="p0355" num="0355">Preferably, reaction (MIV) and reaction (MVO) are done under inert atmosphere. </p><p id="p0356" num="0356">Preferably, compound (IV) is selected from the group consisting of NaBH<sub>4</sub>, DIBAL-H and mixtures thereof. </p><p id="p0357" num="0357"> Compound (IV) used in reaction (MIV) and compound (IV) used in reaction (MVO) can be independently from each identical or different. </p><p id="p0358" num="0358">Preferably, in the reaction (MIV) and in reaction (MVO), from 1 to 50 mol equivalents, more preferably from 1 to 20 mol equivalents, even more preferably from 2 to 10 mol equivalents, of compound (IV) are used, the mol equivalents being based the mol of compound of formula (V) or of formula (Va). </p><p id="p0359" num="0359">Reaction (MIV) and reaction (MVO) can be done in the presence of a salt (MIV), salt (MIV) is selected from the group consisting of LiCl, CaCl<sub>2</sub>, A1C1<sub>3</sub>, ZnCl<sub>2</sub> and mixtures thereof. </p><p id="p0360" num="0360">Preferably, if salt (MIV) is used in the reaction (MIV) and in reaction (MVO), from 1 to 20 mol equivalents, more preferably from 1 to 10 mol equivalents, even more preferably from 1.5 to 5 mol equivalents, of salt (MIV) are used, the mol equivalents being based the mol of compound of formula (V) or of formula (Va). </p><p id="p0361" num="0361">After reaction (MIV) and reaction (MVO), the compound of formula (IV) or of formula (V0) respectively can be isolated by standard methods such as washing, extraction, filtration, concentration and drying. The compound of formula (IV) or of formula (V0) respectively can be purified before or after isolation, preferably by chromatography or crystallization from an appropriate solvent. 
<!-- EPO <DP n="44"/>-->
 Reaction (MII0-I-IVa) and reaction (MlVOa) are similar reactions and can be done under similar reaction parameters ranges as defined herein, with the individual reaction parameters for each of said two reactions being selected independently from each other. Preferably, the reaction time of reaction (MII0-I-IVa) and of reaction (MlVOa) is from 1 min to 168 h, more preferably from 2 to 144 h, even more preferably from 12 to 120 h. </p><p id="p0362" num="0362">Reaction (MII0-I-IVa) and reaction (MlVOa) are usually done in a solvent (MlVOa). </p><p id="p0363" num="0363">Preferably, solvent (MlVOa) is selected from the group consisting of N,N- dimethylformamide, N,N-dimethylacetamide, Ν,Ν-dimethylsulfoxide, acetonitrile, acetone, 1,4-dioxane, THF, water, methanol, ethanol and mixtures thereof. </p><p id="p0364" num="0364">Preferably, the amount of solvent (MlVOa) is from 1 to 500 fold, more preferably from 5 to 50 fold, even more preferably from 10 to 30 fold, of the weight of compound of formula (V0). </p><p id="p0365" num="0365">Preferably, in reaction (MII0-I-IVa) and in reaction (MlVOa), from 1 to 20 mol equivalents, more preferably from 1 to 10 mol equivalents, even more preferably from 1 to 5 mol equivalents, of compound (II0-I-IVa) or of compound (RIVOa) respectively are used, the mol equivalents being based the mol of compound of formula (V0). </p><p id="p0366" num="0366">Preferably, reaction (MII0-I-IVa) and reaction (MlVOa) are done under inert atmosphere. </p><p id="p0367" num="0367">Preferably, reaction (MII0-I-IVa) and reaction (MlVOa) are done in the presence of compound of formula (HOSu). </p><p id="p0368" num="0368">Preferably, in reaction (MII0-I-IVa) and reaction (MlVOa), from 1 to 20 mol equivalents, more preferably from 1 to 10 mol equivalents, even more preferably from 1 to 5 mol equivalents, of compound of formula (HOSu) are used, the mol equivalents being based the mol of compound (II0-I-IVa) or of compound (RIVOa) respectively. </p><p id="p0369" num="0369">After reaction (MII0-I-IVa) and reaction (MlVOa), compound of formula (III0-I-IVa) or of formula (IVOa) respectively can be isolated by standard methods such as washing, extraction, filtration, concentration and drying. Any of the compounds can be purified before or after isolation, preferably by chromatography or crystallization from an appropriate solvent. 
<!-- EPO <DP n="45"/>-->
 Further subject of the invention is a method (MVa) for the preparation of compound of formula (Va), with the compound of formula (Va) as defined herein, also with all its preferred embodiments; </p><p id="p0370" num="0370">method (MVa) comprises a step (MVa); </p><p id="p0371" num="0371">step (MVa) comprises a reaction (MVa), wherein a compound of formula (VI) is reacted with a compound of formula (SGM); </p><p id="p0372" num="0372"><img id="imgf000045_0001" he="84" wi="73" file="imgf000045_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0373" num="0373">R30 SG R31 (SGM) </p><p id="p0374" num="0374">R31 is connected to SG via the bond denoted with (***) in the formulae of SG and is -OTs, -OMs, -OTf, -Br, -CI or -I; </p><p id="p0375" num="0375">R30 is as defined herein, also with all its preferred embodiments; </p><p id="p0376" num="0376"> SG, n4, n3, AA<sup>n4</sup>, (3), Rl, R2 are as defined herein, also with all their preferred embodiments. </p><p id="p0377" num="0377">Preferably, method (Mil) comprises as a further step the step (MVa), wherein compound of formula (Va) is prepared. 
<!-- EPO <DP n="46"/>-->
 Preferably, the reaction temperature of reaction (MVa) is from 0 to 150 °C, more preferably from 20 to 100 °C, even more preferably from 30 to 60 °C. </p><p id="p0378" num="0378">Preferably, the reaction time of reaction (MVa) is from 1 min to 168 h, more preferably from 1 to 144 h, even more preferably from 12 to 120 h. </p><p id="p0379" num="0379">Reaction (MVa) is usually done in a solvent (MVa). </p><p id="p0380" num="0380"> Preferably, solvent (MVa) is selected from the group consisting of N,N-dimethylformamide, N,N-dimethylacetamide, Ν,Ν-dimethylsulfoxide, acetonitnle, acetone, 1,4-dioxane, THF and mixtures thereof. </p><p id="p0381" num="0381">Preferably, the amount of solvent (MVa) is from 1 to 500 fold, more preferably from 5 to 50 fold, even more preferably from 10 to 30 fold, of the weight of compound of formula (VI). Preferably, in the reaction (MVa), from 1 to 20 mol equivalents, more preferably from 1 to 10 mol equivalents, even more preferably from 1.5 to 5 mol equivalents, of compound (SGM) are used, the mol equivalents being based the mol of compound of formula (VI). </p><p id="p0382" num="0382">Preferably, the reaction (MVa) is done under inert atmosphere. </p><p id="p0383" num="0383">Reaction (MVa) are usually done in the presence of a base (MVa). </p><p id="p0384" num="0384"> Preferably, base (MVa) is selected from the group consisting of K<sub>2</sub>C0<sub>3</sub>, Na<sub>2</sub>C0<sub>3</sub>, </p><p id="p0385" num="0385">diisopropylethylamine, triethylamine, pyridine, 4-dimethylaminopyridine and mixtures thereof. </p><p id="p0386" num="0386">Preferably, in the reaction (MVa), from 1 to 20 mol equivalents, more preferably from 1 to 10 mol equivalents, even more preferably from 1.5 to 5 mol equivalents, of base (MVa) are used, the mol equivalents being based the mol of compound of formula (VI). After the reaction (MVa), compound of formula (Va) can be isolated by standard methods such as washing, extraction, filtration, concentration and drying. Any of the compounds can be purified before or after isolation, preferably by chromatography or crystallization from an appropriate solvent. 
<!-- EPO <DP n="47"/>-->
 Reaction (MVb) and reaction (MIIIO) are similar reactions and can be done under similar reaction parameters ranges as defined herein, with the individual reaction parameters for each of said two reactions being selected independently from each other. Preferably, in reaction (MVb) and in reaction (MIIIO), from 1 to 500 mol equivalents, more preferably from 5 to 100 mol equivalents, even more preferably from 10 to 50 mol equivalents, of HC1 are used, the mol equivalents being based the mol of compound of formula (Va) or of formula (IV0) respectively. Preferably, the reaction time of reaction (MVb) and of reaction (MIIIO) is from 1 min to 168 h, more preferably from 1 to 48 h, even more preferably from 2 to 24 h. </p><p id="p0387" num="0387">Reaction (MVb) and reaction (MIIIO) is usually done in a solvent (MVb). </p><p id="p0388" num="0388">Preferably, solvent (MVb) is selected from the group consisting of N,N-dimethylformamide, N,N-dimethylacetamide, Ν,Ν-dimethylsulfoxide, acetonitrile, acetone, 1,4-dioxane, THF, water, methanol, ethanol and mixtures thereof. </p><p id="p0389" num="0389">Preferably, the amount of solvent (MVb) is from 1 to 500 fold, more preferably from 5 to 50 fold, even more preferably from 10 to 30 fold, of the weight of compound of formula (Va) or of formula (IV0). </p><p id="p0390" num="0390">Preferably, the reaction (MVb) and reaction (MIIIO) is done under inert atmosphere. </p><p id="p0391" num="0391">After reaction (MVb) and reaction (MIIIO), compound of formula (V) or of formula (III0) respectively can be isolated by standard methods such as washing, extraction, filtration, concentration and drying. They can be isolated in protonated form of their salts or in unprotonated form. </p><p id="p0392" num="0392"> Any of the compounds can be purified before or after isolation, preferably by chromatography or crystallization from an appropriate solvent. </p><p id="p0393" num="0393">Further subject of the invention is a method (MVI) for the preparation of compound of formula (VI), with the compound of formula (VI) being as defined herein, also with all its preferred embodiments; </p><p id="p0394" num="0394">method (MVI) comprises a step (MVIa) and optionally a step (MVIb); 
<!-- EPO <DP n="48"/>-->
 in step (MVIa) the n3 AA<sup>n</sup> are consecutively connected to a compound of formula (VII-1) by peptide coupling reactions and then to the respective products of the preceding peptide coupling reactions; </p><p id="p0395" num="0395"><img id="imgf000048_0001" he="56" wi="78" file="imgf000048_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 step (MVIb) comprises a reaction (MVIb), wherein the N-terminal amino group of AA<sup>n</sup> </p><p id="p0396" num="0396"> denoted with (3) in formula (VI) is reacted with a compound NTermProt; </p><p id="p0397" num="0397"> NTermProt is selected from the group consisting of C<sub>1-4</sub> alkyl iodide, C<sub>1-4</sub> alkyl bromide, Cl-C(0)-(GRPEG)<sub>m4</sub>-R3, R3-C(0)-0-C(0)-R3 and PGNPrec; </p><p id="p0398" num="0398">PGNPrec is a reagent which provides for the introduction of PGN on the N-terminal amino group of AA<sup>n3</sup> denoted with (3) in formula (VI); </p><p id="p0399" num="0399">GRPEG, m4, R3 and PGN have the same definition as above, also with all their preferred embodiments; </p><p id="p0400" num="0400">n4, n3, AA<sup>n4</sup> and (3) are as defined herein, also with all their preferred embodiments. </p><p id="p0401" num="0401">Preferably, method (Mil) comprises as further steps the step (MVa), wherein compound of formula (Va) is prepared, and the step (MVIa) and optionally the step (MVIb), wherein compound of formula (VI) is prepared. </p><p id="p0402" num="0402">Compound of formula (VII-1) is a known compound and can be prepared by known methods. </p><p id="p0403" num="0403">For simplicity sake, AA<sup>n4</sup> in this text is used both for the covalently bonded amino acid </p><p id="p0404" num="0404"> residue, e.g. in formula (II), and for the amino acid used in method (MVIa). 
<!-- EPO <DP n="49"/>-->
 In case that AA<sup>n</sup> has a side chain with a functional group, this functional group can be protected by a protecting group commonly used for protecting functional groups of side chains of amino acids. Preferably, NTermProt is Ac<sub>2</sub>0. </p><p id="p0405" num="0405"> Preferably, PG Prec is Boc<sub>2</sub>0, FmocCl or CbzCl. </p><p id="p0406" num="0406">Method (MVIa) is done using methodology, parameters and reagents commonly used in peptide synthesis, and which are known to the skilled person. Above cited references give the necessary information. </p><p id="p0407" num="0407">Preferably, the reaction time of reaction (MVIb) is from 1 min to 168 h, more preferably from 1 to 48 h, even more preferably from 2 to 24 h. Reaction (MVIb) is usually done in a solvent (MVIb). </p><p id="p0408" num="0408"> Preferably, solvent (MVIb) is selected from the group consisting of N,N-dimethylformamide, N,N-dimethylacetamide, Ν,Ν-dimethylsulfoxide, acetonitrile, acetone, 1,4-dioxane, THF, water, methanol, ethanol and mixtures thereof. Preferably, the amount of solvent (MVIb) is from 1 to 500 fold, more preferably from 2 to 50 fold, even more preferably from 5 to 20 fold, of the weight of compound of formula (VII-1). </p><p id="p0409" num="0409">More preferably, method (MVIa) and reaction (MVIb) are done consecutively in the same solvent. </p><p id="p0410" num="0410">More preferably, method (MVIa) and reaction (MVIb) are done consecutively in the same solvent and in one pot. </p><p id="p0411" num="0411">Preferably, in the method (MVIa), from 1 to 20 mol equivalents, more preferably from 1 to 10 mol equivalents, even more preferably from 1 to 5 mol equivalents, of NTermProt are used, the mol equivalents being based the mol of compound of formula (VII-1). </p><p id="p0412" num="0412">Preferably, the reaction (MVIb) is done under inert atmosphere. 
<!-- EPO <DP n="50"/>-->
 After the method (MVIa) or reaction (MVIb), the reaction product of the method (MVIa) or of the reation (MVIb), each of which is a respective compound of formula (VI), can be isolated by standard methods such as washing, extraction, filtration, concentration and drying. Any of the compounds can be purified before or after isolation, preferably by chromatography or crystallization from an appropriate solvent. </p><p id="p0413" num="0413">Compound of formula (SGM) is a known compound and can be prepared according to known methods. </p><p id="p0414" num="0414">Preferably, compound of formula (SGM) is selected from the group consisting of compound SGM-II and compound SGM-III. </p><p id="p0415" num="0415">Preferably, compound SGM-II is prepared by reacting a compound of formula (HSGH-II) first with Boc<sub>2</sub>0 and then with compound (SGM-II-R31). </p><p id="p0416" num="0416"> Compound (SGM-II-R31) is selected from the group consisting of p-toluenesulfonyl chloride, p-toluenesulfonic anhydride, methanesulfonyl chloride, methanesulfonic anhydride, trifluoromethanesulfonyl chloride and trifluoromethanesulfonic anhydride, SOCl<sub>2</sub>, (COCl)<sub>2</sub>, POCI3, PCI3, PCI5, POBr<sub>3</sub>, PBr<sub>3</sub>, PBr<sub>5</sub>, N-bromosuccinimide, </p><p id="p0417" num="0417"> N-iodosuccinimide, HC1, HBr, HI and mixtures thereof. </p><p id="p0418" num="0418"> Preferably, compound (SGM-II-R31) is TsCl. </p><p id="p0419" num="0419">H<sub>2</sub>N CH- SGPEG OH (HSGH-II) </p><p id="p0420" num="0420"> mlO ml </p><p id="p0421" num="0421">Preferably, compound SGM-III is prepared by reacting a compound of formula (HSGH-III) first with Boc<sub>2</sub>0 and then with a compound of formula (HSGHReac-1). 
<img id="imgf000050_0001" he="11" wi="144" file="imgf000050_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0422" num="0422">(HSGHReac-1)</p><p id="p0423" num="0423"><img id="imgf000050_0002" he="14" wi="21" file="imgf000050_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/><!-- EPO <DP n="51"/>-->
 Compound of formula (HSGH-II) is preferably a compound of formula (HSGH-II- 1) or a compound of formula (HSGH-II-2). </p><p id="p0424" num="0424">H<sub>2</sub>N, .OH </p><p id="p0425" num="0425"> O<sup>'</sup> (HSGH-II- 1) 
<img id="imgf000051_0001" he="10" wi="91" file="imgf000051_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0426" num="0426">Compound SGM-II is preferably a compound of formula (SGM-II-1) or a compound of formula (SGM-II-2). </p><p id="p0427" num="0427">,NH ,OTs (SGM-II-1) </p><p id="p0428" num="0428"> Boc </p><p id="p0429" num="0429">Boc ,OTs (SGM-II-2) </p><p id="p0430" num="0430">Compound of formula (HSGH-III) is preferably a compound of formula (HSGH-III- 1) or a compound of formula (HSGH-III-2). </p><p id="p0431" num="0431">.0. </p><p id="p0432" num="0432"> H<sub>2</sub>N <sup>'</sup> ^ (HSGH-III-1) </p><p id="p0433" num="0433">H<sub>2</sub>N <sup>v "</sup>NH<sub>2</sub> (HSGH-III-2) </p><p id="p0434" num="0434">Compound SGM-III is preferably a compound of formula (SGM-III-1) or a compound of formula (SGM-III-2). </p><p id="p0435" num="0435"><img id="imgf000051_0002" he="18" wi="152" file="imgf000051_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/><!-- EPO <DP n="52"/>--><img id="imgf000052_0001" he="18" wi="98" file="imgf000052_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0436" num="0436">Compound of formula (HSGH-II) and compound of formula (HSGH-III) are a known compound, can be prepared according to known methods, and are often even commercially available. </p><p id="p0437" num="0437">Compounds of formulae (CGIMR-IV), (CGIMR-III), (CGlMR-IIa), (HOSu) and compound </p><p id="p0438" num="0438"> (COUP ADD) are known compounds, can be prepared by known methods and are often even commercially available. </p><p id="p0439" num="0439">Preferably, compound of formula (CGIMR-IV) is prepared by reacting a compound of </p><p id="p0440" num="0440"> formula (CGIMR-IV-OH) with a compound of formula (HOSu); </p><p id="p0441" num="0441">(CGIMR-IV-OH) 
<img id="imgf000052_0002" he="29" wi="51" file="imgf000052_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 with the compound of formula (HOSu) as defined herein; preferably, compound of formula (CGIMR-IV-OH) is prepared by reacting compound of formula (MA) with compound of formula (AC); </p><p id="p0442" num="0442"><img id="imgf000052_0003" he="17" wi="81" file="imgf000052_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 with compound of formula (MA) and m30 as defined herein, also with all their preferred embodiments. 
<!-- EPO <DP n="53"/>-->
 Any of the above defined reactions can be done under similar reaction conditions with the individual reaction parameters for each of these reactions being selected independently from each other: </p><p id="p0443" num="0443">with respect to pressure: any of the above defined reactions can be done under vacuum, at atmospheric pressure or even under pressure, the pressure can for example be up to 10 bar, preferably they are done under atmospheric pressure; </p><p id="p0444" num="0444">with respect to temperature: preferably, the reaction temperature of any of the above defined reactions is from -20 to 100 °C, more preferably from 0 to 75 °C, even more preferably from 10 to 50 °C; </p><p id="p0445" num="0445">with respect to reaction time: the reaction time of any of the above defined reactions is from 1 min to 168 h, more preferably from 0.5 to 24 h, even more preferably from 1 to 12 h; if not stated otherwise for any of the above defined reactions. </p><p id="p0446" num="0446">In particular, compound of formula (I) is selected from the group consisting of compound of formula (10), compound of formula (11), compound of formula (12), compound of formula (12-101), compound of formula (13), compound of formula (14), compound of formula (15), compound of formula (15-102) and compound of formula (16); </p><p id="p0447" num="0447"><img id="imgf000053_0001" he="77" wi="153" file="imgf000053_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/><!-- EPO <DP n="54"/>-->
 53 </p><p id="p0448" num="0448"><img id="imgf000054_0001" he="230" wi="171" file="imgf000054_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="55"/>-->
 54 </p><p id="p0449" num="0449"><img id="imgf000055_0001" he="210" wi="139" file="imgf000055_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="56"/>-->
 55 </p><p id="p0450" num="0450"><img id="imgf000056_0001" he="198" wi="176" file="imgf000056_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="57"/>--><img id="imgf000057_0001" he="245" wi="171" file="imgf000057_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="58"/>-->
 wherein doxorubicin is the compound of formula (DOXO), which is connected via the amino group denoted with (dl) in formula (10), (11), (12), (12-101), (13), (14), (15), (15-102) and (16) respectively and in formula (DOXO). In particular, compound of formula (II) is selected from the group consisting of compound of formula (20), compound of formula (21), compound of formula (22), compound of formula (23), compound of formula (24), compound of formula (25), compound of formula (26), compound of formula (20-CAMPTO), compound of formula (21-CAMPTO), compound of formula (22-CAMPTO), compound of formula (23-CAMPTO) and compound of formula (21-TAXO-tl-l); </p><p id="p0451" num="0451">doxorubicin 
<!-- EPO <DP n="59"/>-->
</p><p id="p0452" num="0452"> </p><p id="p0453" num="0453"><img id="imgf000059_0001" he="187" wi="147" file="imgf000059_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="60"/>-->
  </p><p id="p0454" num="0454"><img id="imgf000060_0001" he="165" wi="143" file="imgf000060_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="61"/>--></p><p id="p0455" num="0455">60 </p><p id="p0456" num="0456"><img id="imgf000061_0001" he="171" wi="139" file="imgf000061_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="62"/>--></p><p id="p0457" num="0457"><img id="imgf000062_0001" he="70" wi="118" file="imgf000062_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0458" num="0458"><img id="imgf000062_0002" he="78" wi="140" file="imgf000062_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0459" num="0459">5 
<img id="imgf000062_0003" he="78" wi="128" file="imgf000062_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 
<!-- EPO <DP n="63"/>-->
</p><p id="p0460" num="0460"><img id="imgf000063_0001" he="78" wi="170" file="imgf000063_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0461" num="0461"><img id="imgf000063_0002" he="99" wi="157" file="imgf000063_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0462" num="0462">wherein </p><p id="p0463" num="0463">doxorubicin is the compound of formula (DOXO), which is connected via the amino group denoted with (dl) in formula (20), (21), (22), (23), (24), (25) and (26) respectively and in formula (DOXO); 
<!-- EPO <DP n="64"/>-->
 camptothecin is the compound of formula (CAMPTO), which is connected via the hydroxy group denoted with (cl) in formula (20-CAMPTO), (21 -CAMPTO), (22-CAMPTO) and (23 -CAMPTO) respectively and in formula (CAMPTO); </p><p id="p0464" num="0464">taxo-tl-1 is the compound of formula (TAXO), which is connected via the hydroxy group denoted with (tl) in formula (21-TAXO-tl-l), in formula (TAXO-tl-1) and in formula</p><p id="p0465" num="0465">(TAXO). </p><p id="p0466" num="0466"><img id="imgf000064_0001" he="85" wi="148" file="imgf000064_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0467" num="0467">In particular, compound of formula (III) is selected from the group consisting of compound of formula (30), compound of formula (31), compound of formula (32), compound of formula (33), compound of formula (34), compound of formula (35) and compound of formula (36). 
<!-- EPO <DP n="65"/>-->
</p><p id="p0468" num="0468">64 </p><p id="p0469" num="0469"><img id="imgf000065_0001" he="185" wi="112" file="imgf000065_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="66"/>-->
 65 </p><p id="p0470" num="0470"><img id="imgf000066_0001" he="166" wi="102" file="imgf000066_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="67"/>--></p><p id="p0471" num="0471">66 </p><p id="p0472" num="0472"><img id="imgf000067_0001" he="169" wi="110" file="imgf000067_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="68"/>--></p><p id="p0473" num="0473"><img id="imgf000068_0001" he="78" wi="105" file="imgf000068_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0474" num="0474">In particular, compound of formula (IIIO) is compound of formula (300); </p><p id="p0475" num="0475">camptothecin </p><p id="p0476" num="0476"><img id="imgf000068_0002" he="69" wi="93" file="imgf000068_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 wherein </p><p id="p0477" num="0477">camptothecin is the compound of formula (CAMPTO), which is connected via the hydroxy group denoted with (cl) in formula (300) respectively and in formula (CAMPTO). </p><p id="p0478" num="0478">In particular, compound of formula (III0-I-IVa) is compound of formula (320). 
<!-- EPO <DP n="69"/>-->
</p><p id="p0479" num="0479"><img id="imgf000069_0001" he="78" wi="105" file="imgf000069_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0480" num="0480">In particular, compound of formula (IV) is selected from the group consisting of compound of formula (40), compound of formula (41), compound of formula (42), compound of formula (43), compound of formula (44), compound of formula (45) and compound of formula (46). </p><p id="p0481" num="0481"><img id="imgf000069_0002" he="66" wi="93" file="imgf000069_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="70"/>--></p><p id="p0482" num="0482"> </p><p id="p0483" num="0483"><img id="imgf000070_0001" he="231" wi="144" file="imgf000070_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="71"/>--></p><p id="p0484" num="0484"><img id="imgf000071_0001" he="66" wi="110" file="imgf000071_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><img id="imgf000071_0002" he="74" wi="93" file="imgf000071_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0485" num="0485"><img id="imgf000071_0003" he="70" wi="105" file="imgf000071_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0486" num="0486"> In particular, compound of formula (IVO) is compound of formula (400); 
<!-- EPO <DP n="72"/>-->
</p><p id="p0487" num="0487"><img id="imgf000072_0001" he="69" wi="93" file="imgf000072_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/>
 wherein </p><p id="p0488" num="0488">camptothecin is the compound of formula (CAMPTO), which is connected via the hydroxy group denoted with (cl) in formula (400) respectively and in formula (CAMPTO). </p><p id="p0489" num="0489">In particular, compound of formula (IVOa) is compound of formula (400a). </p><p id="p0490" num="0490"><img id="imgf000072_0002" he="69" wi="95" file="imgf000072_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0491" num="0491">In particular, compound of formula (V) is selected from the group consisting of compound of formula (50), compound of formula (50-1), compound of formula (51), compound of formula (51-1), compound of formula (52), compound of formula (52-1), compound of formula (53), compound of formula (53-1), compound of formula (54), compound of formula (54-1), 
<!-- EPO <DP n="73"/>-->
 compound of formula (54-2), compound of formula (54-3), compound of formula (55), compound of formula (55-1), compound of formula (56) and compound of formula (56-1).</p><p id="p0492" num="0492"><img id="imgf000073_0001" he="66" wi="99" file="imgf000073_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><img id="imgf000073_0002" he="66" wi="99" file="imgf000073_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="74"/>--></p><p id="p0493" num="0493">73 </p><p id="p0494" num="0494"><img id="imgf000074_0001" he="240" wi="152" file="imgf000074_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="75"/>-->
 74 </p><p id="p0495" num="0495"><img id="imgf000075_0001" he="227" wi="138" file="imgf000075_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="76"/>-->
 75 </p><p id="p0496" num="0496"><img id="imgf000076_0001" he="222" wi="148" file="imgf000076_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="77"/>-->
 76 </p><p id="p0497" num="0497"><img id="imgf000077_0001" he="237" wi="146" file="imgf000077_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="78"/>-->
 77 </p><p id="p0498" num="0498"><img id="imgf000078_0001" he="244" wi="145" file="imgf000078_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="79"/>-->
 In particular, compound of formula (VI) is selected from the group consisting of compound of formula (6), compound of formula (6-1), compound of formula (6-2), compound of formula (6-3), compound of formula (6-4), compound of formula (6b), compound of formula (6b-l), compound of formula (6b-2), compound of formula (6b-3), compound of formula (6b-4), compound of formula (6c) and compound of formula (6-5). </p><p id="p0499" num="0499"><img id="imgf000079_0001" he="59" wi="93" file="imgf000079_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0500" num="0500"><img id="imgf000079_0002" he="59" wi="86" file="imgf000079_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="80"/>--></p><p id="p0501" num="0501"><img id="imgf000080_0001" he="59" wi="87" file="imgf000080_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><img id="imgf000080_0002" he="58" wi="63" file="imgf000080_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0502" num="0502">BocHN </p><p id="p0503" num="0503"> (6-4) 
<img id="imgf000080_0003" he="59" wi="46" file="imgf000080_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 
<!-- EPO <DP n="81"/>-->
 80 </p><p id="p0504" num="0504"><img id="imgf000081_0001" he="219" wi="146" file="imgf000081_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="82"/>-->
 81 </p><p id="p0505" num="0505"><img id="imgf000082_0001" he="212" wi="142" file="imgf000082_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="83"/>--><img id="imgf000083_0001" he="59" wi="111" file="imgf000083_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0506" num="0506">Further subject of the invention is a compound selected from the group consisting of compound of formula (I), compound of formula (II), compound of formula (He), compound of formula (III), compound of formula (IV), compound of formula (IV-IIa), compound of formula (V), compound of formula (Va), compound of formula (VI), compound of formula (III0-IIa), compound of formula (IIIO), compound of formula (IVO), compound of formula (IVOa), compound of formula (V0) and compound of formula (III0-I-IVa); with these compounds being as defined herein, also with all their preferred embodiments. </p><p id="p0507" num="0507">Further subject of the invention is a compound selected from the group consisting of compound of formula (10), compound of formula (11), compound of formula (12), compound of formula (12-101), compound of formula (13), compound of formula (14), compound of formula (15), compound of formula (15-102), compound of formula (16), compound of formula (20c), compound of formula (20), compound of formula (21), compound of formula (22), compound of formula (23), compound of formula (24), compound of formula (25), compound of formula (26), compound of formula (20-CAMPTO), compound of formula (21- CAMPTO), compound of formula (22-CAMPTO), compound of formula (23-CAMPTO), compound of formula (21-TAXO-tl-l), compound of formula (30), compound of formula (31), compound of formula (32), compound of formula (33), compound of formula (34), compound of formula (35), compound of formula (36), compound of formula (300), compound of formula (320), compound of formula (40), compound of formula (41), compound of formula (42), compound of formula (43), compound of formula (44), compound of formula (45), compound of formula (46), compound of formula (400), compound of formula (400a), compound of formula (50), compound of formula (50-1), compound of formula (51), compound of formula (51-1), compound of formula (52), compound of formula 
<!-- EPO <DP n="84"/>-->
 (52-1), compound of formula (53), compound of formula (53-1), compound of formula (54), compound of formula (54-1), compound of formula (54-2), compound of formula (54-3), compound of formula (55), compound of formula (55-1), compound of formula (56), compound of formula (56-1), compound of formula (500), compound of formula (6), compound of formula (6-1), compound of formula (6-2), compound of formula (6-3), compound of formula (6-4), compound of formula (6b), compound of formula (6b- 1), compound of formula (6b-2), compound of formula (6b-3), compound of formula (6b-4), compound of formula (6c) and compound of formula (6-5); with these compounds being as defined herein. </p><p id="p0508" num="0508">Further subject of the invention is the use of the compound of formula (I), the compound of formula (I) being as defined herein, also in all its preferred embodiments, for the preparation of a pharmaceutical composition or of a drug. </p><p id="p0509" num="0509"> Further subject of the invention is a pharmaceutical composition or a drug, wherein the </p><p id="p0510" num="0510"> pharmaceutical composition and the drug comprise the compound of formula (I), the compound of formula (I) being as defined herein, also in all its preferred </p><p id="p0511" num="0511"> embodiments. </p><p id="p0512" num="0512"> Further subject of the invention is a compound of formula (I), a pharmaceutical composition or a drug, wherein the pharmaceutical composition and the drug comprise the compound of formula (I), the compound of formula (I) being as defined herein, also in all its preferred embodiments, </p><p id="p0513" num="0513"> for use in treatment of a disease or an illness, preferably of cancer. </p><p id="p0514" num="0514">Compound of formula (II) can be readily covalently attached to a ligand LI. It was surprising, that the protein drug conjugates of the instant invention, which comprise a connecting group CG2, CG2 being derived from o-hydrox-p-amino benzylic alcohol, and which comprise a linear peptide residue, in particular the compounds of formula (I), show increased plasma stability, and release the drug without the drug being chemically modified, Furtehrmore, they show good water solubility and low aggregation. 
<!-- EPO <DP n="85"/>-->
 Abbreviations </p><p id="p0515" num="0515"> DCM dichoromethane </p><p id="p0516" num="0516"> DIBAL-H diisobutylaluminium hydride </p><p id="p0517" num="0517"> DIPEA N,N-diisopropylethylamine </p><p id="p0518" num="0518">DMA N,N-dimethylacetamide </p><p id="p0519" num="0519"> DMAP 4-dimethylaminopyridine </p><p id="p0520" num="0520"> DMF N,N-dimethylformamide </p><p id="p0521" num="0521"> EDTA ethylenediaminetetraacetic acid </p><p id="p0522" num="0522"> EEDQ 2-ethoxy- 1 -ethoxycarbonyl- 1 ,2-dihydroquinoline </p><p id="p0523" num="0523">ESI-MS electrospray ionisation mass spectrometry </p><p id="p0524" num="0524"> EtOAc ethyl acetate </p><p id="p0525" num="0525"> HIC hydrophobic interaction chromatography </p><p id="p0526" num="0526"> MeCN acetonitrile </p><p id="p0527" num="0527"> NAP-25 column NAP-25 columns of GE Healthcare are disposable columns prepacked with Sephadex™ G-25 DNA Grade and require only gravity to run</p><p id="p0528" num="0528">NMR nuclear magnetic resonance </p><p id="p0529" num="0529"> PE petroleum ether </p><p id="p0530" num="0530"> Rf retention factor in TLC </p><p id="p0531" num="0531"> RP-HPLC reversed phase HPLC </p><p id="p0532" num="0532">RT room temperature </p><p id="p0533" num="0533"> SAFC Sigma Aldrich Fine Chemicals </p><p id="p0534" num="0534"> SEC-HPLC size exclusion chromatography HPLC </p><p id="p0535" num="0535"> TBTU 2-(lH-benzotriazole-l-yl)-l, 1,3,3-tetramethylaminium tetrafluorob orate</p><p id="p0536" num="0536">THF tetrahydrofurane </p><p id="p0537" num="0537">TFA Trifluoroacetic acid </p><p id="p0538" num="0538"> TLC thin layer chromatography </p><p id="p0539" num="0539">Raw Materials </p><p id="p0540" num="0540">compound of formula (DOXO) doxorubicin, commercially available as hydrochloride salt from Beijing Zhongshuo Pharmaceutical Technology Development Co. Ltd. </p><p id="p0541" num="0541">daunorubicin commercially available as hydrochloride salt from </p><p id="p0542" num="0542"> Aldrich 
<!-- EPO <DP n="86"/>-->
 PBS The PBS used in the experiments had the composition </p><p id="p0543" num="0543"> KH2P04: 144 mg/L, NaCl: 9000 mg/L and Na2HP04: 795 mg/L Example 1 </p><p id="p0544" num="0544"> To a mixture of p-amino salicylic acid (15.0 g) and MeOH (113.0 ml) at 0 °C, cone. H<sub>2</sub>SO<sub>4</sub> (30.0 ml) was added dropwise. The resulting mixture was heated to reflux and stirred for 2 hours to form a homogeneous solution. The reaction mixture was then cooled to RT. Water (360 ml) was added, followed by solid NaHC0<sub>3</sub> until pH 7. The resulting mixture was filtered, the wet cake was washed with water (3 times with 80 mL each) and dried under vacuum at 55 °C to afford 14.7 g of compound of formula (VII-1) as a solid (89% yield). </p><p id="p0545" num="0545">1H MR (400 MHz, CDC1<sub>3</sub>, 20 °C) delta 3.90 (1H, s), 4.12 (2H, brs), 6.16 to 6.19 (2H, m), 7.62 to 7.65 (1H, m). </p><p id="p0546" num="0546">ESI-MS: 168.0 (M+H)+ Example 2 </p><p id="p0547" num="0547"> To a mixture of H-Cit-OH (40.0 g, 1.0 eq.) and Na<sub>2</sub>C0<sub>3</sub> (50.0 g, 2.0 eq.) in water (300 ml) and THF (150 ml), a solution of di-tert-butyl dicarbonate (60.0 g, 1.2 eq.) in THF (100 ml) was added dropwise within 1 hour. The resulting mixture was allowed to stir at RT overnight.</p><p id="p0548" num="0548">After that, the suspension was washed with PE (2 times with 150 ml each), then the mixture was concentrated to about 300 ml under vacuum. The mixture was acidified to pH 2 with 4.0</p><p id="p0549" num="0549">M aqueous KHSO<sub>4</sub>, then extracted with EtOAc (5 times with 150 ml each). The organic phases were combined and washed with saturated brine (100 ml), dried over anhydrous </p><p id="p0550" num="0550"> Na<sub>2</sub>S0<sub>4</sub> and filtered. The filtrate was evaporated to dryness to afford 52.0 g of Boc-Cit-OH as white solid (83 % yield). </p><p id="p0551" num="0551">1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 1.38 (9H, s), 1.36 to 1.43 (2H, m), 1.47 to 1.69 (2H, m), 2.93 (2H, q, J = 6.3 Hz), 3.82 to 3.87 (1H, m), 5.36 (2H, brs), 5.92 (1H, t, J = 5.6 Hz), 7.07 (1H, d, J = 8.0 Hz), 12.44 (1H, brs). </p><p id="p0552" num="0552">ESI-MS: 275.8 (M+H)+ , 550.8 (2M+H)+ 
<!-- EPO <DP n="87"/>-->
 Example 3 </p><p id="p0553" num="0553"> Boc-Cit-OH (53.0 g, 1.0 eq.), prepared according to example 2, and EEDQ (72.0 g, 1.5 eq.) were added to THF (400 ml). To this mixture was then added compound of formula (VII-1) (49.0 g, 1.5 eq.), prepared according to example 1. The resulting mixture was stirred at RT for 14 hours. Then the reaction mixture was diluted with water (500 ml), extracted with EtOAc (3 times with 250 ml each). The organic phases were combined and washed with 1.0 M aqueous solution of citric acid (2 time with 150 ml each) and saturated brine (150 ml). After that, the organic phase was dried over anhydrous Na<sub>2</sub>S0<sub>4</sub>, then concentrated to dryness, the crude product was purified by silica gel chromatography (eluent PE : EtOAc = 4: l to 2: l to l : l (v/v) to pure EtOAc) and isolated to afford 62.5 g of compound of formula (6-4) as yellow solid (76 % yield). </p><p id="p0554" num="0554">Analysis by silica gel TLC: EtOAc as eluent (Rf = 0.3, UV254) 1H MR (400 MHz, CDC1<sub>3</sub>, 20 °C) delta 1.40 (9H, s), 1.57 to 1.83 (4H, m), 3.08 to 3.16 (2H, m), 3.90 (3H, s), 4.43 (1H, s), 5.26 (2H, s), 5.85 (2H, s), 7.11 (1H, d, J = 8.8 Hz), 7.28 (1H, s), 7.68 (1H, d, J = 8.8 Hz), 9.74 (1H, s), 10.82QH, brs). </p><p id="p0555" num="0555">ESI-MS: 325.2 (M-tBuOCO+2H)+ </p><p id="p0556" num="0556">Example 4 </p><p id="p0557" num="0557"> Compound of formula (6-4) (62.0 g, 1 eq.), prepared according to example 3, was suspended in a solution of 15% (w/w) HC1 in 1,4-dioxane (100 ml), the resulting mixture was stirred at RT for 1 hour. The reaction mixture was then concentrated under vacuum to afford 51.6 g of compound of formula (6-3) as HC1 salt, being a white solid (98 % yield). </p><p id="p0558" num="0558">Example 5 </p><p id="p0559" num="0559"> Compound of formula (6-3) as HC1 salt (75.6 g, 1.0 eq.), prepared according to example 4, Boc-L-Val (43.0g, 1.0 eq.) and TBTU (135.5 g, 2.0 eq.) were dissolved in DMF (250 ml). Then DIPEA (71.2 g, 2.6 eq.) was added. The resulting solution was stirred at RT for 17 h. The reaction mixture was then diluted with water (750 ml), extracted with EtOAc (5 times with 200 ml each), the organic phases were combined and washed with 1.0 M aqueous NaHC0<sub>3</sub> solution (3 times with 300 ml each) and then with saturated brine (150 ml). The organic phase was collected and concentrated to dryness, the crude product was then purified 
<!-- EPO <DP n="88"/>-->
 by silica gel chromatography (eluent DCM : MeOH = 20 : 1 to 10 : 1 to 7 : 1 (v/v) and isolated to afford 62.0 g of compound of formula (6-2) as a solid (57% yield). </p><p id="p0560" num="0560">Analysis by silica gel TLC: DCM : MeOH = 6 : 1 (v/v) as eluent (Rf = 0.4, UV254) </p><p id="p0561" num="0561">1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.84 (6H, dd, Jl = 17.2 Hz, J2 = 6.8 Hz), 1.39 (9H, s), 1.42 to 1.51 (2H, m), 1.55 to 1.73 (2H, m), 1.93 to 1.98 (1H, m), 2.90 to 3.08 (2H, m), 3.82 to 3.84 (1H, m), 3.88 (3H, s), 4.39 to 4.45 (1H, m), 5.43 (2H, s), 6.01 (1H, t, J = 5.8 Hz), 6.72 (1H, d, J = 8.8 Hz), 7.09 (1H, dd, Jl = 8.8 Hz, J2 = 2.0 Hz), 7.73 (1H, d, J = 8.8 Hz), 8.08 (1H, d, J = 7.2 Hz), 10.34 (1H, s), 10.62 (1H, brs). </p><p id="p0562" num="0562">ESI-MS: 524.3 (M+H)+, 424.3 (M-tBuOCO+2H)+ </p><p id="p0563" num="0563">Example 6 </p><p id="p0564" num="0564">Compound of formula (6-2) (62.0 g, 1 eq.), prepared according to example 5, was suspended in a solution of 15% (w/w) HC1 in 1,4-dioxane (200 ml), the resulting mixture was stirred at RT for 1 hour. The reaction mixture was then concentrated under vacuum to afford 52.4 g of compound of formula (6-1) as HC1 salt, being a white solid (97% yield). Example 7 </p><p id="p0565" num="0565"> Compound of formula (6-1) as HC1 salt (52.4 g, 1.0 eq.), prepared according to example 6, acetic anhydride (60.0 g, 5.0 eq.), pyridine (100.0 g, 11.0 eq.) and methanol (150 ml) were mixed and stirred at RT for 7 days. The suspension was filtered and the resulting wet cake was washed with MeOH (4 times with 200 ml each), then dried under vacuum to afford 32.9 g of compound of formula (6) as a white solid (62 % yield). </p><p id="p0566" num="0566">1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.86 (6H, dd, Jl = 12.4 Hz, J2 = 6.8 Hz), 1.35 to 1.50 (2H, m), 1.56 to 1.74 (2H, m), 1.87 (3H, s), 1.94 to 2.00 (1H, m), 2.93 to 3.06 (2H, m), 3.87 (3H, s), 4.20 (1H, t, J = 7.6 Hz), 4.34 to 4.39 (1H, m), 5.43 (2H, s), 6.00 (1H, t, J = 5.2 Hz), 7.11 (1H, dd, Jl = 8.8 Hz, J2 = 1.6 Hz), 7.41 (1H, d, J = 1.6 Hz), 7.73 (1H, d, J = 8.8 Hz), 7.89 (1H, d, J = 8.4 Hz), 8.21 (1H, d, J = 7.2 Hz), 10.24 (1H, s), 10.62 (1H, s). </p><p id="p0567" num="0567">ESI-MS: 466.3 (M+H)+ , 931.3 (2M+H)+ 
<!-- EPO <DP n="89"/>-->
 Example 8 </p><p id="p0568" num="0568"> Compound of formula (MA) (5.5 g, 1.0 eq.) and beta-alanine (5.0 g, 1.0 eq.) in DMF (30.0 ml), were stirred under nitrogen atmosphere for 2 hours. The mixture was then cooled to 0 °C. Compound of formula (HOSu) (8.0 g, 1.3 eq.) and DCC (24.0 g, 2.0 eq.) were added. Then the reaction mixture was allowed to warm up to RT and stirred at RT overnight. The reaction mixture was then filtered, the resulting wet cake was washed with DMF (40.0 ml), the organic phases were combined and then diluted with water (120 ml) and extracted with DCM (3 times with 50 ml each). The organic phases were combined, washed with water (50 ml), then with 5% (w/w) aqueous NaHC03 solution (50 ml) and then with saturated brine (50 ml). The organic phase was dried over anhydrous Na<sub>2</sub>S0<sub>4</sub>, then concentrated until solid started to precipitate. Then PE (20 ml) was added to the mixture and the resulting mixture was stirred at RT for 10 min. The mixture was then filtered, the wet cake was washed with PE (20 ml) and then dried under vaccum at 40 °C overnight to afford 4.0 g of compound of formula </p><p id="p0569" num="0569">(CGlMR-IV-1) as a white solid (27 % yield). </p><p id="p0570" num="0570">(CGlMR-IV-1) 
<img id="imgf000089_0001" he="32" wi="54" file="imgf000089_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0571" num="0571">1H MR (400 MHz, CDC1<sub>3</sub>, 20 °C) delta 2.84 (4H, s), 3.04 (2H, t, J = 7.0 Hz), 3.95 (2H, t, J = 7.0 Hz), 6.75 (2H, s). </p><p id="p0572" num="0572">ESI-MS: 267.2 (M+H)+ , 289.4 (M+Na)+ Example 9 </p><p id="p0573" num="0573"> To a mixture of compound of formula (HSGH-II-1) (10.0 g, 1.0 eq.), MeOH (50 ml) and Et3N (10.7 g, 1.1 eq.), a solution of Boc<sub>2</sub>0 in MeOH (22.8 g, 1.1 eq. Boc<sub>2</sub>0 in 50 ml MeOH) was added dropwise. Then the resulting mixture was stirred at RT for 15 hours and then dried under vacuum to afford 20.0 g of compound of formula (Boc-HSGH-II-1) as a slightly yellow oil (quantitative yield). 
<!-- EPO <DP n="90"/>-->
 
<img id="imgf000090_0001" he="13" wi="102" file="imgf000090_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0574" num="0574">1H NMR (400 MHz, CDC1<sub>3</sub>, 20 °C) delta 1.44 (9H, s), 2.73 (1H, brs), 3.32 (2H, q, J = 5.2 Hz), 3.54 to 3.58 (4H, m), 3.72 to 3.74 (2H, m), 5.15 (1H, brs). </p><p id="p0575" num="0575">Example 10 </p><p id="p0576" num="0576"> To a mixture of compound of formula (Boc-HSGH-II-1) (6.17 g, 1 eq.), prepared according to example 9, pyridine (2.86 g, 1.2 eq) and DCM (30 ml) at 0 °C, DMAP (0.366 g, 0.1 eq) were added. A mixture of tosyl chloride (6.31 g, 1.1 eq) and DCM (45 ml) was added dropwise. The resulting mixture was stirred at RT for 8 days. Then the resulting mixture was poured onto DCM (100 ml), the resulting mixture was washed with water (1 time with 100 ml), the organic phase was then dried over anhydrous Na<sub>2</sub>S0<sub>4</sub>. The resulting solution was further concentrated and purified by silica gel chromatography (PE : EtOAc = 6 : 1 to PE : EtOAc = 1 : 1 (v/v)) to afford 8.1 g of compound of formula (SGM-II-1) as a colorless oil (75% yield). </p><p id="p0577" num="0577">1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.86 (6H, dd, Jl = 12.4 Hz, J2 = 6.8 Hz), 1.35 to 1.50 (2H, m), 1.56 to 1.74 (2H, m), 1.87 (3H, s), 1.94 to 2.00 (1H, m), 2.93 to 3.06 (2H, m), 3.87 (3H, s), 4.20 (1H, t, J = 7.6 Hz), 4.34 to 4.39 (1H, m), 5.43 (2H, s), 6.00 (1H, t, J = 5.2 Hz), 7.11 (1H, dd, Jl = 8.8 Hz, J2 = 1.6 Hz), 7.41 (1H, d, J = 1.6 Hz), 7.73 (1H, d, J = 8.8 Hz), 7.89 (1H, d, J = 8.4 Hz), 8.21 (1H, d, J = 7.2 Hz), 10.24 (1H, s), 10.62 (1H, s). </p><p id="p0578" num="0578">Example 11 </p><p id="p0579" num="0579"> A mixture of compound of formula (6) (3.00 g, 1 eq), prepared according to example 7, compound of formula (SGM-II-1) (4.65 g, 2 eq), prepared according to example 10, K<sub>2</sub>C0<sub>3</sub> (1.82 g, 2 eq) and anhydrous DMF (30 ml) was heated to 50 °C and stirred under nitrogen atmosphere for 7 days. Then the reaction mixture was concentrated to dryness under vacuum. To the residue methanol (30 ml) was added, the resulting mixture was stirred for 10 min and then filtered. The wet cake was washed with methanol (3 times with 10 ml each). The organic phase were combined and then concentrated. The residue was purified by silica gel column chromatography (DCM : MeOH = 7 : 1 (v/v)) to afford 3.40 g of compound of formula (50-1) as a slightly yellow solid (81% yield). 
<!-- EPO <DP n="91"/>-->
 1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) δ 0.86 (6H, dd, Jl = 12.8 Hz, J2 = 6.8 Hz), 1.38 to 1.51 (2H, m), 1.56 to 1.80 (2H, m), 1.89 (3H, s), 1.92 to 2.01 (1H, m), 2.92 to 3.05 (2H, m), 3.07 to 3.12 (2H, m), 3.50 (2H, t, J = 6.0 Hz), 3.75 to 3.77 (5H, m), 4.08 to 4.10 (2H, m), 4.20 (1H, dd, Jl = 8.4 Hz, J2 = 6.8 Hz), 4.34 to 4.40 (1H, m), 5.42 (2H, s), 5.99 (1H, t, J = 5.8 Hz), 6.74 (1H, t, J = 5.6 Hz), 7.26 (1H, dd, Jl = 8.4 Hz, J2 = 1.6 Hz), 7.49 (1H, d, J = 2.0 Hz), 7.68 (1H, d, J = 8.8 Hz), 7.91 (1H, d, J = 8.4 Hz), 8.19 (1H, d, J = 7.6 Hz),10.20 (1H, s). </p><p id="p0580" num="0580">ESI-MS: 653.4 (M+H)+ , 675.5 (M+Na)+, 553.5 (M-tBuOCO+2H)+ Example 12 </p><p id="p0581" num="0581"> A mixture of compound of formula (50-1) (500 mg), prepared according to example 11, and a solution of 10% (w/w) HC1 in 1,4-dioxane (10 ml) was stirred at RT for 15 hours. The solvent was removed under vacuum to afford 431 mg of compound of formula (50) as HC1 salt, being a slightly yellow solid (quantitative yield). </p><p id="p0582" num="0582">ESI-MS: 553.5 (M+H)+ , 1105.2 (2M+H)+ Example 13 </p><p id="p0583" num="0583"> To a mixture of compound of formula (50) as HC1 salt (1.10 g, 1.0 eq), prepared according to example 12, and anhydrous THF (20 ml) at -30 °C was added a solution of DIBAL-H in hexanes (1 M, 11.9 ml, 6.0 eq). The resulting mixture was then heated to 0 °C and stirred under nitrogen atmosphere for 15 hours. Then methanol (2.0 mL) was added. Then saturated aqueous potassium sodium tartrate solution (10 ml) was added to the mixture and the mixture was stirred for 30 min at RT. The resulting mixture was evaporated to dryness to generate a white residue which was washed with methanol (5 times with 10 ml each). The combined organic phases were concentrated and purified by silica gel column chromatography (DCM : MeOH : Et3N = 65 : 33 : 2 (v/v)) to afford 0.65 g of compound of formula (40) as a white solid (72% yield). 1H MR (400 MHz, DMSO-d<sub>6</sub>, 60 °C) delta 0.86 (6H, t, J = 6.6 Hz), 1.37 to 1.53 (2H, m), 1.63 to 1.79 (2H, m), 1.92 (3H, s), 1.99 to 2.07 (1H, m), 2.70 (2H, brs), 2.99 to 3.02 (2H, m), 3.47 (2H, t, J = 5.6 Hz), 4.07 (2H, t, J = 5.8 Hz), 4.18 (1H, t, J = 7.6 Hz), 4.34 to 4.41 (1H, m), 5.25 (2H, s), 5.90 (1H, brs), 7.16 (1H, d, J = 8.0 Hz), 7.26 (2H, d, J = 8.0 Hz), 7.32 (1H, s), 7.76 (1H, d, J = 7.6 Hz), 7.91 (1H, d, J = 4.4 Hz), 9.69 (1H, s). 
<!-- EPO <DP n="92"/>-->
 ESI-MS: 525.6 (M+H)+ </p><p id="p0584" num="0584">Example 14 </p><p id="p0585" num="0585">To a mixture of compound of formula (40) (500.2 mg, 1.0 eq.), prepared according to example 13, compound of formula (CGlMR-IV-1) (281.0 mg, 1.1 eq), prepared according to example 8, and DMF (9.5 ml) at RT, DIPEA (140.3 mg, 1.1 eq) was added. The resulting mixture was stirred at RT for 17 hours. Then the DMF was removed under vacuum to afford a slightly yellow residue. The residue was then mixed with acetone (10 ml) and stirred at RT for 18 h. The mixture was filtered, the wet cake was washed with acetone (2 times with 5 ml each), then dried under vacuum to afford 515.0 mg of compound of formula (30) as a slightly yellow solid (80% yield). </p><p id="p0586" num="0586">1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.86 (6H, dd, Jl = 11.2 Hz, J2 = 6.8 Hz), 1.32 to 1.48 (2H, m), 1.55 to 1.76 (2H, m), 1.89 (3H, s), 1.94 to 2.02 (1H, m), 2.33 (2H, t, J = 7.2</p><p id="p0587" num="0587">Hz), 2.93 to 3.04 (2H, m), 3.16 to 3.20 (2H, q, J = 5.6 Hz), 3.46 (2H, t, J = 5.8 Hz), 3.60 (2H, t, J = 7.8 Hz), 3.73 (2H, t, J = 4.6 Hz), 4.04 (2H, t, J = 4.6 Hz), 4.18 (1H, dd, Jl = 8.4 Hz, J2 = 6.8 Hz), 4.34 to 4.39 (1H, m), 4.44 (2H, s), 4.88 (1H, brs), 5.42 (2H, s), 6.00 (1H, t, J = 5.4 Hz), 7.00 (2H, s), 7.16 (1H, dd, Jl = 8.4 Hz, J2 = 2.0 Hz), 7.26 (1H, d, J = 8.4 Hz), 7.32 (1H, d, J = 1.6 Hz), 7.92 (1H, d, J = 8.4 Hz), 8.05 (1H, t, J = 5.6 Hz), 8.12 (1H, d, J = 7.6 Hz), 9.88 (1H, s). </p><p id="p0588" num="0588">Example 15 </p><p id="p0589" num="0589"> A mixture of compound of formula (30) (400 mg, 1.0 eq), prepared according to example 14, DIPEA (231.0 mg, 3.0 eq), 4 angstrom molecular sieves (800 mg) and dry DMF (8.0 ml) was stirred for 5 min. Then compound of formula (II- 1) (361.2 mg, 2 eq) was added. The resulting mixture was stirred for 3 h at RT. Then compound of formula (DOXO) as HC1 salt (342.8 mg, 1.0 eq) was added and the mixture was stirred for 4 hours. Then MeCN (40.0 ml) was added. A precipitate had formed and was filtered and washed with a mixture of MeCN and DMF (5 : 1 (v/v), 2 times with 5 ml each). The filtrates were combined and dried under vacuum at 45 °C to get a dark red residue. The residue was washed with MeCN (2 times with 10 ml each), then the residue was dissolved in a mixture of acetone and water (20 : 1 (v/v)) and purified by preparative silica gel TLC (DCM : MeOH = 5 : 1 (v/v), Rf = 0.15). The product was extrated from the silica-gel by a mixture of acetone and water (20 : 1 (v/v), 6 times with 20 ml each), 
<!-- EPO <DP n="93"/>-->
 the combined extraction solutions were dried under vacuum to afford a crude product as a red solid. The crude product was then mixed with acetonitrile (5.0 ml), the mixture was stirred at RT for 5 hours and then filtered. The presscake was mixed with acetonitrile (5.0 ml) and the mixture stirred for 3 hours at RT. The mixture was then filtered. The presscake was dried under vacuum at RT to afford 48.0 mg of compound of formula (20) as a red solid (7% yield). </p><p id="p0590" num="0590">1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.85 (6H, dd, Jl = 11.2 Hz, J2 = 6.8 Hz), 1.13 (3H, d, J = 6.4 Hz), 1.34 to 1.47 (3H, m), 1.57 to 1.72 (2H, m), 1.82 to 1.90 (1H, m), 1.90 (3H, s), 1.93 to 1.98 (1H, m), 2.08 to 2.22 (2H, m), 2.29 (2H, t, J = 7.2 Hz), 2.91 to 3.01 (4H, m), 3.11 to 3.16 (2H, m), 3.41 (2H, t, J = 5.6 Hz), 3.45 to 3.46 (1H, m), 3.54 (2H, t, J = 7.2 Hz), 3.68 to 3.74 (3H, m), 3.98 (3H, s), 4.03 (2H, t, J = 4.0 Hz), 4.17 (2H, t, J = 7.6 Hz), 4.32 to 4.38 (1H, m), 4.58 (2H, d, J = 5.2 Hz), 4.69 (2H, d, J = 5.6 Hz), 4.85 to 4.89 (2H, m), 4.94 (1H, brs), 5.22 (1H, brs), 5.40 (2H, s), 5.46 (1H, brs), 5.98 (1H, t, J = 4.8 Hz), 6.80 (1H, d, J = 8.0 Hz), 6.95 (2H, s), 7.12 (1H, d, J = 8.4 Hz), 7.19 (1H, d, J = 8.4 Hz), 7.36 (1H, s), 7.64 (1H, brs), 7.89 to 7.91 (3H, m), 7.99 (1H, t, J = 5.2 Hz), 8.10 (1H, d, J = 7.2 Hz), 9.92 (1H, s), 13.26 (1H, s), 14.02 (1H, s). </p><p id="p0591" num="0591">ESI-MS: 1245.5 (M+H)+ Example 16 </p><p id="p0592" num="0592"> To a mixture of compound of formula (HSGH-III-1) (110.16 g, 5 eq) and dioxane (400 ml) at 0 °C, a mixture of Boc<sub>2</sub>0 (22.10 g, 1 eq) in dioxane (200 ml) was added dropwise. The resulting mixture was then heated to RT and then stirred for 20 hours. Then the solvent was removed under vacuum. The resulting residue was added to water (300 ml), the resulting mixture was extracted with DCM (2 times with 300 ml each). The organic layer was dried over anhydrous Na<sub>2</sub>S0<sub>4</sub> and then evaporated to dryness. The residue was purified by silica gel column chromatography (DCM : EtOAc =1 : 1 (v/v), then with DCM : MeOH : Et3N = 89 : 9 : 2 (v/v)) to afford 17.7 g of compound of formula (Boc-HSGH-III-1) as a slightly yellow oil (55% yield). H<sub>7</sub> ^^ O O N (Boc-HSGH-III-1)</p><p id="p0593" num="0593"><sup>2</sup> H 
<!-- EPO <DP n="94"/>-->
 1H MR (400 MHz, CDC13, 20 oC) δ 1.44 (9H, s), 1.64 (2H, s), 1.72-1.78 (4H, m), 2.81 (2H, t, J = 6.6 Hz), 3.23 (2H, q, J = 6.0 Hz), 3.55-3.62 (8H, m), 3.64-3.66 (4H, m), 5.14 (1H, brs). Example 17 </p><p id="p0594" num="0594"> To a mixture of compound of formula (Boc-HSGH-III-1) (5.00 g, 1.0 eq), prepared according to example 18, K<sub>2</sub>C0<sub>3</sub> (4.30 g, 2.0 eq) and DCM (40 ml) at 0 °C, a mixture of compound of formula (HSGHReac-1) (2.17 g, 1.2 eq) in DCM (20 ml) was added dropwise within 1 hour. The resulting mixture was warmed to RT and stirred for 20 hours. Then the solid was filtered, the cake was washed with DCM (2 times with 5 ml each). The filtrates were combined and evaporated to dryness. The residue was then purified by silica gel column chromatography (eluent EtOAc : PE = 3 : 1) to afford 5.6 g of compound of formula (SGM-III-1) as a slightly yellow oil (90 % yield). 1H MR (400 MHz, CDC13, 20 oC) δ 1.44 (9H, s), 1.64 (2H, s), 1.73-1.86 (4H, m), 3.23 (2H, q, J = 6.0 Hz), 3.44 (2H, q, J = 6.0 Hz), 3.54 (2H, t, J = 6.0 Hz), 3.58-3.66 (10H, m), 4.04 (2H, s), 4.98 (1H, brs), 7.31 (1H, brs). </p><p id="p0595" num="0595">Example 18 </p><p id="p0596" num="0596">Compound of formula (6) (5.80 g, 1.0 eq), prepared according to example 7, K<sub>2</sub>C0<sub>3</sub> (5.18 g, 2.0 eq), compound of formula (SGM-III-1) (9.95 g, 2.0 eq), prepared according to example 17, and DMF (45 ml) were mixed. The resulting mixture was then heated to 50 °C and stirred for 7 days under nitrogen atmosphere. The resulting reaction mixture was evaporated to dryness under vacuum. Methanol (40 ml) was added to the residue, the resulting mixture was stirred for 10 min and then filtered. The wet cake was washed with methanol (3 times with 10 ml each). The organic filtrates were collected and combined and then evaporated. The residue was purified by silica gel column chromatography (DCM : MeOH = 7 : 1 (v/v)) to afford 7.20 g of compound of formula (51-1) as a slightly yellow solid (70% yield). 1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.86 (6H, dd, Jl = 13.6 Hz, J2 = 6.8 Hz), 1.32 to 1.49 (2H, m), 1.37 (9H, s), 1.55 to 1.78 (6H, m), 1.89 (3H, s), 1.94 to 1.99 (1H, m), 2.93 to 3.07 (4H, m), 3.26 (2H, q, J = 6.8 Hz), 3.37 (2H, t, J = 6.4 Hz), 3.43 to 3.52 (10H, m), 3.81 (3H, s), 4.20 (1H, dd, Jl = 8.4 Hz, J2 = 6.8 Hz), 4.35 to 4.41 (1H, m), 4.53 (2H, s), 5.44 (2H, s), 6.03 (1H, t, J = 5.6 Hz), 6.74 (1H, t, J = 5.6 Hz), 7.36 (1H, dd, Jl = 8.4 Hz, J2 = 2.0 Hz), 
<!-- EPO <DP n="95"/>-->
 7.41 (1H, d, J = 2.0 Hz), 7.80 (1H, d, J = 8.8 Hz), 7.90 (1H, d, J = 8.4 Hz ), 8.06 (1H, t, J = 5.6 Hz), 8.21 (1H, d, J = 7.2 Hz), 10.32 (1H, s). </p><p id="p0597" num="0597">ESI-MS: 726.6 (M-tBuOCO+2H)+, 826.3 (M+H)+, 848.5 (M+Na)+ </p><p id="p0598" num="0598">Example 19 </p><p id="p0599" num="0599"> Compound of formula (51-1) (1.00 g), prepared according to example 18, and a solution of 15% (v/v) HC1 in 1,4-dioxane (10 ml) were mixed. The mixture was stirred at RT for 3 hours. The solvent was removed under vacuum to afford 0.99 g of compound of formula (51) as HC1 salt, being a slightly yellow solid (quantitative yield). </p><p id="p0600" num="0600">ESI-MS: 726.6 (M+H)+ </p><p id="p0601" num="0601">Example 20 </p><p id="p0602" num="0602">A mixture of compound of formula (51) as HC1 salt (6.08 g, 1 eq), prepared according to example 19, water (100 ml), CaCl<sub>2</sub> (1.86 g, 2.0 eq), and NaBH<sub>4</sub> (1.27 g, 4.0 eq) was stirred at RT. Further NaBH<sub>4</sub> was added portion wise (1.27 g, 4.0 eq. after a total of 15 hours stirring; 1.27 g, 4.0 eq. after a total of 20 hours stirring; 1.27 g, 4.0 eq. after a total of 24 hours of stirring). After a total of 36 hours of stirring, MeOH (30 ml) was added to the mixture. The reaction mixture was then filtered and the wet cake was washed with MeOH (3 times with 10 ml each). The liquid phase was collected, combined and then evaporated to dryness. The residue was purified by silica gel column chromatography (eluent DCM : MeOH : Et3N = 65 : 33 : 2 (v/v)) to afford 2.70 g of compound of formula (41) as a slightly yellow solid (48% yield). </p><p id="p0603" num="0603">1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.86 (6H, dd, Jl = 10.8 Hz, J2= 6.8 Hz), 1.31 to 1.49 (2H, m), 1.55 to 1.82 (6H, m), 1.90 (3H, s), 1.93 to 2.02 (1H, m), 2.82 (2H, t, J = 7.4 Hz), 2.98 to 3.05 (2H, m), 3.15 to 3.20 (2H, q, J = 6.8 Hz), 3.34 to 3.51 (12H, m), 4.16 to 4.20 (1H, m), 4.34 to 4.41 (1H, m), 4.46 (2H, s), 4.50 (2H, s), 5.47 (2H, s), 6.13 (1H, t, J = 5.6 Hz), 7.25 (2H, s), 7.26 (1H, s), 7.95 (1H, d, J = 8.8 Hz), 8.10 (1H, t, J = 5.6 Hz), 8.14 (1H, d, J = 7.6 Hz), 10.01 (1H, s). </p><p id="p0604" num="0604">ESI-MS: 698.7 (M+H)+ 
<!-- EPO <DP n="96"/>-->
 Example 21 </p><p id="p0605" num="0605"> Compound of formula (41) (2.78 g, 1.0 eq.), prepared according to example 20, compound of formula (CGlMR-IV-1) (1.18 g, 1.1 eq), prepared according to example 8, and DMF (30 ml) were mixed at RT. Then DIPEA (0.58 g, 1.1 eq) was added. The resulting mixture was stirred at RT for 16 hours. Then DMF was removed under vacuum to afford a slightly yellow residue. The residue was then mixed with acetone (30 ml) and the mixture was stirred at RT for 5 hours. Then the mixture was filtered, the wet cake was washed with acetone (2 times with 15 ml each) and then dried under vacuum to afford 2.55 g of compound of formula (31) as a slightly yellow solid (75% yield). </p><p id="p0606" num="0606">1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.86 (6H, dd, Jl = 11.2 Hz, J2 = 6.8 Hz), 1.32 to 1.48 (2H, m), 1.55 to 1.73 (2H, m), 1.89 (3H, s), 1.93 to 2.01 (1H, m), 2.31 (2H, t, J = 7.2 Hz), 2.90 to 3.11 (4H, m), 3.17 (2H, q, J = 6.4 Hz), 3.36 (2H, t, J = 6.4 Hz), 3.44 to 3.60 (8H, m), 3.60 (2H, t, J = 7.2 Hz), 4.19 (1H, dd, Jl = 8.4 Hz, J2 = 6.8 Hz), 4.35 to 4.40 (1H, m), 4.46 (2H, s), 4.51 (2H, s), 5.08 (1H, brs), 5.42 (2H, s), 6.00 (1H, t, J = 5.6 Hz), 7.00 (2H, s), 7.22 (1H, s), 7.25 (1H, s), 7.89 to 7.91 (1H, m), 8.04 (1H, t, J =5.6 Hz), 8.10 (1H, d, J = 7.6 Hz), 9.92 (1H, s). </p><p id="p0607" num="0607">ESI-MS: 831.6 (M-OH)+ ,849.4 (M+H)+ </p><p id="p0608" num="0608">Example 22 </p><p id="p0609" num="0609"> A mixture of compound of formula (31) (500.4 mg, 1.0 eq), prepared according to example 21, DIPEA (305.7 mg, 4.0 eq), 4 angstrom molecular sieves (500.5 mg) and dry DMF (10.0 ml) was stirred for 5 min. Then compound of formula (II- 1 ) (271.1 mg, 1.5 eq.) was added. The resulting mixture was stirred for 5 hours at RT. Then compound of formula (DOXO) as HC1 salt (342.8 mg, 1.0 eq.) was added and the resulting mixture was stirred for 3.5 hours. Then MeCN (50.0 ml) was added. A precipitate had formed and was filtered and washed with a mixture of MeCN with DMF (5 : 1 (v/v), 3 times with 10 ml each). The filtrates were combined and dried under vacuum at 45 °C to afford a dark red residue. The residue was dissolved in a mixture of DCM with MeOH (7 : 1 (v/v)) and purified by preparative silica gel TLC (DCM : MeOH = 7 : 1 (v/v), Rf = 0.15). The product was extrated from the silica gel by a mixture of acetone with water (20 : 1 (v/v), 5 times with 50 ml each), the combined extracts were dried under vacuum to afford the crude product as a red solid. The crude product was then mixed with acetonitrile (30 ml), the mixture was stirred at RT for 18 hours and was then 
<!-- EPO <DP n="97"/>-->
 filtered. The cake was mixed with acetonitrile (10 ml) and the mixture was stirred for 3 hours at RT. The mixture was then filtered. The cake was dried under vacuum at RT to afford 100.3 mg of compound of formula (21) as a red solid (12 % yield). 1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.85 (6H, dd, Jl = 11.8 Hz, J2 = 6.8 Hz), 1.13 (3H, d, J = 6.4 Hz), 1.34 to 1.68 (9H, m), 1.82 to 1.90 (1H, m), 1.90 (3H, s), 1.93 to 2.00 (1H, m), 2.13 to 2.24 (2H, m), 2.30 (2H, t, J = 7.2 Hz), 2.91 to 3.04 (6H, m), 3.10 to 3.15 (2H, m), 3.29 (2H, t, J = 6.0 Hz), 3.37 to 3.49 (11H, m), 3.59 (2H, t, J = 7.2 Hz), 3.68 to 3.76 (1H, m), 3.99 (3H, s), 4.13 to 4.19 (2H, m), 4.33 to 4.41 (3H, m), 4.58 (2H, d, J = 5.6 Hz), 4.71 (1H, d, J = 5.2 Hz), 4.86 (1H, t, J = 5.8 Hz), 4.95 (1H, brs), 5.02 (2H, s), 5.23 (1H, brs), 5.41 (2H, s), 5.46 (1H, brs), 5.99 (1H, t, J = 4.6 Hz), 6.87 (1H, d, J = 7.2 Hz), 7.00 (2H, s), 7.21 to 7.25 (3H, m), 7.66 (1H, t, J = 4.6 Hz), 8.11 (1H, d, J = 7.2 Hz), 9.97 (1H, s), 13.28 (1H, s), 14.04 (1H, s). ESI-MS: 1417.8 (M+H)+ Example 23 </p><p id="p0610" num="0610"> To a mixture of compound of formula (HSGH-III-2) (84.9 g, 5.0 eq.) and CHC1<sub>3</sub> (500 ml) was added a mixture of Boc<sub>2</sub>0 (50.0 g, 1.0 eq.) in CHC1<sub>3</sub> (200 ml) dropwise within 2 hours at room temperature. The resulting solution was stirred for 16 hours at RT. The resulting suspension was filtered and the wet cake was washed with DCM (50 ml). The filtrate was combined and evaporated to dryness to afford a colorless oil. The oil was then dissolved in DCM (200 ml), washed with water (300 ml) and dried over anhydrous Na<sub>2</sub>S0<sub>4</sub>. The resulting organic phase was then evaporated to dryness and the product purified by silica gel column chromatography (eluent DCM : MeOH = 20 : 1 to 5 : 1 (v/v)) to afford 13.0 g of compound of formula (Boc-HSGH-III-2) (33 % yield). 
<img id="imgf000097_0001" he="11" wi="92" file="imgf000097_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 1H MR (400 MHz, CDC1<sub>3</sub>, 20 °C) delta 1.32 (9H, s), 1.46-1.53 (4H, m), 2.64 (2H, t, J = 6.4 Hz), 3.06 to 3.09 (2H, m), 5.22 (1H, brs). </p><p id="p0611" num="0611">Example 24 
<!-- EPO <DP n="98"/>-->
 To a mixture of compound of formula (Boc-HSGH-III-2) (11.3 g), prepared according to example 23, K<sub>2</sub>C0<sub>3</sub> (18.0 g) and DCM (200 ml) at 0 °C was added a mixture of compound of formula (HSGHReac-1) with DCM (50 ml) dropwise within 40 min. The resulting mixture was then heated to RT and stirred for 2 hours. Then aqueous citric acid solution (% by weight, based on the weight of the solution, 180 ml) was added. The organic phase was separated and washed with saturated brine (100 ml), dried over anhydrous Na<sub>2</sub>S0<sub>4</sub> and then evaporated to dryness. The residue was then purified by silica gel column chromatography (eluent PE : EtOAc 2 : 1 to 1 : 1 to 1 : 2 (v/v)) to afford 13.9 g of compound of formula (SGM-III-2) as a white solid (89% yield). </p><p id="p0612" num="0612">1H MR (400 MHz, CDC1<sub>3</sub>, 20 °C) delta 1.46 (9H, s), 1.68 to 1.71 (2H, m), 3.20 (2H, q, J = 6.2 Hz), 3.39 (2H, q, J = 6.4 Hz), 4.07 (2H, s), 4.87 (1H, brs), 7.17 (1H, brs). </p><p id="p0613" num="0613">Example 25 </p><p id="p0614" num="0614">A mixture of compound of formula (6) (5.51 g, 1.0 eq.), prepared according to example 7, compound of formula (SGM-III-2) (6.02 g, 2.0 eq.), prepared according to example 24, K<sub>2</sub>C0<sub>3</sub> (3.31 g, 2.0 eq.), and anhydrous DMF (30 ml) was heated to 50 °C and stirred under nitrogen atmosphere for 7 days. Then the reaction mixture was concentrated to dryness under vacuum. MeOH (40 ml) was added to the residue, the resulting mixture was stirred for 10 min and then filtered. The wet cake was washed with methanol (3 times with 10 ml each). The filtrate was collected, combined and then concentrated. The residue was purified by silica gel column chromatography (eluent DCM : MeOH = 7 : 1 (v/v)) to afford 3.8 g of compound of formula (52-1) as a slightly yellow solid (46% yield). 1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.88 (6H, dd, Jl = 9.6 Hz, J2 = 6.8 Hz), 1.32 to 1.50 (2H, m), 1.52 to 1.82 (4H, m), 1.90 (3H, s), 1.92 to 1.97 (1H, m), 2.91 to 3.05 (4H, m), 3.17 to 3.22 (2H, m), 3.81 (3H, s), 4.13 (1H, t, J = 7.6 Hz), 4.33 to 4.39 (1H, m), 5.42 (2H, s), 5.98 (1H, t, J = 5.8 Hz), 6.80 (1H, t, J = 5.4 Hz), 7.45 (1H, dd, Jl = 8.6 Hz, J2 = 1.8 Hz), 7.50 (1H, d, J = 1.6 Hz), 7.80 (1H, d, J = 8.6 Hz), 8.02 to 8.05 (2H, m), 8.50 (1H, d, J = 11.6 Hz), 10.14 (1H, s). </p><p id="p0615" num="0615">ESI-MS: 580.5 (M-tBuOCO+2H)+, 680.4 (M+H)+, 1359.0 (2M+H)+ Example 26 
<!-- EPO <DP n="99"/>-->
 A mixture of compound of formula (52-1) (3.40 g), prepared according to example 25, and of a solution of 10% (w/w) HCl in 1,4-dioxane (50 ml) was stirred at RT for 15 hours. Then the reaction mixture was concentrated under vacuum to afford 3.20 g of compound of formula (52) as HCl salt, being a white solid (quantitative yield). The crude mixture was used directly in the next step. </p><p id="p0616" num="0616">Example 27 </p><p id="p0617" num="0617"> A mixture of compound of formula (52) as HCl salt (3.00 g, 1 eq.), prepared according to example 26, water (60 ml), CaCl<sub>2</sub> (1.09 g, 2.0 eq.) and NaBH<sub>4</sub> (0.75 g , 4.0 eq.) was stirred at RT. Further amount of NaBH<sub>4</sub> was added portionwise (0.75 g, 4.0 eq. after a total of 15 hours of stirring; 0.74 g, 4.0 eq. after a total of 19 hours of stirring; 0.74 g, 4.0 eq. after a total of 23 hours of stirring). After a total of 40 hours of stirring, MeOH (15 ml) was added to the mixture. The reaction mixture was then filtered and the wet cake was washed with MeOH (3 times with 10 ml each). The filtrate was collected and combined and then evaporated to dryness. The residue was purified by silica gel column chromatography (eluent DCM : MeOH : Et3N = 65 : 33 : 2 (v/v)) to afford 1.05 g of compound of formula (42) as a slightly yellow solid (39% yield). </p><p id="p0618" num="0618">1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.86 (6H, dd, Jl = 11.0 Hz, J2= 6.8 Hz), 1.30 to 1.46 (2H, m), 1.48 to 1.73 (4H, m), 1.89 (3H, s), 1.93 to 2.01 (1H, m), 2.56 (1H, t, J = 6.8 Hz), 2.91 to 3.06 (4H, m), 3.13 to 3.22 (2H, m), 4.16 to 4.20 (1H, m), 4.34 to 4.39 (1H, m), 4.46 (2H, s), 4.50 (2H, s), 5.45 (2H, s), 6.06 (1H, t, J = 5.6 Hz), 7.22 to 7.27 (3H, m), 7.94 (1H, d, J = 8.4 Hz), 8.16 to 8.19 (2H, m), 9.96 (1H, s). ESI-MS: 534.2 (M-OH) +, 552.2 (M+H)+ </p><p id="p0619" num="0619">Example 28 </p><p id="p0620" num="0620"> Compound of formula (42) (940.4 mg, 1.0 eq.), prepared according to example 27, compound of formula (CGlMR-IV-1) (501.2 mg, 1.1 eq.), prepared according to example 8, and DMF (10 ml) were mixed. Then DIPEA (247.0 mg, 1.1 eq.) was added at RT. The resulting mixture was stirred at RT for 4 h. Then DMF was removed under vacuum to get a slightly yellow residue. The residue was then mixed with acetone (20 ml) and the resulting mixture was stirred at RT for 2 hours. Then the mixture was filtered, the wet cake was washed with 
<!-- EPO <DP n="100"/>-->
 acetone (3 times with 5 ml each) and then dried under vacuum to afford 950.0 mg of compound of formula (32) as a slightly yellow solid (79% yield). </p><p id="p0621" num="0621">1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.86 (6H, dd, Jl = 11.2 Hz, J2= 6.8 Hz), 1.34 to 1.46 (2H, m), 1.47 to 1.73 (4H, m), 1.89 (3H, s), 1.94 to 2.01 (IH, m), 2.32 (2H, t, J = 7.6 Hz), 2.92 to 3.05 (4H, m), 3.10 to 3.15 (2H, m), 3.60 (2H, t, J = 7.2 Hz), 4.17 to 4.20 (IH, m), 4.34 to 4.42 (IH, m), 4.46 (2H, s), 4.52 (2H, s), 5.08 (IH, brs), 5.42 (2H, s), 5.99 (IH, t, J = 5.6 Hz), 7.00 (2H, s), 7.21 (IH, s), 7.25 (2H, s), 7.90 (IH, d, J = 8.4 Hz), 7.95 (IH, t, J = 5.6 Hz), 8.05 (IH, t, J = 5.6 Hz), 8.11 (IH, d, J = 7.6 Hz), 9.92 (IH, s). </p><p id="p0622" num="0622">Example 29 </p><p id="p0623" num="0623"> A mixture of compound of formula (32) (402.5 mg, 1.0 eq.), prepared according to example 28, 4 angstrom molecular sieves (800.0 mg), anhydrous DMF (8.0 ml) and compound of formula (II- 1 ) (347.3 mg, 2.0 eq.) was stirred for 5 min. Then DIPEA (297.7 mg, 4.0 eq.) was added. The resulting mixture was stirred for 5 h at RT. Then compound of formula (DOXO) as HC1 salt (332.2 mg, 1.0 eq.) was added and the mixture was then stirred for 4 hours. Then MeCN (40.0 ml) was added. A precipitate had formed and was filtered and washed with a mixture of MeCN and DMF (5 : 1 (v/v), 2 times with 5 ml each). The filtrate was combined and dried under vacuum at 45 °C to get a dark red residue. The residue was dissolved in a mixture of DCM and MeOH (7 : 1 (v/v)) and purified by preparative silica gel TLC (DCM : MeOH = 7 : 1 (v/v), Rf = 0.15). The product was extrated from the silica gel by a mixture of acetone and water (20 : 1 (v/v), 5 times with 50 ml each), the combined extraction solutions were dried under vacuum to afford the crude product as a red solid. The crude product was then mixed with acetonitrile (20 ml), the mixture was stirred at RT for 2 hours and then filtered. The cake was dried under vacuum at RT to afford 74.0 mg of compound of formula (22) as a red solid (10 % yield). </p><p id="p0624" num="0624">1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.84 (6H, dd, Jl = 10.8 Hz, J2 = 6.8 Hz), 1.13 (3H, d, J = 6.4 Hz), 1.30 to 1.49 (5H, m), 1.56 to 1.69 (2H, m), 1.81 to 1.88 (4H, m), 1.93 to 1.98 (IH, m), 2.13 to 2.25 (2H, m), 2.28 (2H, t, J = 7.2 Hz), 2.92 to 3.07 (8H, m), 3.45 (IH, brs), 3.56 (2H, t, J = 7.2 Hz), 3.73 (IH, brs), 3.99 (3H, s), 4.15 to 4.19 (2H, m), 4.35 to 4.38 (IH, m), 4.41 (2H, s), 4.58 (2H, d, J = 5.8 Hz), 4.71 (IH, d, J = 5.6 Hz), 4.85 (IH, t, J = 6.0 Hz), 4.94 (IH, brs), 5.03 (2H, s), 5.22 (IH, brs), 5.42 (2H, s), 5.47 (IH, brs), 6.02 (IH, t, J = 
<!-- EPO <DP n="101"/>-->
4.6 Hz), 6.87 (1H, d, J = 8.0 Hz), 6.97 (2H, s), 7.22 to 7.25 (3H, m), 7.65 (1H, t, J = 4.8 Hz), 7.88 to 7.90 (5H, m), 8.11 (1H, d, J = 7.6 Hz), 9.98 (1H, s), 13.27 (1H, s), 14.02 (1H, s). </p><p id="p0625" num="0625">ESI-MS: 1271.9 (M+H)+, 1294.4 (M+Na) + </p><p id="p0626" num="0626">Exame 30 </p><p id="p0627" num="0627"> To a mixture of compound of formula (HSGH-II-2) (21.24 g, 1.0 eq) and Et<sub>3</sub>N (21.03 g, 1.1 eq.) in MeOH (100 mL) at 0 °C, a solution of Boc<sub>2</sub>0 (43.83 g, 1.1 eq.) in MeOH (50 ml) was added dropwise within 1 hours. The mixture was then warmed to RT and stirred for 24 hours. The resulting mixture was then evaporated to dryness under vacuum to afford 43.05 g of compound of formula (Boc-HSGH-II-2) as a yellow oil (quantitive yield) . 
<img id="imgf000101_0001" he="9" wi="109" file="imgf000101_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 1H NMR (400 MHz, CDC1<sub>3</sub>, 20 °C) delta 1.30 to 1.43 (4H, m), 1.45 (9H, s), 1.48 to 1.61 (4H, m), 1.70 (1H, brs), 3.12 (2H, q, J = 6.8 Hz), 3.64 (2H, t, J = 6.8 Hz), 4.57 (1H, brs). </p><p id="p0628" num="0628">Example 31 </p><p id="p0629" num="0629"> To a mixture of compound of formula (Boc-HSGH-II-2) (20.02 g, 1.0 eq.), prepared according example 30, pyridine (8.02 g, 1.1 eq.) and dichloromethane (50 mL) at 0 °C, a mixture of TsCl (19.33 g, 1.1 eq.) in dichloromethane (75 mL) dropwise within 2 hours. The resulting mixture was stirred at RT for 7 days. The solution was then evaporated to dryness. The residue was washed with a mixture solvent (PE : EtOAc = 6: 1 (v/v), 4 times with 100 ml each) and filtered. The filtrate was combined then evaporated to dryness. The crude product was further purified by silica gel column chromatography (PE : EtOAc = 6: 1 (v/v)) to afford 14.20 of compound of formula (SGM-II-2) as a white solid (41% yield). 
<img id="imgf000101_0002" he="9" wi="98" file="imgf000101_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0630" num="0630">1H NMR (400 MHz, CDC1<sub>3</sub>, 20 °C) delat 1.22 to 1.37 (4H, m), 1.39 tol .47 (11H, ms), 1.62 to 1.68 (2H, m), 2.46 (3H, s), 3.07 (2H, t, J = 6.6 Hz), 4.02 (2H, t, J = 6.4 Hz), 4.52 (1H, brs), 7.36 (2H, d, J = 8.0 Hz), 7.78 to 7.82 (2H, m). 
<!-- EPO <DP n="102"/>-->
 Example 32 </p><p id="p0631" num="0631"> A mixture of compound formula (6) (9.31 g, 1.0 eq.), prepared according to example 7, compound of formula (SGM-II-2), prepared according to example 31 (14.90 g, 2.0 eq.), K<sub>2</sub>CO<sub>3</sub> (5.65 g, 2.0 eq.) and anhydrous DMF (60 mL) was heated to 50 °C and stirred for under N<sub>2</sub> atomsphere 9 days. The reaction mixture was evaporated to dryness. To this residue MeOH (40 mL) was added and, the resulting mixture was stirred for 10 min then filtered, the cake was further washed with MeOH (3 times with 15 ml each). The filtrate was combined and evaporated to dryness. The residue was purified by silica gel column chromatography to afford 6.35 g of compound of fomula (53-1) as a slight yellow solid (48 % yield). </p><p id="p0632" num="0632">1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.86 (6H, dd, Ji = 12.0 Hz, J<sub>2</sub> = 6.8 Hz), 1.24 to 1.33 (2H, m), 1.35 to 1.48 (15H, m), 1.56 to 1.76 (4H, m), 1.89 (3H, s), 1.92 to 2.01 (1H, m), 2.89 to 3.05 (4H, m), 3.75 (3H, s), 3.97 (2H, t, J = 6.2 Hz), 4.17 to 4.21 (1H, m), 4.34 to 4.39 (1H, m), 5.41 (2H, s), 5.99 (1H, t, J = 5.8 Hz), 6.77 (1H, t, J = 5.2 Hz), 7.24 (1H, dd, Ji = 8.6 Hz, h = 1.8 Hz), 7.47 to 7.48 (1H, m), 7.67 (1H, d, J = 8.6 Hz), 7.90 (1H, d, J = 8.6 Hz), 8.18 (1H, d, J = 7.4 Hz),10.17 (1H, s). </p><p id="p0633" num="0633">ESI-MS: 565.0 (M-<sup>i</sup>BuOCO+2H)<sup>+</sup> , 664.8 (M+H)<sup>+</sup> , 1329.1 (2M+H)<sup>+</sup> </p><p id="p0634" num="0634">Example 33 </p><p id="p0635" num="0635"> Compound of fomula (53-1) (8.10 g ), prepared according to example 32, and a solution of 10% (w/w) HC1 in 1,4-dioxane (50 ml) were mixed. The mixture was stirred at RT for 1.5 hours. The solvent was removed under vacuum to afford 9.00 g of compound of formula (53) as HC1 salt, being a white solid (quantitative yield). </p><p id="p0636" num="0636">Example 34 </p><p id="p0637" num="0637"> To a mixture of compound of fomula (53) as HC1 salt (4.01 g, 1.0 eq.), prepared according to example 33, and anhydrous THF (40 mL) at -30 °C was added a solution of DIBAL-H in hexanes (1M, 51.1 ml, 8.1 eq). The resulting mixture was then heated to 0 °C and stirred under nitrogen atmosphere for 2.5 hours then warmed to RT naturally and stirred for 16 hours. The mixture as then cooled to 0 °C. Methanol (10 mL) was added. Then saturated potassium sodium tartarate (100 ml) aqueous solution was added to the mixture and the mixture was stirred for 1 hour at RT. The resulting mixture was evaporated to dryness to generate a white 
<!-- EPO <DP n="103"/>-->
 residue which was mixed with methanol (60 ml) and stirred for 1 hour. The resulting suspension was filterd, the cake was further washed with methanol (3 times with 30 ml each). The combined filtrate was concentrated and purified by silica gel column chromatography (DCM : Methanol : Et<sub>3</sub>N = 66 : 32 :2 (v/v)) to afford 1.81 g of compound of formula (43) as a white solid (53% yield). </p><p id="p0638" num="0638">1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.86 (6H, dd, Ji = 10.4 Hz, J<sub>2</sub> = 6.8 Hz), 1.31 to 1.46 (8H, m), 1.55 to 1.74 (4H, m), 1.90 (3H, s), 1.94 to 2.02 (1H, m), 2.60 (2H, t, J = 6.8 Hz), 2.91 to 3.05 (2H, m), 3.92 (2H, t, J = 6.4 Hz), 4.16 to 4.20 (1H, m), 4.34 to 4.39 (1H, m), 4.44 (2H, s), 5.43 (2H, s), 6.07 (1H, t, J = 5.6 Hz), 7.14 to 7.17 (1H, m), 7.25 (1H, d, J = 8.0 Hz), 7.32 (1H, d, J = 2.0 Hz), 7.94 (1H, d, J = 8.4 Hz), 8.13 (1H, d, J = 7.6 Hz), 9.90 (1H, s). </p><p id="p0639" num="0639">ESI-MS: 519.9 (M-OH<sup>"</sup>)<sup>+</sup> , 538.0 (M+H)<sup>+</sup> , 1129.5 (2M+H)<sup>+</sup> Example 35 </p><p id="p0640" num="0640"> A mixture of compound of formula (43) (1.13 g, 1.0 eq), prepared according to example 34, maleice anhydride (207.3 mg, 1.1 eq), and DMF (10 mL) was stirred at RT for 20 h. To the resulting solution was added compound of fomula (HOSu) (225.1 mg, 1.0 eq) and EDC (in its mono hydrogen chloride form) (745.0 mg, 2.0 eq). The resulting mixture was further stirred at RT for 4 days. The mixture was evaporated to dryness then mixted with acetone (30 ml). The resulting mixture was stirried at RT for 20 h then filtered. The cake was furhter washed with acetone (3 times with 15 ml each) and then dried under vacuum to afford 1.10 g of compound of formula (33) as a slightly yellow solid (90% yield). 1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.86 (6H, dd, Ji = 10.2 Hz, J<sub>2</sub> = 6.8 Hz), 1.26 to 1.55 (8H, m), 1.59 to 1.78 (4H, m), 1.90 (3H, s), 1.93 to 2.02 (1H, m), 2.95 to 3.06 (2H, m), 3.41 (2H, t, J = 7.0 Hz), 3.89 (2H, t, J = 6.2 Hz), 4.16 to 4.20 (1H, m), 4.34 to 4.40 (1H, m), 4.43 (2H, s), 5.42 (2H, brs), 6.05 (1H, brs), 7.00 (2H, s), 7.15 to 7.18 (1H, m), 7.24 to 7.29 (2H, m), 7.93 (1H, d, J = 8.4 Hz), 8.11 (1H, d, J = 7.6 Hz), 9.87 (1H, s). </p><p id="p0641" num="0641">ESI-MS: 599.6 (M-OH<sup>"</sup>)<sup>+</sup> , 639.8 (M+Na)<sup>+</sup> Example 36 
<!-- EPO <DP n="104"/>-->
 A mixture of compound of formula (33) (50.2 mg, 1.0 eq), parpared according to example 35, 4 angstrom molecular sieves (100.0 mg), anhydrous DMF (1.0 ml) and compound of formula (II- 1 ) (37.0 mg, 1.6 eq) was stirred at RT for 5 min. Then DIPEA (46.5 mg, 4.4 eq) was added. The resulting mixture was stirred at RT for 3.5 hours. Then compound of formula (DOXO) as HC1 salt (37.8 mg, 0.86 eq) was added and the mixture was then stirred for 4.5 hours. Then MeCN (5.0 ml) was added. A precipitate had formed and was filtered and washed with a mixture of MeCN and DMF (5: l(v/v), 2 times with 1 ml each). The filtrate was combined and dried under vacuum at 45 °C to get a dard redidue. The residue was dissolved in the mixture of DCM and MeOH (10: 1, v/v, 3 ml) and purified by preparative silica gel TLC (DCM: </p><p id="p0642" num="0642">MeOH = 7: 1, (v/v), Rf = 0.35). The product was extracted from the silica gel by a mixture of acetone and water (20: 1, v/v, 6 times with 3 ml each). The combined extraction solutions were dried under vacuum to afford the crude product as a red solid. The curde product was then mixed with acetonitrile (5 ml), the mixture was stirred at RT for 2 hours and then filtered. The cake was washed with acetonitrile (2 times with 1 ml each) then dried under vacuum at 25 °C to afford 9.0 mg of compound of formula (23) as a red solid (9 % yield). </p><p id="p0643" num="0643">1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.84 (6H, dd, Ji = 10.2 Hz, J<sub>2</sub> = 6.8 Hz), 1.13 (3H, d, J = 6.4 Hz), 1.19 to 1.23 (2H, m), 1.35 to 1.50 (7H, m), 1.56 to 1.68 (4H, m), 1.81 to 1.86 (1H, m), 1.88 (3H, s), 1.91 to 2.01 (1H, m), 2.11 to 2.23 (2H, m), 2.91 to 3.01 (4H, m), 3.32 (2H, t, J = 6.8 Hz), 3.45 to 3.47 (1H, m), 3.69 to 3.74 (1H, m), 3.98 (3H, s), 4.15 to 4.19 (2H, m), 4.32 to 4.37 (1H, m), 4.58 (2H, d, J = 5.8 Hz), 4.66 (2H, d, J = 6.8 Hz), 4.82 to 4.93 (4H, m), 5.23 (1H, brs), 5.39 (2H, s), 5.46 (1H, brs), 5.96 (1H, t, J = 5.6 Hz), 6.74 (1H, d, J = 8.0 Hz), 6.93 (2H, s), 7.10 to 7.18 (2H, m), 7.31 (1H, brs), 7.62 to 7.65 (1H, m), 7.89 to 7.90 (3H, m), 8.09 (1H, d, J = 7.4 Hz), 9.88 (1H, s), 13.26 (1H, s), 14.02 (1H, s). </p><p id="p0644" num="0644">ESI-MS: 1185.8 (M+H)<sup>+</sup> , 1208.4 (M+Na)<sup>+</sup> Example 37 </p><p id="p0645" num="0645"> A mixture of Z-L-Val (1.47 g, 0.95 eq), anhydrous DMF (15 ml), TBTU (2.97 g, 1.5 eq) and DIPEA (2.00 g, 2.5 eq) was stirred at RT for 15 min. To the resulting mixture was added compound of fomula (6-3) as HC1 salt (2.23 g, 1.0 eq), prepared according to exmaple 4. The mixture was further stirred at RT for 14 hours then evaporated to dryness at 45 °C. Water (150 ml) was then added, the resulting mixture was extracted with EtOAc (3 times with 200 ml each). The combined organic phase was washed with 250 ml saturated brine then dried over 
<!-- EPO <DP n="105"/>-->
 anhydrous Na<sub>2</sub>S0<sub>4</sub>. The resulting solution was concerntrated then purified by silica gel column chromatography) (PE: EA = 1 :2 to DCM : MeOH = 10: 1 (v/v)) to afford 2.92 g of compound of formula (6-5) as a white solid (85%) yield. 1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.87 (6H, dd, Ji = 17.6 Hz, J<sub>2</sub> = 6.8 Hz), 1.36 to 1.50 (2H, m), 1.58 to 1.74 (2H, m), 1.94 to 2.02 (1H, m), 2.91 to 3.08 (2H, m), 3.87 (3H, s), 3.90 to 3.96 (1H, m), 4.37 to 4.43 (1H, m), 5.04 (2H, s), 5.43 (2H, s), 5.99 (1H, t, J = 5.6 Hz), 7.10 (1H, dd, Ji = 8.8 Hz, J<sub>2</sub> = 2.0 Hz), 7.30 to 7.37 (6H, m), 7.41 (1H, d, J = 2.0 Hz), 7.74 (1H, d, J = 8.8 Hz), 8.19 (1H, d, J = 7.2 Hz), 10.32 (1H, s), 10.62 (1H, s). </p><p id="p0646" num="0646">ESI-MS: 557.6 (M+H)<sup>+</sup> , 579.9 (M+Na)<sup>+</sup>, 1114.8 (2M+H)<sup>+</sup> , 1136.5 (2M+Na)<sup>+</sup> Example 38 </p><p id="p0647" num="0647"> A mixture of compound of formula (6-5) (20.00 g, 1.0 eq), prepared according to example 37, K<sub>2</sub>CC"3 (9.91 g, 2.0 eq) and anhydrous DMF (80 ml). The resulting mixture was heated to 50 °C and stirred for 0.5 hour. Compound of formula (SGM-II-1) (25.79 g, 2.0 eq), prepared according to example 10, was added to the reaction mixture in 4 portions within 2 hours. The reaction mixture was stirred at 50 °C for 3 days then evaporated to dryness at 45 °C. The residue was washed with MeOH (4 times with 20 ml each). The filtrate was combined then concentrated into dryness. The residue was further purified by silica gel column </p><p id="p0648" num="0648">chromatography (DCM : MeOH = 20 : 1, v/v) to afford 22.17 g of compound of formula (54- 1) as a white solid ( 83% yield). </p><p id="p0649" num="0649">1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.87 (6H, dd, Ji = 17.6 Hz, J<sub>2</sub> = 6.8 Hz), 1.36 to 1.49 (11H, m), 1.59 to 1.73 (2H, m), 1.96 to 2.03 (1H, m), 2.92 to 3.14 (4H, m), 3.50 (2H, t, J = 6.0 Hz), 3.74 to 3.76 (5H, m), 3.93 to 3.97 (1H, m), 4.08 (2H, t, J= 4.6 Hz), 4.39 to 4.44 (1H, m), 5.05 (2H, s), 5.42 (2H, s), 5.98 (1H, t, J = 5.6 Hz), 6.73 (1H, t, J = 5.4 Hz), 7.25 (1H, dd, Ji = 8.6 Hz, J<sub>2</sub> = 1.56 Hz), 7.30 to 7.36 (6H, m), 7.48 (1H, s), 7.69 (1H, d, J = 8.6 Hz), 8.15 (1H, d, J = 7.2 Hz), 10.28 (1H, s). </p><p id="p0650" num="0650">ESI-MS: 745.0 (M+H)<sup>+</sup> , 1488.8 (2M+H)<sup>+</sup>, 645.3 (M-<sup>i</sup>BuOCO+2H)<sup>+</sup> </p><p id="p0651" num="0651">Example 39 
<!-- EPO <DP n="106"/>-->
 A mixture of compound of formula (54-1) (4.80 g, 1.0 eq), prepared according to example 38, methanol (200 ml) and Pd/C (5%, 0.24 g) was degased for three times then stirred under H<sub>2</sub> atmosphere (6 bar) at 30 °C for 18 hours. The resulting mixture was filtered, the filtrate was concentrated to dryness under vacuum to afford 3.96 g of compound of formula (54-2) as a white solid (quantitative yield.) </p><p id="p0652" num="0652">1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.81 (3H, d, J = 6.8 Hz), 0.90 (3H, d, J = 6.8 Hz), 1.36 to 1.49 (11H, m), 1.58 to 1.78 (2H, m), 1.91 to 1.99 (1H, m), 2.92 to 3.12 (5H, m),</p><p id="p0653" num="0653">3.50 (2H, t, J = 6.0 Hz), 3.75 to 3.77 (5H, m), 4.09 (2H, t, J = 4.8 Hz), 4.47 (1H, s), 5.45 (2H, s), 6.07 (1H, t, J = 5.6 Hz), 6.72 (1H, t, J = 5.2 Hz), 7.24 (1H, dd, Ji = 8.6 Hz, J<sub>2</sub> = 1.6 Hz),</p><p id="p0654" num="0654">7.51 (1H, d, J= 1.4 Hz), 7.69 (1H, d, J = 8.6 Hz), 8.24 (1H, d, J = 8.6 Hz), 10.42 (1H, s). </p><p id="p0655" num="0655">ESI-MS: 611.8 (M+H)<sup>+</sup> , 1221.4 (2M+Na)<sup>+</sup>, 512.0 (M-<sup>i</sup>BuOCO+2H)<sup>+</sup> Example 40 </p><p id="p0656" num="0656"> A mixture of N, N-dimethylglycine (0.48 g, 1.0 eq), DMF (15 ml) and TBTU (3.01 g, 2.0 eq) was cooled to 0 °C. The resulting mixture was then stirred for 15 min followed by addition of compound of formula (54-2) (2.86 g, 1.0 eq), prepared according to example 39. The mixture was then warmed to RT naturally and further stirred for 18 hours. The resulting mixture was then evaporated to dryness. The resulting residue was purified by silica gel column chromatography (DCM : MeOH = 7 : 1, (v/v)) to afford 2.78 g of compound of formula (54- 3) as a white solid (85% yield). </p><p id="p0657" num="0657">1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.82 (3H, d, J = 6.8 Hz), 0.89 (3H, d, J = 6.8 Hz), 1.36 to 1.49 (11H, m), 1.56 to 1.75 (sH, m), 1.98 to 2.06 (1H, m), 2.33 (6H, s), 2.92 to 3.04 (2H, m), 3.06 to 3.11 (4H, m), 3.50 (2H, t, J = 6.0 Hz), 3.74 to 3.77 (5H, m), 4.09 (2H, t, J = 4.6 Hz), 4.30 to 4.34 (1H, m), 4.36 to 4.41 (1H, m), 5.43 (2H, s), 6.01 (1H, t, J = 5.8 Hz), 6.73 (1H, t, J = 5.2 Hz), 7.25 (1H, dd, Ji = 8.6 Hz, J<sub>2</sub> = 1.8 Hz), 7.28 to 7.32 (1H, m), 7.35 to 7.39 (1H, m), 7.46 (1H, d, J = 1.6 Hz), 7.55 (1H, d, J = 8.4 Hz), 7.68 (1H, d, J = 8.6 Hz), 7.82 (1H, d, J = 9.0 Hz), 7.85 to 7.87 (1H, m), 8.38 (1H, d, J = 7.2 Hz), 10.30 (1H, s). </p><p id="p0658" num="0658">ESI-MS: 696.2 (M+H)<sup>+</sup> , 1391.1(2M+H)<sup>+</sup>, 596.3 (M-<sup>i</sup>BuOCO+2H)<sup>+</sup> </p><p id="p0659" num="0659">Example 41 
<!-- EPO <DP n="107"/>-->
 A mixture of compound of formula (54-3), prepared according to example 40, and a solution of 10% (w/w) HC1 in 1,4-dioxane (50 ml) was stirred at RT for 18 hours. The solvent was removed under vacuum to afford 5.60 g of compound of formula (54) as di-HCl salt, being a white solid (quantitative yield). </p><p id="p0660" num="0660">ESI-MS: 596.4 (M+H)<sup>+</sup> , 1191.3 (2M+H)<sup>+</sup> Example 42 </p><p id="p0661" num="0661"> To a mixture of compound of formula (54) as di-HCl salt (1.00 g, 1.0 eq), prepared according to example 41 and anhydrous THF (15 ml) was at 0 °C was added a solution of DIBAL-H in hexanes (1 M, 10 ml, 6.7 eq). The resulting mixture was further at 0 °C for 1.5 hours. Then methanol (10 ml) was added dropwise. Then saturated potassium sodiu tartarate aqueous solution (30 mL) was added and stirred at RT for 1 hour. The resulting mixture was evaporated to dryness. The resulting residue was washed with MeOH (3 times with 10 ml each). The combined filtrate was concentrated then purified by silica gel column </p><p id="p0662" num="0662">chromatography (DCM : MeOH : Et<sub>3</sub>N = 65 : 33 :2 (v/v)) to afford 0.43 g of compound of formula (44) as a white solid (yield 51%). </p><p id="p0663" num="0663">1H MR (400 MHz, DMSO-d<sub>6</sub>, 60 °C) delta 0.82 (3H, d, J = 6.8 Hz), 0.87 (3H, d, J = 6.8 Hz), 1.32 to 1.50 (2H, m), 1.55 to 1.74 (2H, m), 1.97 to 2.06 (1H, m), 2.23 (6H, s), 2.73 (2H, t, J = 5.6 Hz), 2.91 (2H, brs), 2.93 to 3.06 (2H, m), 3.50 (2H, t, J = 5.6 Hz), 3.75 (2H, t, J = 4.6 Hz), 4.05 to 4.07 (2H, m), 4.29 to 4.33 (1H, m), 4.35 to 4.40 (1H, m), 4.45 (2H, s), 5.41 (2H, s), 6.02 (1H, t, J = 5.6 Hz), 7.15 (1H, dd, Ji = 8.4 Hz, J<sub>2</sub>= 1.6 Hz), 7.26 (1H, d, J = 8.0 Hz), 7.31 (1H, d, J = 1.6 Hz), 7.63 (1H, d, J = 9.2 Hz), 8.31 (1H, d, J = 7.4 Hz), 9.97 (1H, s). </p><p id="p0664" num="0664">ESI-MS: 550.3((M-OH<sup>"</sup>)<sup>+</sup>, 568.2 (M+H)<sup>+</sup> , 1134.7 (2M+H)<sup>+</sup> Example 43 </p><p id="p0665" num="0665"> To a mixture of compound of formula (44) (1.10 g , 1.0 eq), prepared according to example 42, compound of formula (CGlMR-IV-1) (0.57 g, 1.1 eq), prepared according to example 8, and DMF (4.0 ml) at RT, DIPEA (0.28 g, 1.1 eq) was added. The resulting mixture was stirred at RT for 18 hours. Then the DMF was removed under vacuum to afford a slightly yellow residue which was then mixed with acetone (20 ml) and stirred at RT for 18 hours. 
<!-- EPO <DP n="108"/>-->
 The mixture was filtered, the cake was washed with acetone (2 times with 5 ml each), then dried under vacuum to afford 1.1 1 g of compound of formula (34) (80% yield). </p><p id="p0666" num="0666">1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.82 (3H, d, J = 6.8 Hz), 0.88 (3H, d, J = 6.8 Hz), 1.34 to 1.46 (2H, m), 1.55 to 1.73 (2H, m), 1.97 to 2.05 (1H, m), 2.25 (6H, s), 2.34 (2H, t, J = 7.0 Hz), 2.95 to 3.06 (4H, m), 3.17 to 3.21 (2H, m), 3.46 (2H, t, J = 5.8 Hz), 3.60 (2H, t, J = 7.2 Hz), 3.73 (2H, t, J = 4.4 Hz), 4.03 (2H, t, J = 4.4 Hz), 4.29 to 4.33 (1H, m), 4.35 to 4.40 (1H, m), 4.45 (2H, s), 4.86 (1H, brs), 5.41 (2H, s), 5.99 (1H, t, J = 5.6 Hz), 7.00 (2H, s), 7.14 to 7.16 (1H, m), 7.26 to 7.30 (2H, m), 7.67 (1H, d, J = 9.2 Hz), 8.03 (1H, t, J = 5.2 Hz), 8.30 (1H, d, J = 7.4 Hz), 9.95 (1H, s). </p><p id="p0667" num="0667">ESI-MS: 701.3(M-OH<sup>"</sup>)<sup>+</sup>, 719.2 (M+H)<sup>+</sup> , 1436.7 (2M+H)<sup>+</sup> </p><p id="p0668" num="0668">Example 44 </p><p id="p0669" num="0669">A mixture of compound of formula (II- 1 ) (169.4 mg, 2.0 eq), anhydrous DMF (4.0 ml) and 4 angstrom molecular sieves (400.0 mg) was stirred at RT for 15 min. To the resulting mixture was added DIPEA (107.9 mg, 3.0 eq.) and compound of formula (34), (200.0 mg, 1.0 eq), prepared according to example 43. The resulting mixture was further stirred for 2.5 hours. Then compound of formula (DOXO) as HC1 salt (161.8 mg, 1.0 eq) was added and further stirred for 2 hours. Then MeCN (20 ml) was added. A precipitate had formed and was filtered and washed with a mixture of MeCN and DMF (5 : 1 (v/v), 3 times with 3 ml each). The filtrates were combined and dried under vacuum at 48 °C. The resulting residue was dissolved in a mixture of DCM and MeOH (5 : 1 (v/v), 5 ml) and purified by preparative silica gel TLC (DCM : MeOH = 4: 1 (v/v), Rf = 0.5). The product was extracted from the silica-gel by a mixture of acetone and water (7 : 1 (v/v), 6 times with 10 ml each). The combined extraction solutions were dried under vacuum to afford a crude product as a red solid. The crude product was then mixed with acetonitrile (5 mL), stirred at RT for 2 hours then filtered. The wet cake was dried under vacuum at RT to afford 7.0 mg of compound of fomula (24) as a red solid (2 % yield.) </p><p id="p0670" num="0670">1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.80 (3H, d, J = 6.8 Hz), 0.86 (3H, d, J = 6.6 Hz), 1.13 (3H, d, J = 6.4 Hz), 1.32 to 1.52 (3H, m), 1.57 to 1.69 (2H, m), 1.82 to 1.88 (1H, m), 1.95 to 2.04 (1H, m), 2.10 to 2.18 (2H, m), 2.24 (6H, s), 2.29 (2H, t, J = 7.4 Hz), 2.92 to 3.02 (6H, m), 3.12 to 3.16 (2H, m), 3.41 (2H, t, J = 5.6 Hz), 3.45 (1H, brs), 3.55 (2H, t, J = 7.2 
<!-- EPO <DP n="109"/>-->
 Hz), 3.69 to 3.74 (3H, m), 3.99 (3H, s), 4.03 (2H, brs), 4.13 to 4.17 (1H, m), 4.28 to 4.31 (1H, m), 4.33 to 4.38 (1H, m), 4.58 (2H, d, J = 5.2 Hz), 4.69 (1H, d, J = 5.6 Hz), 4.86 (1H, t, J = 6.0 Hz), 4.90 (1H, s), 4.95 (1H, t, J = 4.4 Hz), 5.23 (1H, brs), 5.40 (2H, s), 5.47 (1H, s), 6.00 (1H, t, J = 5.6 Hz), 6.79 (1H, d, J = 8.0 Hz), 6.95 (2H, s), 7.12 (1H, d, J = 8.2 Hz), 7.19 (1H, d, J = 8.2 Hz), 7.34 (1H, s), 7.64 to 7.68 (2H, m), 7.91 (2H, d, J = 4.8 Hz), 7.98 (1H, t, J = 5.2 Hz), 8.30 (1H, d, J = 7.2 Hz), 10.02 (1H, s), 13.27 (1H, s), 14.02 (1H, s). </p><p id="p0671" num="0671">ESI-MS: 1288.3 (M+H)<sup>+</sup> Example 45 </p><p id="p0672" num="0672"> A mixture of compound of formula (VII-1) (26.10 g, 1.5 eq), prepared according to example 1, THF (150 ml), Boc-L-Lys(Ac)-OH (30.00 g, l .Oeq) and EEDQ (51.45 g, 2.0 eq) was stirred at RT for 24 hours. The mixture was then evaporated to dryness. The residue was purified by silica gel column chromatography (PE : EtOAc = 2 : 1 (v/v) to pure EtOAc) to afford 26.00 g of compound of formula (6b-4) as a slightly yellow solid (57 % yield). </p><p id="p0673" num="0673">1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 1.21 to 1.34 (4H, m), 1.38 (9H, s), 1.58 to 1.66 (2H, m), 1.77 (3H, s), 3.00 to 3.04 (2H, m), 3.87 (3H, s), 3.99 to 4.07 (1H, m), 7.08 to 7.11 (2H, m), 7.40 (1H, d, J = 2.0 Hz), 7.74 (1H, d, J = 8.8 Hz), 7.78 to 7.81 (1H, m), 10.20 (1H, s), 10.62 (1H, s). </p><p id="p0674" num="0674">ESI-MS: 437.9 (M+H)<sup>+</sup> , 460.3 (M+Na)<sup>+</sup>, 875.1 (2M+H)<sup>+</sup> , 896.9 (2M+Na)<sup>+</sup>, 338.1(M- <sup>i</sup>BuOCO+2H)<sup>+</sup> Example 46 </p><p id="p0675" num="0675"> Compound of formula (6b-4) (26.00 g), prepared according to example 45, was suspended in a solution of 10% (w/w) HC1 in 1,4-dioxane (150 ml), the resulting mixture was stirred at RT for 3 hours. The reaction mixture was then concentrated under vacuum to afford 22.05 g of compound of formula (6b-3) as HC1 salt, being a yellow solid (quantitative yield). </p><p id="p0676" num="0676">ESI-MS: 339.2 (M+H) <sup>+</sup> </p><p id="p0677" num="0677">Example 47 
<!-- EPO <DP n="110"/>-->
 A mixture of compound of formula (6b-3) as HC1 salt (25.21g, 1.0 eq), prepared according to example 46, Boc-L-Val-OH (13.25 g, 1.0 eq), TBTU (23.66 g, 1.1 eq), DIPEA (19.05 g, 2.2eq) and DMF (100 ml) was stirrd at RT for 18 hours. The resulting mixture was evaporated to dryness then purified by silica gel chromatography (DCM : MeOH = 10 : 1 to 7 : 1, (v/v)) to afford 30.80 g of compound of formula (6b-2) as a slightly yellow solid (90% yield). </p><p id="p0678" num="0678">1H MR (400 MHz, CDC1<sub>3</sub>, 20 °C) delta 1.39 to 1.46 (14H, m), 1.49 to 1.56 (2H, m), 1.74 to 1.83 (1H, m), 1.95 to 2.02 (4H, m), 3.17 to 3.30 (2H, m), 3.92 (3H, s), 4.17 to 4.22 (1H, m), 4.54 to 4.60 (1H, m), 5.53 (1H, brs), 6.32 (1H, brs), 7.15 (1H, d, J = 8.0 Hz), 7.31 (1H, brs), 7.38 (1H, s), 7.72 (1H, dd, Ji = 8.8 Hz, J<sub>2</sub> = 1.0 Hz), 9.38 (1H, brs), 10.80 (1H, s). </p><p id="p0679" num="0679">ESI-MS: 509.3 (M+H)<sup>+</sup> , 1017.0 (2M+H)<sup>+</sup> , 1038.8 (2M+Na)<sup>+</sup>, 409.5 (M-<sup>i</sup>BuOCO+2H)<sup>+</sup> </p><p id="p0680" num="0680">Example 48 </p><p id="p0681" num="0681">Compound of formula (6b-2) (30.80 g), prepared according to example 47, was suspended in a solution of 10% (w/w) HC1 in 1,4-dioxane (150 ml), the resulting mixture was stirred at RT for 23 hours. The reaction mixture was then concentrated under vacuum to afford 25.90 g of compound of formula (6b-l) as HC1 salt, being a white solid (96 % yield). ESI-MS: 409.0 (M+H) <sup>+</sup> </p><p id="p0682" num="0682">Example 49 </p><p id="p0683" num="0683"> A mixture of compound of formula (6b-l) as HC1 salt (15.32 g, 1.0 eq), prepared according to example 48, methanol (100 ml), pyridine (9.0 ml, 3.2 eq) and acetic anhydride (14.0 ml, 4.3 eq) was stirred at RT for 60 hours. The resulting mixture was evaporated to dryness under vacuum. The residue was purified by silica gel column chromatography (DCM : MeOH = 15 : 1 to 7 : 1, (v/v)) to afford 12.51 g of compound of formula (6b) as a slightly yellow solid (80 % yield). 1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 1.21 (3H, d, J = 7.0 Hz), 1.29 to 1.38 (4H, m), 1.61 to 1.74 (2H, m), 1.78 (3H, s), 1.86 (3H, s), 2.99 to 3.04 (2H, m), 3.87 (3H, s), 4.27 to 4.34 (2H, m), 7.14 (1H, d, J = 8.8 Hz), 7.42 (1H, brs), 7.73 (1H, d, J = 8.6 Hz), 7.81 (1H, t, J = 5.2 Hz), 8.09 (1H, d, J = 7.0 Hz), 10.18 (1H, s), 10.62 (1H, s). 
<!-- EPO <DP n="111"/>-->
 ESI-MS: 451.3 (M+H)<sup>+</sup> , 473.6 (M+Na)<sup>+</sup>, 900.9 (2M+H)<sup>+</sup> , 923.1 (2M+Na)<sup>+</sup> </p><p id="p0684" num="0684">Example 50 </p><p id="p0685" num="0685"> A mixture of compound of formula (6b) (6.73 g, 1.0 eq), prepared according to example 49, compound of formula (SGM-II-1) (11.50 g, 2.1 eq), prepared according to example 10, K<sub>2</sub>CO<sub>3</sub> (4.40 g, 2.1 eq.) and anhydrous DMF (60 ml) was heated to 0 °C and stirred under nitrogen atmosphere for 8 days. The resulting mixture was evaporated to dryness, the residue was washed with MeOH (3 times with 15 ml each). The filtrates were combined and evaporated to dryness. The residue was purified by silica gel solumn chromatography (DCM : MeOH = 15 : 1 to 7 : 1, (v/v))to afford 7.64 g of compound of formula (55-1) as a white solid (81 % yield). </p><p id="p0686" num="0686">1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 1.21 (3H, d, J = 7.2 Hz), 1.25 to 1.40 (13H, m), 1.59 to 1.74 (2H, m), 1.78 (3H, s), 1.87 (3H, s), 2.99 to 3.04 (2H, m), 3.08 to 3.12 (2H, m), 3.50 (2H, t, J = 6.0 Hz), 3.75 to 3.77 (5H, m), 4.09 (2H, t, J = 4.6 Hz), 4.24 to 4.34 (2H, m), 6.74 (1H, t, J = 5.4 Hz), 7.28 (1H, dd, Ji = 8.6 Hz, J<sub>2</sub> = 1.6 Hz), 7.51 (1H, d, J = 1.6 Hz), 7.69 (1H, d, J = 8.6 Hz), 7.81 (1H, t, J = 5.2 Hz), 8.08 to 8.13 (2H, m), 10.14 (1H, s). </p><p id="p0687" num="0687">ESI-MS: 638.2 (M+H)<sup>+</sup> , 660.4 (M+Na)<sup>+</sup>, 1275.0 (2M+H)<sup>+</sup> , 538.4 (M-<sup>i</sup>BuOCO+2H)<sup>+</sup> </p><p id="p0688" num="0688">Example 51 </p><p id="p0689" num="0689"> Compound of formula (55-1) (7.60 g), prepared according to example 50, was suspended in 10% (w/w) HC1 in 1,4-dioxane (50 ml), the resulting mixture was stirred at RT for 5 hours. The reaction mixture was then concentrated under vacuum to afford 6.72 g of compound of formula (55) as HC1 salt, being a white solid (98 % yield). </p><p id="p0690" num="0690">ESI-MS: 538.5 (M+H)<sup>+</sup> , 1074.8 (2M+ H)<sup>+</sup> , 1097.0 (2M+Na)<sup>+</sup> </p><p id="p0691" num="0691">Example 52 </p><p id="p0692" num="0692">To a mixture of compound of fomula (55) as HC1 salt (6.00 g, 1.0 eq.), prepared according to example 51, and anhydrous THF (50 mL) at 0 °C was added a solution of DIBAL-H in hexanes (1M, 63.0 ml, 6.0 eq). The resulting mixture was then heated to 0 °C and stirred under nitrogen atmosphere for 6 hours. Then methanol (10 mL) was added. After that, saturated potassium sodium tartarate (150 ml) aqueous solution was added to the mixture and 
<!-- EPO <DP n="112"/>-->
 the mixture was stirred at RT for 15 hours. The resulting mixture was evaporated to dryness to generate a white residue which was further washed with methanol (3 times with 50 ml each). The filtrates were combined then concentrated, and purified by silica gel column chromatography (DCM : Methanol : Et<sub>3</sub>N = 75 : 25 :2 (v/v)) to afford 3.27 g of compound of formula (45) as a white solid (61% yield). </p><p id="p0693" num="0693">1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 1.22 (3H, d, J = 4.4 Hz), 1.27 to 1.41 (4H, m), 1.62 to 1.78 (2H, m), 1.79 (3H, s), 1.88 (3H, s), 2.68 (2H, t, J = 5.6 Hz), 2.99 to 3.03 (2H, m), 3.46 (2H, t, J = 5.6 Hz), 3.73 (2H, t, J = 4.4 Hz), 4.04 (2H, t, J = 4.4 Hz), 4.21 to 4.38 (2H, m), 4.45 (2H, s), 5.36 (1H, s), 7.22 to 7.28 (2H, m), 7.40 (1H, s), 8.00 (1H, t, J = 5.4 Hz), 8.16 (1H, d, J = 8.0 Hz), 8.27 (1H, d, J = 6.8 Hz), 10.05 (1H, s). </p><p id="p0694" num="0694">ESI-MS: 510.5 (M+H)<sup>+</sup> , 1019.6 (2M+H)<sup>+</sup> , 492.6 (M-OH<sup>"</sup>)<sup>+</sup> Example 53 </p><p id="p0695" num="0695"> To a mixture of compound of formula (45) (1.20 g , 1.0 eq), prepared according to example 52, compound of formula (CGlMR-IV-1) (0.69 g, 1.1 eq), prepared according to example 8, and DMF (25 ml) at RT, DIPEA (0.34 g, 1.1 eq) was added. The resulting mixture was stirred at RT for 2 hours. Then the DMF was removed under vacuum to afford a slightly yellow residue which was then mixed with acetone (50 ml) and stirred at RT for 1 hour. The mixture was filtered, the cake was washed with acetone (2 times with 10 ml each), then dried under vacuum to afford 1.12 g of compound of formula (35) (72% yield). </p><p id="p0696" num="0696">1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 1.20 (3H, d, J = 7.2 Hz), 1.24 to 1.40 (4H, m), 1.58 to 1.75 (2H, m), 1.78 (3H, s), 1.87 (3H, s), 2.33 (2H, t, J = 7.2 Hz), 2.98 to 3.03 (2H, m), 3.16 to 3.21 (2H, m), 3.46 (2H, t, J = 5.8 Hz), 3.60 (2H, t, J = 7.2 Hz), 3.72 to 3.75 (2H, m), 4.04 (2H, t, J = 4.4 Hz), 4.24 to 4.36 (2H, m), 4.44 (2H, d, J = 5.6 Hz), 4.86 (1H, t, J = 5.6 Hz), 7.00 (2H, s), 7.16 to 7.18 (1H, m), 7.26 to 7.28 (1H, m), 7.34 (1H, d, J = 1.4 Hz), 7.80 (1H, t, J = 5.4 Hz), 7.99 (1H, d, J = 8.0 Hz), 8.03 (1H, t, J = 5.4 Hz), 8.10 (1H, d, J = 6.8 Hz), 9.79 (1H, s). </p><p id="p0697" num="0697">ESI-MS: 661.5 (M+H)<sup>+</sup> , 643.6 (M-OH<sup>"</sup>)<sup>+</sup> </p><p id="p0698" num="0698">Example 54 
<!-- EPO <DP n="113"/>-->
 A mixture of compound of formula (35) (400.0 mg, 1.0 eq), parpared according to example 53, 4 angstrom molecular sieves (800.0 mg), anhydrous DMF (4.0 ml) and compound of foluma (II-l) (373.0 mg, 2.0 eq) was stirred at RT for 5 min. Then DIPEA (313.5 mg, 4.0 eq) was added. The resulting mixture was stirred at RT for 5 hours. Then compound of formula (DOXO) as HC1 salt (328.0 mg, 0.9 eq) was added and the mixture was then stirred for 4 hours. Then MeCN (20 ml) was added. A precipitate had formed and was filtered and washed with a mixture of MeCN and DMF (5 : 1 (v/v), 2 times with 10 ml each). The filtrate was combined and dried under vacuum at 45 °C to get a dard redidue. The residue was dissolved in the mixture of DCM and MeOH (7 : 1, v/v, 5 ml) and purified by preparative silica gel TLC (DCM: MeOH = 7: 1, (v/v), Rf = 0.15). The product was extracted from the silica gel by a mixture of acetone and water (20: 1, v/v, 10 times with 20 ml each). The combined extraction solutions were dried under vacuum to afford the crude product as a red solid. The curde product was then mixed with acetonitrile (10 ml), the mixture was stirred at RT for 0.5 hour and then filtered. The cake was washed with acetonitrile (5 ml) then dried under vacuum at RT to afford 100.7 mg of compound of formula (25) as a red solid (13 % yield). </p><p id="p0699" num="0699">1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) δ 1.13 (3H, d, J = 6.4 Hz), 1.20 (3H, d, J = 7.2 Hz), 1.24 to 1.38 (4H, m), 1.48 to 1.51 (1H, m), 1.59 to 1.73 (2H, m), 1.77 (3H, s), 1.82 to 1.86 (4H, m), 2.12 to 2.23 (2H, m), 2.29 (2H, t, J = 7.2 Hz), 2.89 to 3.02 (4H, m), 3.11 to 3.15 (2H, m), 3.41 (2H, t, J = 5.6 Hz), 3.46 (1H, brs), 3.54 (2H, t, J = 7.2 Hz), 3.68 to 3.76 (3H, m), 3.98 (3H, s), 4.03 (2H, brs), 4.14 to 4.18 (1H, m), 4.22 to 4.34 (2H, m), 4.58 (2H, d, J = 5.2 Hz), 4.70 (1H, d, J = 5.8 Hz), 4.85 to 4.92 (4H, m), 5.22 (1H, brs), 5.46 (1H, s), 6.81 (1H, d, J = 8.0 Hz), 6.95 (2H, s), 7.14 to 7.20 (2H, m), 7.39 (1H, s), 7.61 to 7.64 (1H, m), 7.82 (1H, t, J = 5.2 Hz), 7.88 to 7.91 (2H, m), 7.98 to 8.03 (2H, m), 8.12 (1H, d, J = 6.8 Hz), 9.89 (1H, s), 13.24 (1H, s), 14.00 (1H, s). </p><p id="p0700" num="0700">ESI-MS: 1252.1 (M+Na) <sup>+</sup> Example 55 </p><p id="p0701" num="0701">Compound of formula (6-1) as HC1 salt (22.81 g, 1.0 eq.), prepared according to example 6, 2- [2-(2-Methoxyethoxy)ethoxy] acetic acid (8.00 g, 0.9 eq.), purchased from Aldrich, TBTU (24.00 g, 1.5 eq), and DIPEA (16.00 g, ) were dissolved in DMF (100 ml). The resulting solution was stirred at RT for 20 h. The reaction mixture was concentrated to dryness, the 
<!-- EPO <DP n="114"/>-->
 residue was then purified by silica gel chromatography (eluent DCM : MeOH = 10 : 1 to 7 : 1 (v/v)) to afford 12.02 g of compound of formula (6c) as a slightly yellow solid (41 % yield). </p><p id="p0702" num="0702">1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.86 (6H, dd, Ji = 24.4 Hz, J<sub>2</sub> = 6.8 Hz), 1.37 (9H, s), 1.39 to 1.52 (2H, m), 1.56 to 1.75 (4H, m), 1.97 to 2.06 (1H, m), 2.91 to 3.07 (4H, m), 3.19 to 3.22 (2H, m), 3.42 to 3.47 (2H, m), 3.52 to 3.64 (6H, m), 3.81 (3H, s), 3.95 (2H, brs), 4.30 to 4.34 (1H, m), 4.36 to 4.41 (1H, m), 4.53 (2H, s), 5.43 (2H, s), 6.01 (1H, t, J = 5.8 Hz), 6.78 (1H, t, J = 5.2 Hz), 7.34 to 7.40 (2H, m), 7.45 (1H, d, J = 8.8 Hz), 7.79 (1H, d, J = 8.4 Hz), 8.04 (1H, t, J = 5.6 Hz), 8.38 (1H, d, J = 7.2 Hz), 10.36 (1H, s). </p><p id="p0703" num="0703">ESI-MS: 584.7 (M+H) <sup>+</sup>, 1167.2 (2M+H)<sup>+</sup> Example 56 </p><p id="p0704" num="0704"> A mixture of compound of formula (6c) (8.01 g, 1.0 eq.), prepared according to example 55, compound of formula (SGM-III-2) (6.89 g, 2.0 eq.), prepared according to example 24,</p><p id="p0705" num="0705">K<sub>2</sub>CO<sub>3</sub> (3.80 g, 2.0 eq.), and anhydrous DMF (60 ml) was heated to 50 °C and stirred under nitrogen atmosphere for 7 days. Then the reaction mixture was concentrated to dryness under vacuum. Dichloromethane (15 ml) was added to the residue, the resulting mixture was purified by silica gel column chromatography (eluent DCM : MeOH = 7 : 1 (v/v)) to afford 5.52 g of compound of formula (56-1) as a slightly yellow solid (50% yield). </p><p id="p0706" num="0706">1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) δ 0.86 (6H, dd, Ji = 24.4 Hz, J<sub>2</sub> = 6.8 Hz), 1.37 (9H, s), 1.39 to 1.52 (2H, m), 1.56 to 1.75 (4H, m), 1.97 to 2.06 (1H, m), 2.91 to 3.07 (4H, m), 3.19 to 3.22 (2H, m), 3.42 to 3.47 (2H, m), 3.52 to 3.64 (6H, m), 3.81 (3H, s), 3.95 (2H, brs), 4.30 to 4.34 (1H, m), 4.36 to 4.41 (1H, m), 4.53 (2H, s), 5.43 (2H, s), 6.01 (1H, t, J = 5.8 Hz), 6.78 (1H, t, J = 5.2 Hz), 7.34 to 7.40 (2H, m), 7.45 (1H, d, J = 8.8 Hz), 7.79 (1H, d, J = 8.4 Hz), 8.04 (1H, t, J = 5.6 Hz), 8.38 (1H, d, J = 7.2 Hz), 10.36 (1H, s). </p><p id="p0707" num="0707">ESI-MS: 698.7 (M-<sup>i</sup>BuOCO+2H)<sup>+</sup> , 798.3 (M+H)<sup>+</sup> , 820.7 (M+Na)<sup>+</sup>, 1595.7 (2M+H)<sup>+</sup> </p><p id="p0708" num="0708">Example 57 </p><p id="p0709" num="0709"> Compound of formula of (56-1), prepared according to example 56, was suspended in 10% (w/w) HC1 in 1,4-dioxane (60 ml). The resulting mixture was stirred at RT for 8 hours then 
<!-- EPO <DP n="115"/>-->
 concentrated to afford 4.99 g of compound of formula (56) as a white solid (quantitative yield). </p><p id="p0710" num="0710">ESI-MS: 698.4 (M+H)<sup>+</sup> , 1394.6 (2M+H)<sup>+</sup> </p><p id="p0711" num="0711">Example 58 </p><p id="p0712" num="0712"> A mixture of compound of formula (56) as HC1 salt (4.91 g, 1.0 eq.), prepared according to example 57, water (45 ml), CaCl<sub>2</sub> (1.49 g, 2.0 eq.) and NaBH<sub>4</sub> (1.02 g , 4.0 eq.) was stirred at RT. Further amount of NaBH<sub>4</sub> was added portionwise (1.02 g, 4.0 eq. after a total of 2.5 hours of stirring; 1.01 g, 4.0 eq. after a total of 4 hours of stirring; 1.03 g, 4.0 eq. after a total of 6 hours of stirring). After a total of 22 hours of stirring, MeOH (20 ml) was added to the mixture. The reaction mixture was then filtered and the wet cake was washed with MeOH (3 times with 15 ml each). The filtrate was collected and combined and then evaporated to dryness. The residue was purified by silica gel column chromatography (eluent DCM : MeOH : Et<sub>3</sub>N = 80 : 20 : 2.5 (v/v)) to afford 1.12 g of compound of formula (46) as a slightly yellow solid (25% yield). </p><p id="p0713" num="0713">1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) δ 0.86 (6H, dd, Ji = 22.8 Hz, J<sub>2</sub>= 6.8 Hz), 1.32 to 1.48 (4H, m), 1.51 to 1.73 (4H, m), 1.96 to 2.06 (1H, m), 2.58 (2H, t, J= 6.8 Hz), 2.91 to 3.06 (2H, m), 3.16 to 3.21 (2H, m), 3.22 (3H, s), 3.52 to 3.64 (8H, m), 3.95 (2H, brs), 4.29 to 4.33 (1H, m), 4.36 to 4.41 (2H, m), 4.46 (2H, s), 4.51 (2H, s), 5.44 (2H, s), 6.10 (1H, t, J = 5.6 Hz), 7.22 to 7.27 (3H, m), 7.48 (1H, d, J = 8.8 Hz), 8.19 (1H, t, J= 5.4 Hz), 8.34 (1H, d, J = 7.6 Hz), 10.05 (1H, s). ESI-MS: 652.4 (M-OH<sup>"</sup>)<sup>+</sup> , 670.4 (M+H)<sup>+</sup> , 1338.7 (2M+H)<sup>+</sup> Example 59 </p><p id="p0714" num="0714"> To a mixture of compound of formula (46) (250.7 mg , 1.0 eq), prepared according to example 58, compound of formula (CGlMR-IV-1) (103.1 g, 1.1 eq), prepared according to example 8, and DMF (4 ml) at RT, DIPEA (53.6 mg, 1.1 eq) was added. The resulting mixture was stirred at RT for 1 hour. Then the DMF was removed under vacuum to afford a slightly yellow residue which was then mixed with acetone (5 ml) and stirred at RT for 1 
<!-- EPO <DP n="116"/>-->
 hour. The mixture was filtered, the cake was washed with acetone (3 times with 3 ml each), then dried under vacuum to afford 253.7 g of compound of formula (36) (83% yield). </p><p id="p0715" num="0715">1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.85 (6H, dd, Ji = 23.0 Hz, J<sub>2</sub>= 6.8 Hz), 1.36 to 1.54 (4H, m), 1.58 to 1.72 (2H, m), 1.97 to 2.05 (1H, m), 2.32 (2H, t, J= 7.2 Hz), 2.92 to 3.05 (4H, m), 3.08 to 3.13 (2H, m), 3.22 (3H, s), 3.44 (2H, t, J = 4.8 Hz), 3.52 to 3.62 (8H, m), 3.95 (2H, s), 4.29 to 4.33 (1H, m), 4.35 to 4.40 (1H, m), 4.46 (2H, s), 4.52 (2H, d, J = 5.2 Hz), 5.08 (1H, t, J = 5.6 Hz), 5.42 (2H, s), 6.01 (1H, t, J = 5.2 Hz), 6.99 (2H, s), 7.20 to 7.27 (3H, m), 7.46 (1H, d, J = 8.8 Hz), 7.95 (1H, t, J= 5.4 Hz), 8.05 (1H, t, J= 5.8 Hz), 8.31 (1H, d, J = 7.6 Hz), 10.00 (1H, s). </p><p id="p0716" num="0716">ESI-MS: 803.4 (M-OH<sup>"</sup>)<sup>+</sup> , 821.1 (M+H)<sup>+</sup> , 1641.1 (2M+H)<sup>+</sup> </p><p id="p0717" num="0717">Example 60 </p><p id="p0718" num="0718">A mixture of compound of formula (36) (201.3 mg, 1.0 eq), parpared according to example 59, 4 angstrom molecular sieves (400.0 mg), anhydrous DMF (4.0 ml) and compound of foluma (II-l) (146.9 mg, 2.0 eq) was stirred at RT for 10 min. Then DIPEA (105.7 mg, 3.3 eq) was added. The resulting mixture was stirred at RT for 4.5 hours. Then compound of formula (DOXO) as HC1 salt (142.1 mg, 1.0 eq) was added and the mixture was then stirred for 2.5 hours. Then MeCN (20 ml) was added. A precipitate had formed and was filtered and washed with a mixture of MeCN and DMF (5 : 1 (v/v), 4 times with 4 ml each). The filtrate was combined and dried under vacuum at 45 °C to get a dard redidue. The residue was dissolved in the mixture of DCM and MeOH (7 : 1, v/v, 3 ml) and purified by preparative silica gel TLC (DCM: MeOH = 7: 1, (v/v), Rf = 0.3). The product was extracted from the silica gel by a mixture of acetone and water (10: 1, v/v, 6 times with 10 ml each). The combined extraction solutions were dried under vacuum to afford the crude product as a red solid. The curde product was then mixed with acetonitrile (5 ml), the mixture was stirred at RT for 2 hour and then filtered. The cake was washed with acetonitrile (2 times with 2 ml each) then dried under vacuum at RT to afford 33.2 mg of compound of formula (26) as a red solid (10 % yield). </p><p id="p0719" num="0719">1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.84 (6H, dd, Ji = 23.2 Hz, J<sub>2</sub> = 6.8 Hz), 1.13 (3H, d, J = 6.4 Hz), 1.30 to 1.70 (7H, m), 1.82 to 1.87 (4H, m), 1.97 to 2.04 (1H, m), 2.08 to 2.22 (2H, m), 2.28 (2H, t, J = 7.2 Hz), 2.91 to 3.09 (8H, m), 3.22 (3H, s), 3.42 to 3.46 (3H, m), 3.52 to 3.61 (8H, m), 3.70 to 3.76 (1H, m), 3.95 (2H, s), 3.99 (3H, s), 4.13 to 4.18 (2H, 
<!-- EPO <DP n="117"/>-->
 m), 4.28 to 4.32 (1H, m), 4.34 to 4.41 (3H, m), 4.58 (2H, d, J = 5.6 Hz), 4.70 (1H, d, J = 5.2 Hz), 4.85 (1H, t, J = 5.8 Hz), 4.94 (1H, brs), 5.03 (2H, s), 5.22 (1H, brs), 5.41 (2H, s), 5.46 (1H, brs), 5.99 (1H, t, J = 5.4 Hz), 6.86 (1H, d, J = 8.0 Hz), 6.97 (2H, s), 7.19-7.24 (3H, m), 7.44 (1H, d, J = 8.8 Hz), 7.65 (1H, t, J = 4.8 Hz), 7.85 to 7.91 (4H, m), 8.30 (1H, d, J = 7.2 Hz), 10.04 (1H, s), 13.26 (1H, s), 14.02 (1H, s). </p><p id="p0720" num="0720">ESI-MS: 1390.2 (M+H)<sup>+</sup> </p><p id="p0721" num="0721">Example 61 </p><p id="p0722" num="0722">A mixture of compound of formula (TAXO) (200.0 mg, 1.0 eq), 4 angstrom molecular sieves (100.0 mg), anhydrous DCM (4.0 ml) and compound of foluma (II-l) (146.9 mg, 2.0 eq) at 0 °C was stirred for 10 min. To the mixture was then added pyridine (28.1 mg, 1.5 eq). The resulting mixture was further stirred for 41 hours at 0 °C under N<sub>2</sub>. To the mixture was then added N,N'-Dimethyl-l,2-ethylenediamine (102.0 mg, 5.0 eq.) at 0 °C under N<sub>2</sub>. After stirred for 2 hours, the mixture was filtered. The cake was washed with dichloromehane (1 mL). The filtrate was combined then evaporated to dryness to give yellow residue. The residue was further purified by preparative silica gel TLC (DCM : MeOH = 7 : 1, (v/v)) to afford 220.0 mg of compound of formula (TAXO-tl-1) as a slightly yellow solid in 96% isolated yield. ESI-MS: 968.5 (M+Na) <sup>+</sup> </p><p id="p0723" num="0723">Example 62 </p><p id="p0724" num="0724"> A mixture of compound of formula (31) (252.0 mg, 1.2 eq), prepared according to example 21, compound of formula (II- 1 ) (136.0 mg, 1.8 eq), 4 angstrom molecular sieves (100.0 mg) and anhydrous DMF (1 ml) was stirred at RT for 10 min. Then DIPEA (80.1 mg, 2.5 eq) was added. The resulting mixture was stirred for 2 hours at RT. Then compound of formula (XXXX), prepared according to example 61, was added. The resulting mixture was stirred for 2 hours. The resulting suspension was filtered; the cake was further washed with DCM (3 times with 10 ml each). The filtrate was combined then evaporated to dryness at 35 °C. The resulting residue was mixed with DCM (30 ml) and stirred for 0.5 hour. The resulting suspension was filtered, the cake was further washed with DCM (2 times with 5 ml each). The filtrate was dried under vacuum at RT. The crude product was dissolved in the mixed solvent of CH<sub>2</sub>Cl<sub>2</sub>-MeOH (8 : 1, (v/v)) and further purified by preparative silica gel TLC (DCM : MeOH = 8 : 1, (v/v)). The product was extrated from the silia-gel by a mixture of THF-water 
<!-- EPO <DP n="118"/>-->
 (20: 1 (v/v), 6 times with 30 ml each), dried under vacuum to afford the crude product as a white solid. The crude product was then mixed with Et<sub>2</sub>0 (5 ml), stirred at 25 °C for 0.5 hour then filtered. The cake was washed with Et<sub>2</sub>0 (3 times with 5 ml each) then dried under vacuum at RT to afford 100.0 mg of compound of formula (21-TAXO-tl-l) as a white solid in 21 % isolated yield. </p><p id="p0725" num="0725">ESI-MS: 1842.1 (M+H) <sup>+</sup>, 1864.5 (M+Na) <sup>+</sup> </p><p id="p0726" num="0726">Comparative Example 1 </p><p id="p0727" num="0727">T a mixture of Boc-Cit-OH (1.00 g, 1.0 eq.), prepared according to example 2, EEDQ (1.35 g, 1.5 eq.) and THF (15 ml), p-amino benzoic acid methyl ester (0.82 g, 1.5 eq.) was added. The resulting mixture was stirred at RT for 14 hours. Then the solvent was removed under vacuum and the residue was purified by silica gel chromatography (eluent PE : EtOAc = 6 : 1 (v/v) then DCM : MeOH = 10 : 1 (v/v)) to afford 1.2 g of compound of formula (Comp-6-4) as a white solid (81 % yield). </p><p id="p0728" num="0728"><img id="imgf000118_0001" he="59" wi="100" file="imgf000118_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0729" num="0729">Analysis by silica gel TLC: eluent EtOAc (Rf = 0.35, UV254) </p><p id="p0730" num="0730">1H NMR (400 MHz, CDC1<sub>3</sub>, 20 °C) delta 1.28 to 1.45 (11H, m), 1.55 to 1.65 (2H, m), 2.91 to 3.08 (2H, m), 3.83 (3H, s), 4.09 to 4.14 (1H, m), 5.43 (2H, s), 5.99 (1H, t, J = 5.6 Hz), 7.10 (1H, d, J = 7.6 Hz), 7.75 to 7.77 (2H, m), 7.91 to 7.93 (2H, m), 10.32QH, s). ESI-MS: 309.3 (M-tBuOCO+2H)+, 409.2 (M+H)+, 817.1 (2M+H)+ 
<!-- EPO <DP n="119"/>-->
 Comparative Example 2 </p><p id="p0731" num="0731"> A mixture of compound of formula (Comp-6-4) (1.66 g), prepared according to comparative example 1, and of a solution of 15% (w/w) HC1 in 1,4-dioxane (10 ml) was stirred at RT for 3 hours. The reaction mixture was then concentrated under vacuum to afford 1.38 g of compound of formula (Comp-6-3) as HC1 salt, being a white solid (98 % yield). </p><p id="p0732" num="0732"><img id="imgf000119_0001" he="58" wi="115" file="imgf000119_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0733" num="0733">Comparative Example 3 </p><p id="p0734" num="0734"> To a mixture of compound of formula (Comp-6-3) as HC1 salt (14.50 g, 1.0 eq.), prepared according to comparative example 2, Boc-L-Val (10.05 g, 1.1 eq.), TBTU (27.00 g, 2.0 eq.) and DMF (80 ml) was added DIPEA (16.31 g, 3.0 eq.). The resulting mixture was stirred at RT for 16 hours. Then the mixture was diluted with water (120 ml), and then extracted with EtOAc (5 times with 100 ml each), the organic phases were combined and evaporated to dryness, the resulting residue was purified by silica gel column chromatography (eluent DCM : MeOH = 20 : 1 to 10 : 1 to 7 : 1 (v/v)) to afford 12.9 g of compound of formula (Comp-6-2) as a solid (60% yield). </p><p id="p0735" num="0735"><img id="imgf000119_0002" he="58" wi="119" file="imgf000119_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/><!-- EPO <DP n="120"/>-->
 1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.85 (6H, dd, Jl = 17.4 Hz, J2 = 6.6 Hz), 1.39 (9H, s), 1.43 to 1.50 (2H, m), 1.57 to 1.76 (2H, m), 1.91 to 1.97 (1H, m), 2.91 to 3.09 (2H, m), 3.83 (3H, s), 3.85 to 3.88 (1H, m), 4.43 to 4.48 (1H, m), 5.43 (2H, s), 5.99 (1H, t, J = 5.8 Hz), 6.72 (1H, d, J = 8.8 Hz), 7.73 to 7.76 (2H, m), 7.90 to 7.94 (2H, m), 8.07 (1H, d, J = 7.6 Hz), 10.39 (1H, s). </p><p id="p0736" num="0736">Comparative example 4 </p><p id="p0737" num="0737"> A mixture of compound of formula (Comp-6-2) (12.3 g), prepared according to comparative example 3, and of a solution of 10% (w/w) HC1 in dioxane (60 ml) was stirred at RT for 3 hours. The mixture was then concentrated under vacuum to afford 10.9 g of compound of formula (Comp-6-1) as HC1 salt, being a white solid (quantitative yield). </p><p id="p0738" num="0738"><img id="imgf000120_0001" he="58" wi="87" file="imgf000120_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0739" num="0739">Comparative Example 5 </p><p id="p0740" num="0740"> To a mixture of compound of formula (Comp-6-1) as HC1 salt (10.20 g, 1.0 eq.), prepared according to comparative example 4, and anhydrous THF (150 ml) at -20 °C was added a solution of DIBAL-H in hexanes (1 M, 120.0 ml, 6.2 eq.). The mixture was warmed to RT and stirred for 14 hours. Then MeOH (20 ml) was added, followed by a saturated aqueous potassium sodium tartrate solution (180 ml) was added and the mixture was stirred for 30 min at RT. The resulting mixture was evaporated to dryness to afford a white residue which was washed with MeOH (5 times with 50 ml each). The eluents were combined, concentrated and purified by silica gel column chromatography (eluent DCM : MeOH = 10: 1 to 7: 1 to 5: 1 (v/v)) to afford 5.10 g or compound of formula (Comp-10) as a white solid (58% yield). 
<!-- EPO <DP n="121"/>-->
</p><p id="p0741" num="0741"><img id="imgf000121_0001" he="51" wi="86" file="imgf000121_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0742" num="0742">1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.89 (6H, dd, Jl = 24.0 Hz, J2 = 6.8 Hz), 1.33 to 1.50 (2H, m), 1.56 to 1.77 (2H, m), 1.96 to 2.04 (1H, m), 2.92 to 3.07 (2H, m), 3.30 (1H, d, J = 5.2 Hz), 4.12 (2H, brs), 4.43 (2H, s), 4.47 to 4.52 (1H, m), 5.12 (1H, brs), 5.50 (2H, s), 6.10 (1H, t, J = 5.6 Hz), 7.24 (2H, d, J = 8.8 Hz), 7.54 to 7.57 (2H, m), 8.37 (1H, d, J = 5.8 Hz), 10.11 (1H, s). </p><p id="p0743" num="0743">ESI-MS: 380.4 (M+H)+, 759.2 (2M+H)+ </p><p id="p0744" num="0744">Comparative Example 6 </p><p id="p0745" num="0745"> To a mixture of compound of formula (Comp-10) (1.02 g, 1.0 eq.), prepared according to comparative example 5, compound of formula (CGlMR-IV-2) (0.92 g, 1.1 eq.) </p><p id="p0746" num="0746"><img id="imgf000121_0002" he="27" wi="153" file="imgf000121_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 and DMF (15 ml) at RT was added DIPEA (0.39 g, 1.1 eq.). The resulting mixture was stirred at RT for 16 hours. Then the DMF was removed under vacuum to afford a slightly yellow residue. The residue was then mixed with acetone (20 ml) and the mixture was then stirred at RT for 5 hours. The mixture was filtered, the wet cake was washed with acetone (2 times with 10 ml each) and then dried under vacuum to afford 1.05 g of compound of formula (Comp- 11) as a slightly yellow solid (67% yield). 
<!-- EPO <DP n="122"/>-->
</p><p id="p0747" num="0747"><img id="imgf000122_0001" he="53" wi="133" file="imgf000122_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0748" num="0748">1H NMR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.84 (6H, dd, Jl = 12.2 Hz, J2 = 6.6 Hz), 1.17 to 1.31 (2H, m), 1.37 to 1.75 (8H, m), 1.95 to 2.00 (1H, m), 2.11 to 2.21 (2H, m), 2.92 to 3.06 (2H, m), 3.38 (2H, t, J = 6.8 Hz), 4.18 to 4.22 (1H, m), 4.38 to 4.39 (1H, m), 4.43 (2H, d, J = 4.8 Hz), 5.09 (1H, t, J = 5.2 Hz), 5.41 (2H, s), 5.98 (1H, t, J = 5.6 Hz), 7.00 (2H, s), 7.23 (2H, d, J = 8.0 Hz), 7.55 (2H, d, J = 8.2 Hz), 7.81 (2H, d, J = 8.4 Hz), 8.06 (1H, d, J = 7.2 Hz), 9.90 (1H, s). Comparative example 7 </p><p id="p0749" num="0749"> A mixture of compound of formula (Comp-11) (350.0 mg, 1.0 eq.), prepared according to comparative example 6, DIPEA (307.0 mg, 3.9 eq.), 500.0 mg 4 angstrom molecular sieves and anhydrous DMF (5.0 ml) was stirred for 25 min. Then compound of formula (II- 1 ) (280.0 mg, 1.5 eq.) was added. The resulting mixture was stirred at RT for 3 hours. Then compound of formula (DOXO) as HC1 salt (368.8 mg, 1.0 eq.) was added and then the mixture was stirred for 12 hours. Then MeCN (25.0 ml) was added to the reaction mixture. A precipitate had formed and was filtered and washed with a mixture of MeCN and DMF (5 : 1 (v/v), 3 times with 5 ml each). The filtrates were combined and dried under vacuum at 45 °C to afford a dark red residue. The residue was dissolved in a mixture of DCM and MeOH (7 : 1 (v/v)) and purified by preparative silica gel TLC (DCM : MeOH = 7 : 1 (v/v), Rf = 0.15). The product was extracted from the silica gel by a mixture of acetone and water (20 : 1 (v/v), 10 times with 50 ml each), the combined extracts were dried under vacuum to afford the crude product as a red solid. The crude product was then mixed with acetonitrile (20 ml), the mixture was stirred at RT for 18 hours then filtered. The cake was mixed with acetonitrile (10 ml) and the mixture was stirred for 3 hours at RT. The mixture was then filtered. The cake was dried under vacuum at RT to afford 61.0 mg of compound of formula (Comp-12) as a red solid (8.7 % yield); 
<!-- EPO <DP n="123"/>-->
 in formula (Comp-12) doxorubicin is the compound of formula (DOXO), which is connected via the amino group denoted with (dl) in formula (Comp-12) and in formula (DOXO). </p><p id="p0750" num="0750"><img id="imgf000123_0001" he="58" wi="163" file="imgf000123_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0751" num="0751">1H MR (400 MHz, DMSO-d<sub>6</sub>, 20 °C) delta 0.85 (6H, dd, Jl = 12.0 Hz, J2 = 6.8 Hz), 1.12 (3H, d, J = 6.4 Hz), 1.16 to 1.22 (2H, m), 1.31 to 1.50 (7H, m), 1.54 to 1.71 (2H, m), 1.82 to 1.88 (1H, m), 1.91 to 2.01 (1H, m), 2.10 to 2.22 (4H, m), 2.89 to 3.03 (4H, m), 3.38 (2H, t, J = 6.8 Hz), 3.44 (1H, m), 3.71 to 3.75 (1H, m), 3.99 (3H, s), 4.16 to 4.20 (2H, m), 4.33 to 4.39 (1H, m), 4.58 (2H, d, J = 5.6 Hz), 4.71 (1H, d, J = 5.6 Hz), 4.86 (1H, t, J = 6.0 Hz), 4.89 (2H, s), 4.95 (1H, brs), 5.22 (1H, d, J = 2.8 Hz), 5.40 (2H, s), 5.47 (1H, s), 5.99 (1H, t, J = 4.8 Hz), 6.84 (1H, d, J = 8.0 Hz), 7.00 (2H, s), 7.24 (2H, d, J = 8.4 Hz), 7.55 (2H, d, J = 8.4 Hz), 7.66 (1H, t, J = 4.8 Hz), 7.80 (1H, d, J = 8.4 Hz), 7.92 (2H, d, J = 4.8 Hz), 8.06 (1H, d, J = 7.6 Hz), 9.97 (1H, s), 13.28 (1H, s), 14.04 (1H, s). </p><p id="p0752" num="0752">ESI-MS: 1141.7 (M+H)+ </p><p id="p0753" num="0753">Example 100 </p><p id="p0754" num="0754">General Method description for the preparation of compounds of formula (I) given in Table 1: </p><p id="p0755" num="0755"> To a 10 mM aqueous solution of N-acetyl-cysteine (2500 μΐ, 5 eq.) was added a 10 mM solution of the respective compound of formula (II) in N,N-dimethylacetamide (500 μΐ). The pH was adjusted to 7.5 with a 0.3 M sodium hydrogen phosphate solution, and the reaction mixture stirred for 2 h at 20 °C. The resulting respective solution of compound of formula (I) was used / tested without further purification. 
<!-- EPO <DP n="124"/>-->
 Details are given in Table (1) </p><p id="p0756" num="0756">Table 1 </p><p id="p0757" num="0757"> Example Compound of formula (II) Compound of formula (I)</p><p id="p0758" num="0758">100-1 Compound of formula (Comp-12), Compound of formula (Comp-13) prepared according to comparative example 7 </p><p id="p0759" num="0759"> 100-2 Compound of formula (23), Compound of formula (13) prepared according to example 36 </p><p id="p0760" num="0760"> 100-3 Compound of formula (20), Compound of formula (10) prepared according to example 15 </p><p id="p0761" num="0761"> 100-4 Compound of formula (21), Compound of formula (11) prepared according to example 22 </p><p id="p0762" num="0762"> 100-5 Compound of formula (22), Compound of formula (12) prepared according to example 29 </p><p id="p0763" num="0763"> 100-6 Compound of formula (25), Compound of formula (15) prepared according to example 54 </p><p id="p0764" num="0764"> 100-7 Compound of formula (26), Compound of formula (16) prepared according to example 60 </p><p id="p0765" num="0765"> 100-8 Compound of formula (24), Compound of formula (14) prepared according to example 44 
<!-- EPO <DP n="125"/>-->
</p><p id="p0766" num="0766"><img id="imgf000125_0001" he="42" wi="47" file="imgf000125_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0767" num="0767">Method RP-HPLC </p><p id="p0768" num="0768"> RP-HPLC analysis of the respective solution of compounds of formula (I), prepared according to example 100, was done with the following parameter: </p><p id="p0769" num="0769">Luna 5u C18 250 x 4.6 mm column (purchased form Phenomenex), solvent A: 0.1 % (v/v) TFA in water, solvent B: 0.1 % (v/v) TFA in acetonitrile, 100% solvent A for 10 min., gradient from 0 to 70% solvent B over next 70 min., and to 100% over next 3 min., 1 ml/min., detection at 254 nm. </p><p id="p0770" num="0770">RT = retention time </p><p id="p0771" num="0771">Values are given in Table 2 </p><p id="p0772" num="0772">Table 2 RT </p><p id="p0773" num="0773"> compound of formula (DOXO) 44.9 min. </p><p id="p0774" num="0774"> compound of formula (Comp-13) 54.5 min. </p><p id="p0775" num="0775"> compound of formula (13) 55.1 min. </p><p id="p0776" num="0776"> compound of formula (10) 51.2 min. </p><p id="p0777" num="0777"> compound of formula (11) 51.7 min. </p><p id="p0778" num="0778"> compound of formula (12) 50.7 min. 
<!-- EPO <DP n="126"/>-->
 compound of formula (15) 50.6 min. </p><p id="p0779" num="0779"> compound of formula (16) 52.2 min. </p><p id="p0780" num="0780"> compound of formula (14) 48.3 min. </p><p id="p0781" num="0781">Solubility test </p><p id="p0782" num="0782"> The respective solution of compound of formula (I) (15, 48 and 96 μΐ respectively), prepared according to example 100 were mixed with water (135, 102 and 54 μΐ respectively) to get a total of 150 μΐ of the respective three diluted solutions. These three diluted solutions have a concentration of 1.5%, 5.0% and 10.0% of DMA respectively, the % being % by volume, based on the total volume of the water in the respective solutions. These diluted solutions were stirred for 1 h at 20 °C and then analysed by Method RP-HPLC. </p><p id="p0783" num="0783">The solubility of the compounds of formula (I) was assessed by comparison of the peak areas (relative to the most soluble conjugate, namely compound of formula (11), the peak area of which was set to 100%, denoted with (*ref) in Table 3), values are given in Table 3 : </p><p id="p0784" num="0784"><img id="imgf000126_0001" he="76" wi="145" file="imgf000126_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0785" num="0785">The higher solubilities, especially at the more relevant low DMA concentration, of the compound of formula (I) compared to the reference linker compound of formula (Comp-13) provide two advantages: </p><p id="p0786" num="0786"> 1) A higher yield when compound of formula (I) is synthesized, thanks to reduced </p><p id="p0787" num="0787"> aggregation </p><p id="p0788" num="0788"> 2) Superior pharmacokinetic 
<!-- EPO <DP n="127"/>-->
 Cathepsin B release of compound of formula (DOXO) </p><p id="p0789" num="0789"> Bovine spleen cathepsin B (SAFC C6286-10UN, 10 units) was dissolved in 1 ml of a pH 5.0 aqueous acetate buffer (25 mM acetate and 1 mM EDTA) to procide for a cathepsin B stock solution. </p><p id="p0790" num="0790"> This cathepsin B stock solution (16 μΐ) was mixed with a aqueous solution of 30 mM dithiothreitol and 15 mM EDTA (32 μΐ) and the resulting solution was left to stand without stirring for 15 min. at 20 °C. Then an aqueous solution of 25 mM acetate and 1 mM EDTA (1175 μΐ), the respective solution of compound of formula (I) (142 μΐ, prepared according to example 100), N,N-dimethylacetamide (53.7 μΐ), and a 10 mM aqueous solution of daunorubicin as internal standard for assigning peaks based on retention time (157.7 μΐ) were added. The resulting solution was incubated for 2 days at 37 °C. Aliquots (100 μΐ) were periodically removed as given in Table 4 and analysed undiluted by Method RP-HPLC. The relative percentage of released compound of formula (DOXO) relative to respective compound of formula (I) during the experiment are given in Table 4: </p><p id="p0791" num="0791"><img id="imgf000127_0001" he="61" wi="145" file="imgf000127_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0792" num="0792">All compounds showed drug release in the presence of Cathepsin B. Stability in human serum </p><p id="p0793" num="0793"> To human serum (SAFC H4522, 950 μΐ) was added the respective solution of compound of formula (I) (950 μΐ, prepared according to example 100) and a 10 mM aqueous solution of daunorubicin as internal standard (100 μΐ). The resulting solution was incubated at 37 °C for 7 days. Aliquots (100 μΐ) were periodically removed as given in Table 4, diluted with 0 to 5 °C methanol (400 μΐ), filtered, and the resulting filtrate analyzed by Method RP-HPLC. 
<!-- EPO <DP n="128"/>-->
 Released compound of formula (DOXO) was quantified relative to the daunorubicin (the internal standard), values are given in Table 5: </p><p id="p0794" num="0794"><img id="imgf000128_0001" he="62" wi="156" file="imgf000128_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/>
 All branched linkers proved to have good stability. </p><p id="p0795" num="0795">Example 101 </p><p id="p0796" num="0796"> A compound of formula (12-101), derived from compound of formula (22) and monoclonal anti-interleukin-lb antibody was prepared as follows: </p><p id="p0797" num="0797">Monoclonal anti-interleukin-lb antibody produced in mouse (5 mg, Sigma article No 13642) was mixed in PBS (8.0 ml). </p><p id="p0798" num="0798"> To an aliquot of this solution (3 ml) was added a 1.0 mM aqueous solution of tris(2- carboxyethyl)phosphine hydrochloride (25 μΐ, 2.0 eq.) and the mixture was stirred for 90 min. at 20 °C. A 1.0 mM solution of compound of formula (22), prepared according to example 29, in N,N-dimethylacetamide (64.4 μΐ, 5.15 eq.) was added and the resulting mixture further stirred for 30 min at 20 °C. A 1.0 mM aqueous solution of N-acetyl-cysteine (64.4 μΐ, 5.15 eq.) was added and the resulting mixture further stirred for 36 min. at 20 °C to yield a so called conjugation mix. A NAP-25 column was rinsed with PBS (25 ml), loaded with the conjugation mix (2.5 ml) and eluted with PBS (5.0 ml). Fractions were collected and those that contained protein were pooled. The pooled protein solution, which comprised compound of formula (12-101), was analysed by Method SEC-HPLC (results are given in Table 6) and by Method HIC with the monoclonal anti-interleukin-lb antibody suspended in PBS. </p><p id="p0799" num="0799">Example 102 
<!-- EPO <DP n="129"/>-->
 A compound of formula (15-102), derived from compound of formula (25) and monoclonal anti-interleukin-lb antibody was prepared as follows: </p><p id="p0800" num="0800"> Monoclonal anti-interleukin-lb antibody produced in mouse (5 mg, Sigma article No 13642, as used in example 101) was mixed in PBS (8.0 ml). To an aliquot of this solution (3 ml) was added a 1.0 mM aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (25 μΐ, 2.0 eq.) and the mixture was stirred for 90 min. at 20 °C. A 1.0 mM solution of compound of formula (25), prepared according to example 54, in N,N-dimethylacetamide (64.4 μΐ, 5.15 eq.) was added and the mixture further stirred for 30 min. at 20 °C. A 1.0 mM aqueous solution of N-acetyl-cysteine (64.4 μΐ, 5.15 eq.) was added and the mixture further stirred for 42 min. at 20 °C to yield a so called conjugation mix. A NAP-25 column was rinsed with PBS (25 ml), loaded with the conjugation mix (2.5 ml) and eluted with PBS (5.0 ml). </p><p id="p0801" num="0801">Fractions were collected and those that contained protein were pooled. The pooled protein solution, which comprised compound of formula (15-102), was analysed by Method SEC- HPLC (results are given in Table 6) and by Method HIC with the monoclonal anti- interleukin-lb antibody suspended in PBS. </p><p id="p0802" num="0802">Method SEC-HPLC </p><p id="p0803" num="0803"> SEC-HPLC analysis of respective pooled protein solution was done with the following parameters: </p><p id="p0804" num="0804">TSK G3000SWXL 300 x 7.8 mm column (Silica based column with mean pore size of 250 Angstrom and mean particle size of 5 micrometer, purchased from Tosoh Bioscience), eluent 10% (v/v) isopropanol in 0.2 M potassium phosphate buffer, 0.5 ml/min., detection at 280 nm. RT = retention time </p><p id="p0805" num="0805"> The peak and therewith the retention time of the respective compound of formula (I) was identified by comparison with the unmodified Monoclonal anti-interleukin-lb antibody, which was used as substrate in the examples 101 and 102. </p><p id="p0806" num="0806">HMW = high molecular weight fraction, not assigned </p><p id="p0807" num="0807">LMW = low molecular weight fraction, not assigned </p><p id="p0808" num="0808">Table 6 RT purity HMW LMW</p><p id="p0809" num="0809">Monoclonal anti-interleukin-lb antibody 15.5 min. 92.1% 7.6% 0.3% as used in examples 101 and 102 </p><p id="p0810" num="0810"> Compound of formula (12-101), 15.6 min. 92.4% 7.5% 0.1% 
<!-- EPO <DP n="130"/>-->
 prepared according to example 101 </p><p id="p0811" num="0811"> Compound of formula (15-102), 15.6 min. 91.5% 8.4% 0.1% prepared according to example 102 </p><p id="p0812" num="0812">Method HIC </p><p id="p0813" num="0813"> HIC analysis of respective pooled protein solution was done with the following parameters: TSK-gel Butyl-NPR 4.6 mm x 35 mm column (NPR means non-porous resin, </p><p id="p0814" num="0814">polymethacrylate base material with mean particle size 2,5 micrometer, purchased from Tosoh Bioscience), solvent A: 50 mM sodium phosphate buffer, solvent B: 25% (v/v) isopropanol in 50 mM sodium phosphate buffer, gradient from 100% solvent A to 100% solvent B over 12 min., 0.8 ml/min, detection at 280 nm. FIG 1 shows the obtained chromatogram. </p><p id="p0815" num="0815">Legend of FIG 1 : </p><p id="p0816" num="0816"> Continuous line ^^^^— The monoclonal anti-interleukin-lb antibody used in examples </p><p id="p0817" num="0817"> 101 and 102 </p><p id="p0818" num="0818"> Dashed line —<sup>■</sup> —<sup>■</sup> —<sup>■</sup> Compound of formula (12-101), prepared according to example </p><p id="p0819" num="0819"> 101 </p><p id="p0820" num="0820"> Dotted line Compound of formula (15-102), prepared according to example </p><p id="p0821" num="0821"> 102 </p><p id="p0822" num="0822"> AU absorption unit 
</p></description><claims mxw-id="PCLM44727241" ref-ucid="WO-2012113847-A1" lang="EN" load-source="patent-office"><claim-statement><!-- EPO <DP n="131"/>-->Claims </claim-statement><claim id="clm-0001" num="1"><claim-text>1. A method (MI) for connecting a ligand LI with a drug DR, </claim-text><claim-text> LI is selected from the group consisting of amino acids LI-AA, mono- or polyclonal </claim-text><claim-text> antibodies LI-Ab, antibody fragments LI-AbFrag, proteins Ll-Prot and peptides Li-Pep; DR is a pharmaceutically active drug; characterized that a linker LIN is used to covalently connect LI with DR; LIN comprises a connecting group CG2; </claim-text><claim-text> CG2 is derived from o-hydroxy p-amino benzylic alcohol and is a connecting group of formula (CG2-1); </claim-text><claim-text><img id="imgf000131_0001" he="56" wi="82" file="imgf000131_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> denotes the connecting site which is used to connect LI; </claim-text><claim-text> denotes the connecting site which is used to connect DR; </claim-text><claim-text> ^****** denotes the connecting site to which a linear peptide is connected, said peptide has </claim-text><claim-text> 2 to 8 amino acid residues; </claim-text><claim-text>(4) denotes the p-amino group of the o-hydroxy p-amino benzylic alcohol from which </claim-text><claim-text> CG2 is derived. </claim-text></claim><claim id="clm-0002" num="2"><claim-text>2. Method (MI) according to claim 1, </claim-text><claim-text>wherein LI is covalently connected with DR in form of a compound of formula (I); <!-- EPO <DP n="132"/>--> CGI hSG -CG2— HT4 -CG3 -T2 DRRes </claim-text><claim-text> nl n2 n2 </claim-text><claim-text> Tl </claim-text><claim-text>LIRes</claim-text><claim-text> <img id="imgf000132_0001" he="19" wi="79" file="imgf000132_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> Rl ^ ) ^ R2 </claim-text><claim-text>CG2 is as defined in claim 1; is a connecting group selected from the group consisting of connecting group of formula (CGI -I), connecting group of formula (CGI -II), connecting group of formula (CGI -III) and connecting group of formula (CGI -IV); </claim-text><claim-text> <img id="imgf000132_0002" he="73" wi="105" file="imgf000132_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> (CGI -III) (CGI -IV) m30 and m32 are identical or different and independently from each other 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; (*) in the formulae of CGI denotes the bond between Tl and CGI, </claim-text><claim-text>the covalently connected LI forms in compound of formula (I) a ligand residue LIRes, which is covalently connected to CGI via Tl; </claim-text><claim-text>LI is a compound of formula (LIRes-Tl-H); <!-- EPO <DP n="133"/>--> LIRes Tl H (LIRes-H) </claim-text><claim-text>LIRes is selected from the group consisting of amino acid residue LIRes- AA, mono- or </claim-text><claim-text> polyclonal antibody residue LIRes-Ab, antibody fragment residue LIRes-AbFrag, protein residue LIRes-Prot and peptide residue LIRes-Pep; </claim-text><claim-text> LI has a functional group selected from the group consisting of SH, OH or NH<sub>2</sub>, which forms in formula (I) the Tl, the Tl is bonded to CGI via the bond (*); </claim-text><claim-text> Tl is -S-, -O- or - H-; nl is 0 or 1; </claim-text><claim-text>SG is a spacer group selected from the group consisting of spacer group of formula (SG-II) and spacer group of formula (SG-III); </claim-text><claim-text> <img id="imgf000133_0001" he="14" wi="112" file="imgf000133_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> \ (***\ </claim-text><claim-text> HN- -CH SGPEG CH -NH / </claim-text><claim-text> ml l ml m\2 (SG-III) </claim-text><claim-text> o ml and m2 are identical or different and independently from each other 0 or 1; </claim-text><claim-text>mlO, ml 1 and ml2 are identical or different and independently from each other 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; with the proviso, that m2 and mlO are not simultaneously 0; </claim-text><claim-text>with the proviso, that ml, mi l and ml2 are not simultaneously 0; </claim-text><claim-text>SGPEG is a connecting group of formula (SGPEG-I); <!-- EPO <DP n="134"/>--> CH<sub>2</sub> CH<sub>2</sub> O- <sup>~</sup>CH<sub>2</sub> CH<sub>2</sub> (SGPEG-I) m20 m20 is 1, 2, 3, 4, 5 or 6; n2 is 0 or 1; </claim-text><claim-text>T4 is -0-; </claim-text><claim-text>CG3 is selected from the group consisting of connecting group of formula (CG3-I) and </claim-text><claim-text> connecting group of formula (CG3-II); </claim-text><claim-text> <img id="imgf000134_0001" he="17" wi="68" file="imgf000134_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> <img id="imgf000134_0002" he="25" wi="111" file="imgf000134_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text>R5 and R6 are identical or different and independently from each other C<sub>1-4</sub> alkyl; for nl being 1, the (**) in the formulae of CGI and in the formulae of SG denote the bond </claim-text><claim-text> between to CGI and SG, and the (***) in the formula of SG and in the formula of CG2 denote the bond between SG and CG2; in case that CGI is a connecting group of formula (CGI -I), the nitrogen atom denoted with (**) in SG forms an endocyclic nitrogen atom, thereby replacing the hydrogen atom of said nitrogen atom by an endocyclic bond; for nl being 0, the (**) in the formulae of CGI and the (***) in the formula of CG2 denote the bond between CGI and CG2; <!-- EPO <DP n="135"/>--> with the proviso, that in case that nl is 0, then CGI is not a connecting group of formula (CGI- i); for n2 being 1, the (****) in the formula of CG2 and in the formula of CG3 denote the bonds, with which CG2 and CG3 are bonded to T4; and the (*****) i<sub>n</sub> the formula of CG3 denotes the bond between CG3 and T2; for n2 being 0, the (****) in the formula of CG2 denotes the bond between CG2 and T2; the (******) in the formula of CG2 denotes the bond between CG2 and AA<sup>n4</sup>; the covalently connected DR forms in compound of formula (I) a drug residue DRRes, which is covalently connected to CG2 via T2; </claim-text><claim-text>DR is a compound of formula (DRRes-T2-H); </claim-text><claim-text>H T2 DRRes (DRRes-T2-H) </claim-text><claim-text>DRRes is a drug residue derived from DR; DR has a functional group selected from the group consisting of -N(R4)H, -OH or -SH, which forms in formula (I) the T2; </claim-text><claim-text>T2 is -N(R4)-, -O- or -S-; </claim-text><claim-text>R4 is H or C alkyl; n3 is 2, 3, 4, 5, 6, 7 or 8; </claim-text><claim-text>n4 is an integer from 1 to n3; </claim-text><claim-text> AA<sup>n4</sup> is an amino acid residue, with n4 being the index of said amino acid residue, and (AA<sup>n4</sup>)<sub>n3</sub> is a linear peptide with n3 amino acid residues AA<sup>n4</sup> and with n4 denoting the position of the amino acid residue AA<sup>n4</sup> in the peptide starting from CG2, in which peptide the individual amino acid residues are connected to each other via a peptide bond, with AA<sup>1</sup> being the first amino acid residue in the chain and being connected to CG2 via the bond (******), with the bond (******) being an amid bond of the carboxylic acid group of <!-- EPO <DP n="136"/>--> AA<sup>1</sup> with the amino group denoted with (4) of CG2, and with AA<sup>n3</sup> being the last amino acid residue in the chain, and with the individual AA<sup>n4</sup> being independently from each other identical or different; </claim-text><claim-text> denotes the N-terminal amino group of said linear peptide, which is the amino group of </claim-text><claim-text>Rl and R2 are identical or different and independently from each other selected from the group consisting of hydrogen, C<sub>1-4</sub> alkyl, C(0)-(CH<sub>2</sub>-0-)<sub>m</sub>5-(GRPEG)<sub>m</sub>4-R3 and PGN; R3 is Ci-4 alkyl; </claim-text><claim-text>m4 is 0 or 1; </claim-text><claim-text>m5 is 0 or 1; </claim-text><claim-text>PGN is a protecting group; </claim-text><claim-text> GRPEG is a connecting group of formula (GRPEG-I); </claim-text><claim-text>CH- -CH -o - (GRPEG-I) </claim-text><claim-text> m21 m21 is 1, 2, 3, 4, 5 or 6 </claim-text></claim><claim id="clm-0003" num="3"><claim-text>3. A method (MI) according to claim 2; </claim-text><claim-text>wherein compound of formula (I) is prepared in a step (MI); </claim-text><claim-text>step (MI) comprises a reaction (MI), wherein a compound of formula (II) is reacted with a compound of formula (LIRes-Tl-H); </claim-text><claim-text>DRRes </claim-text><claim-text> <img id="imgf000136_0001" he="38" wi="117" file="imgf000136_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> Rl ^ (3) ^ R2 <!-- EPO <DP n="137"/>--> is a connecting group selected from the group consisting of connecting group of formula (CG1M-I), connecting group of formula (CG1M-II), connecting group of formula (CG1M-III) and connecting group of formula (CG1M-IV); </claim-text><claim-text> <img id="imgf000137_0001" he="75" wi="119" file="imgf000137_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> (CG1M-III) (CG1M-IV) </claim-text><claim-text>XI is CI, Br or I; </claim-text><claim-text> SG, nl, n4, n3, AA<sup>n4</sup>, (3), Rl, R2, T4, CG3, n2, T2, DRRes, m30 and m32 are as defined claim 2; </claim-text><claim-text> CG2 is as defined in claim 1. </claim-text></claim><claim id="clm-0004" num="4"><claim-text>4. A method (Mil) for the preparation of compound of formula (II), with the compound of formula (II) as defined in claim 3, </claim-text><claim-text>wherein </claim-text><claim-text>in case that n2 is 1 and CG3 is a connecting group of formula (CG3-I), then method (Mil) </claim-text><claim-text> comprises a step (Mlla) and a step (Mllb); </claim-text><claim-text>in case that n2 is 1 and CG3 is a connecting group of formula (CG3-II), then method (Mil) comprises the step (Mlla), a step (MIIc), a step (Mild) and a step (Mile); in case that n2 is 0 and CG1M is a connecting group of formula (CG1M-IV) then method (Mil) comprises one step, a step (MIIO-IV), or two steps, a step (MII0-I-IVa) and a step (MIIO- I-IVb); <!-- EPO <DP n="138"/>--> in case that n2 is 0 and CG1M is a connecting group of formula (CG1M-III) then method (Mil) comprises a step (MIIO-III); </claim-text><claim-text>in case that n2 is 0 and CG1M is a connecting group of formula (CG1M-II) then method (Mil) comprises two steps, a step (MII0-IIa) and a step (MllO-IIb), or one step, a </claim-text><claim-text> step (MIIO-IIc); </claim-text><claim-text>in case that n2 is 0 and CG1M is a connecting group of formula (CG1M-I) then method (Mil) comprises one step, a step (MIIO-I), or two steps, a step (MllO-I-IVa) and a step (MIIO-I- IVb); step (Mlla) comprises a reaction (Mlla), wherein a compound of formula (III) is reacted with a compound of formula (II-I); </claim-text><claim-text> <img id="imgf000138_0001" he="38" wi="118" file="imgf000138_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> Rl ^ ) ^ <sub>R2</sub> formula (III) is as defined in claim 2; compound of formula (II-I) is selected from the group consisting of compound of formula (II-l), Ι, Γ-carbonyldiimidazole, 4-nitrophenylchloroformate, phosgene, diphosgene, triphosgene and mixtures thereof; </claim-text><claim-text><img id="imgf000138_0002" he="26" wi="102" file="imgf000138_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> step (Mllb) comprises a reaction (Mllb), wherein the reaction product from the reaction (Mlla) is reacted with a compound of formula (DRRes-T2-H); <!-- EPO <DP n="139"/>--> step (MIIc) comprises a reaction (MIIc), wherein the reaction product from the reaction (Mlla) is reacted with a compound of formula (CG3M-II) to provide a compound of formula (He); </claim-text><claim-text><img id="imgf000139_0001" he="19" wi="75" file="imgf000139_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/><img id="imgf000139_0002" he="52" wi="114" file="imgf000139_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> n2 in formula (lie) is as defined in claim 2; step (Mild) comprises a reaction (Mild), wherein compound of formula (He), prepared in </claim-text><claim-text> reaction (MIIc), is reacted with the compound of formula (II-I); step (Mile) comprises a reaction (Mile), wherein the reaction product from the reaction (Mild) is reacted with a compound of formula (DRRes-T2-H); step (MII0-I-IVa) comprises a reaction (MllO-I-IVa), wherein a compound of formula (III) is reacted with a compound (II0-I-IVa) to provide a compound of formula (III0-I-IVa); <!-- EPO <DP n="140"/>--> <img id="imgf000140_0001" he="20" wi="84" file="imgf000140_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> (AA<sup>n4</sup>) </claim-text><claim-text> n3 (III0-I-IVa) </claim-text><claim-text>Rl ^ (3) ^ R2 n2 is 0 in formula (III0-I-IVa); compound (II0-I-IVa) is selected from the group consisting of p-toluenesulfonyl chloride, p- toluenesulfonic anhydride, methanesulfonyl chloride, methanesulfonic anhydride, trifluoromethanesulfonyl chloride and trifluoromethanesulfonic anhydride and mixtures thereof; selected from the group consisting of -OTs, -OMs and -OTf; step (MII0-I-IVb) comprises a reaction (MII0-I-IVb), wherein compound of formula </claim-text><claim-text> (III0-I-IVa), prepared in reaction (MII0-I-IVa), is reacted with compound of formula (DRRes-T2-H); compound of formula (III) is prepared </claim-text><claim-text>in a step (MIII-IV) for the case that CG1M is a connecting group of formula (CG1M-IV); or in a step (MIII-III) for the case that CG1M is a connecting group of formula (CG1M-III); or in two steps, a step (MIII-IIa) and a step (MIII-IIb), or in one step, a step (MIII-IIc), for the case that CG1M is a connecting group of formula (CG1M-II); or </claim-text><claim-text>a step (MIII-I) for the case that CG1M is a connecting group of formula (CG1M-I); step (MIII-IV) comprises a reaction (MIII-IV) of a compound of formula (IV), <!-- EPO <DP n="141"/>--> <img id="imgf000141_0001" he="38" wi="110" file="imgf000141_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> Rl ^ (3) ^ R2 formula (IV) is as defined in claim 2; with a compound of formula (CGIMR-IV); </claim-text><claim-text> <img id="imgf000141_0002" he="29" wi="56" file="imgf000141_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text>(CGIMR-IV) </claim-text><claim-text>R20 is a residue of formula (R20-1); </claim-text><claim-text> <img id="imgf000141_0003" he="28" wi="21" file="imgf000141_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> (R20-1) step (MIII-III) comprises a reaction (MIII-III) of a compound of formula (IV) with a compound of formula (CG1MR-III); <!-- EPO <DP n="142"/>--> CI </claim-text><claim-text> XI </claim-text><claim-text> o </claim-text><claim-text> (CG1MR-III) step (MIII-IIa) comprises a reaction (MIII-IIa) of the compound of formula (IV) with a compound of formula (CGlMR-IIa) to provide a compound of formula (IV-IIa); </claim-text><claim-text>(CGlMR-IIa) </claim-text><claim-text><img id="imgf000142_0001" he="57" wi="31" file="imgf000142_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/><img id="imgf000142_0002" he="53" wi="113" file="imgf000142_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> step (MIII-IIb) comprises a reaction (MIII-IIb) of compound of formula (IV-IIa) prepared </claim-text><claim-text> (MIII-IIa) with a compound of formula (HOSu); </claim-text><claim-text> <img id="imgf000142_0003" he="28" wi="24" file="imgf000142_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> (HOSu) <!-- EPO <DP n="143"/>--> step (MIII-IIc) comprises a reaction (MIII-IIc) of the compound of formula (IV) with a compound of formula (CGlMR-IIc); </claim-text><claim-text>(CGlMR-IIc)</claim-text><claim-text><img id="imgf000143_0001" he="26" wi="77" file="imgf000143_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> step (MIII-I) comprises a reaction (MIII-I) of a compound of formula (IV) with a compound of formula (MA); </claim-text><claim-text> <img id="imgf000143_0002" he="29" wi="14" file="imgf000143_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text>(MA) compound of formula (IV) is prepared in a step (MIV); </claim-text><claim-text>step (MIV) comprises a reaction (MIV), reaction (MIV) is a reduction of a compound of formula (V) with a compound (IV); <!-- EPO <DP n="144"/>--> </claim-text><claim-text><img id="imgf000144_0001" he="77" wi="65" file="imgf000144_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> compound (IV) is selected from the group consisting of NaBH<sub>4</sub>, BH<sub>3</sub>, DIBAL-H, sodium bis(2- methoxyethoxy)aluminium hydride and mixtures thereof; compound of formula (V) is prepared in a step (MVb); </claim-text><claim-text>step (MVb) comprises a reaction (MVb), wherein R30 is cleaved off from compound of formula (Va) with HC1; </claim-text><claim-text> <img id="imgf000144_0002" he="84" wi="97" file="imgf000144_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text>R30 is connected to SG via the bond denoted with (**) in the formulae of SG and <!-- EPO <DP n="145"/>--> step (MIIO-IV) comprises a reaction (MIIO-IV) of a compound of formula (IIIO) with a compound of formula (CG1MR-IV); </claim-text><claim-text>H- SG -CG2— hT4 -CG3 -T2 DRRes </claim-text><claim-text> nl n2 n2 </claim-text><claim-text>(AA<sup>n4</sup>) </claim-text><claim-text> n3 </claim-text><claim-text> (IIIO) </claim-text><claim-text>Rl (3) R2 n2 is 0 in formula (IIIO); step (MIIO-III) comprises a reaction (MIIO-III) of a compound of formula (IIIO) with a </claim-text><claim-text> compound of formula (CGIMR-III); step (MII0-IIa) comprises a reaction (MII0-IIa) of the compound of formula (IIIO) with a compound of formula (CGlMR-IIa) to provide a compound of formula (III0-IIa); </claim-text><claim-text> <img id="imgf000145_0001" he="42" wi="143" file="imgf000145_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> Rl (3) R2 n2 is 0 in formula (III0-IIa); step (MII0-IIb) comprises a reaction (MII0-IIb) of compound of formula (III0-IIa) prepared in step (MII0-IIa) with a compound of formula (HOSu); <!-- EPO <DP n="146"/>--> step (MIIO-IIc) comprises a reaction (MIIO-IIc) of the compound of formula (IIIO) with a compound of formula (CGlMR-IIc); step (MIIO-I) comprises a reaction (MIIO-I) of a compound of formula (IIIO) with a compound of formula (MA); compound of formula (IIIO) is prepared in a step (MIIIO), </claim-text><claim-text>step (MIIIO) comprises a reaction (MIIIO), wherein R30 is cleaved off from compound of </claim-text><claim-text> formula (IVO) with HC1; </claim-text><claim-text>R30— t-SGH CG2 -CG3 -T2 DRRes </claim-text><claim-text> nl i n2 n2 </claim-text><claim-text>(AA<sup>n4</sup>) </claim-text><claim-text> n3 </claim-text><claim-text> (IVO) </claim-text><claim-text>R1 ) ^ R2 n2 is 0 in formula (IVO); compound of formula (IVO) is prepared in a step (MlVOa) and a step (MlVOb), </claim-text><claim-text>step (MlVOa) comprises a reaction (MlVOa), wherein a compound of formula (VO) </claim-text><claim-text> with a compound (RIVOa) to provide a compound of formula (IVOa); </claim-text><claim-text> <img id="imgf000146_0001" he="19" wi="55" file="imgf000146_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> (AA<sup>n4</sup>) (VO) </claim-text><claim-text> n3 </claim-text><claim-text>R1 <sup>X</sup> (3) ^ R2 <!-- EPO <DP n="147"/>--> <img id="imgf000147_0001" he="19" wi="56" file="imgf000147_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> (AA<sup>n4</sup>) (IVOa) </claim-text><claim-text> n3 </claim-text><claim-text>R 1 ) ^ R2 compound (RIVOa) is selected from the group consisting of p-toluenesulfonyl chloride, p- toluenesulfonic anhydride, methanesulfonyl chloride, methanesulfonic anhydride, trifluoromethanesulfonyl chloride and trifluoromethanesulfonic anhydride, SOCl<sub>2</sub>,</claim-text><claim-text>(COCl)<sub>2</sub>, POCl<sub>3</sub>, PCI3, PCI5, POBr<sub>3</sub>, PBr<sub>3</sub>, PBr<sub>5</sub>, N-bromosuccinimide, </claim-text><claim-text> N-iodosuccinimide, HC1, HBr, HI and mixtures thereof; </claim-text><claim-text>X3 is selected from the group consisting of -OTs, -OMs, -OTf, -CI, -Br and -I; step (MlVOb) comprises a reaction (MlVOb), wherein compound of formula (IVOa), prepared reaction (MIVO), is reacted with compound of formula (DRRes-T2-H); compound of formula (V0) is prepared in a step (MVO), </claim-text><claim-text>step (MVO) comprises a reaction (MVO), reaction (MVO) is a reduction of a compound of </claim-text><claim-text> formula (Va) with a compound (IV); </claim-text><claim-text>CG1M and XI are as defined in claim 3; </claim-text><claim-text> SG, nl, n4, n3, AA<sup>n4</sup>, (3), Rl, R2, T4, CG3, n2, T2, DRRes, compound of formula (DRRes-T2- H), m30, m32, R5 and R6 are as defined in claim 2; </claim-text><claim-text>CG2 is as defined in claim 1. </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. Method (Mil) according to claim 4, wherein </claim-text><claim-text>compound of formula (Va) is prepared in a step (MVa); </claim-text><claim-text>step (MVa) comprises a reaction (MVa), wherein a compound of formula (VI) is reacted with a compound of formula (SGM); <!-- EPO <DP n="148"/>--> </claim-text><claim-text> <img id="imgf000148_0001" he="78" wi="39" file="imgf000148_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text>R30 SG R31 (SGM) R31 is connected to SG via the bond denoted with (***) in the formulae of SG and is -OTs, - OMs, -OTf, -Br, -CI or -I; </claim-text><claim-text>R30 is as defined in claim 4; </claim-text><claim-text> SG, n4, n3, AA<sup>n4</sup>, (3), Rl, R2 are as defined in claim 2. </claim-text></claim><claim id="clm-0006" num="6"><claim-text>6. Method (Mil) according to claim 5, wherein </claim-text><claim-text>compound of formula (VI) is prepared in a step (MVIa) and optionally in a further step (MVIb); in step (MVIa) the n3 AA<sup>n4</sup> are consecutively connected to a compound of formula (VII- 1) by peptide coupling reactions and then to the respective products of the preceding peptide coupling reactions; <!-- EPO <DP n="149"/>--> <img id="imgf000149_0001" he="49" wi="78" file="imgf000149_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> step (MVIb) comprises a reaction (MVIb), wherein the N-terminal amino group of AA<sup>n</sup> denoted with (3) in formula (VI) is reacted with a compound NTermProt; </claim-text><claim-text>NTermProt is selected from the group consisting of C<sub>1 -4</sub> alkyl iodide, C<sub>1-4</sub> alkyl bromide, </claim-text><claim-text> Cl-C(0)-(GRPEG)<sub>m4</sub>-R3, R3-C(0)-0-C(0)-R3 and PGNPrec; </claim-text><claim-text>PGNPrec is a reagent which provides for the introduction of PGN on the N-terminal amino group of AA<sup>n3</sup> denoted with (3) in formula (VI); </claim-text><claim-text>GRPEG, m4, R3 and PGN are as defined in claim 2; </claim-text><claim-text>n4, n3, AA<sup>n4</sup> and (3) are as defined in claim 2. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7. A compound of formula (I), with compound of formula (I) as defined in claim 2. </claim-text></claim><claim id="clm-0008" num="8"><claim-text>8. Compound of formula (I) according to claim 7, wherein compound of formula (I) is selected from the group consisting of compound of formula (10), compound of formula (1 1), compound of formula (12), compound of formula (12-101), compound of formula (13), compound of formula (14), compound of formula (15), compound of formula (15-102) and compound of formula (16); <!-- EPO <DP n="150"/>--> 149 <img id="imgf000150_0001" he="77" wi="154" file="imgf000150_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text><img id="imgf000150_0002" he="104" wi="127" file="imgf000150_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="151"/>--> 150 <img id="imgf000151_0001" he="103" wi="163" file="imgf000151_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text><img id="imgf000151_0002" he="90" wi="116" file="imgf000151_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="152"/>--> 151 <img id="imgf000152_0001" he="104" wi="116" file="imgf000152_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text><img id="imgf000152_0002" he="85" wi="171" file="imgf000152_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="153"/>--> 152 <img id="imgf000153_0001" he="27" wi="30" file="imgf000153_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text> <img id="imgf000153_0002" he="17" wi="17" file="imgf000153_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <img id="imgf000153_0003" he="98" wi="153" file="imgf000153_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <!-- EPO <DP n="154"/>--> </claim-text><claim-text> <img id="imgf000154_0001" he="103" wi="163" file="imgf000154_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text> <img id="imgf000154_0002" he="75" wi="80" file="imgf000154_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text>wherein </claim-text><claim-text> (dl), (d2), (d3) and (d4) in formula (DOXO) denote functional groups; <!-- EPO <DP n="155"/>--> compound of formula (DOXO) is connected via the amino group denoted with (dl) in formula (10), (11), (12), (12-101), (13), (14), (15), (15-102) and (16) respectively and in formula </claim-text><claim-text>(DOXO). </claim-text></claim><claim id="clm-0009" num="9"><claim-text>9. A compound of formula (II), with compound of formula (II) as defined in claim 3. </claim-text></claim><claim id="clm-0010" num="10"><claim-text>10. Compound of formula (II) according to claim 9, wherein compound of formula (II) is selected from the group consisting of compound of formula (20), compound of formula (21), compound of formula (22), compound of formula (23), compound of formula (24), compound of formula (25), compound of formula (26), compound of formula (20-CAMPTO), compound of formula (21-CAMPTO), compound of formula (22-CAMPTO), compound of formula (23- CAMPTO) and compound of formula (21-TAXO-tl-l); </claim-text><claim-text>doxorubicin <!-- EPO <DP n="156"/>--> </claim-text><claim-text>155 <img id="imgf000156_0001" he="99" wi="147" file="imgf000156_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text><img id="imgf000156_0002" he="78" wi="138" file="imgf000156_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="157"/>--> 156 <img id="imgf000157_0001" he="79" wi="106" file="imgf000157_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text> <img id="imgf000157_0002" he="77" wi="143" file="imgf000157_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <!-- EPO <DP n="158"/>--> </claim-text><claim-text>157 <img id="imgf000158_0001" he="83" wi="137" file="imgf000158_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text> <img id="imgf000158_0002" he="78" wi="140" file="imgf000158_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <!-- EPO <DP n="159"/>--> </claim-text><claim-text> <img id="imgf000159_0001" he="70" wi="118" file="imgf000159_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> <img id="imgf000159_0002" he="78" wi="140" file="imgf000159_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text>5 <img id="imgf000159_0003" he="78" wi="128" file="imgf000159_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> <!-- EPO <DP n="160"/>--> </claim-text><claim-text> <img id="imgf000160_0001" he="78" wi="146" file="imgf000160_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text> <img id="imgf000160_0002" he="99" wi="157" file="imgf000160_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text>wherein </claim-text><claim-text>doxorubicin is the compound of formula (DOXO) as defined in claim 8, </claim-text><claim-text>which is connected via the amino group denoted with (dl) in formula (20), (21), (22), (23), (24), (25) and (26) respectively and in formula (DOXO); <!-- EPO <DP n="161"/>--> camptothecin is the compound of formula (CAMPTO), </claim-text><claim-text>(CAMPTO) <img id="imgf000161_0001" he="59" wi="50" file="imgf000161_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> wherein </claim-text><claim-text> (cl) in formula (CAMPTO) denotes a functional group; </claim-text><claim-text>compound of formula (CAMPTO) is connected via the hydroxy group denoted with (cl) formula (20-CAMPTO), (21 -CAMPTO), (22-CAMPTO) and (23 -CAMPTO) respectively and in formula (CAMPTO); taxo-tl-1 is the compound of formula (TAXO), </claim-text><claim-text><img id="imgf000161_0002" he="78" wi="123" file="imgf000161_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="162"/>--> which is connected via the hydroxy group denoted with (tl) in formula (21-TAXO-tl-l) and in formula (TAXO). </claim-text></claim><claim id="clm-0011" num="11"><claim-text>11. A compound selected from the group consisting of </claim-text><claim-text>compound of formula (lie), compound of formula (III), compound of formula (IV), compound of formula (IV-IIa), compound of formula (V), compound of formula (Va), compound of formula (III0-IIa), compound of formula (IIIO), compound of formula (IVO), compound of formula (IVOa), compound of formula (V0) and compound of formula (III0-I-IVa); </claim-text><claim-text>with </claim-text><claim-text>compound of formula (lie), compound of formula (III), compound of formula (IV), compound of formula (IV-IIa), compound of formula (V), compound of formula (Va), compound of formula (III0-IIa), compound of formula (IIIO), compound of formula (IVO), compound of formula (IVOa), compound of formula (V0) and compound of formula (III0-I-IVa) as defined in claim 4. </claim-text></claim><claim id="clm-0012" num="12"><claim-text>12. Compound according to claim 11, </claim-text><claim-text>wherein </claim-text><claim-text>compoun f formula (lie) is compound of formula (20c); </claim-text><claim-text><img id="imgf000162_0001" he="77" wi="134" file="imgf000162_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> compound of formula (III) is selected from the group consisting of compound of formula (30), compound of formula (31), compound of frmula (32), compound of formula (33), compound of formula (34), compound of formula (35) and compound of formula (36); <!-- EPO <DP n="163"/>--> 162 <img id="imgf000163_0001" he="76" wi="104" file="imgf000163_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text><img id="imgf000163_0002" he="99" wi="113" file="imgf000163_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="164"/>--> 163 <img id="imgf000164_0001" he="78" wi="102" file="imgf000164_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text> <img id="imgf000164_0002" he="78" wi="92" file="imgf000164_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <!-- EPO <DP n="165"/>--> </claim-text><claim-text>164 <img id="imgf000165_0001" he="77" wi="110" file="imgf000165_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text> <img id="imgf000165_0002" he="78" wi="104" file="imgf000165_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <!-- EPO <DP n="166"/>--> </claim-text><claim-text><img id="imgf000166_0001" he="78" wi="104" file="imgf000166_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> compound of formula (IIIO) is compound of formula (300); </claim-text><claim-text>camptothecin </claim-text><claim-text><img id="imgf000166_0002" he="69" wi="93" file="imgf000166_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> wherein </claim-text><claim-text>camptothecin is the compound of formula (CAMPTO) as defined in claim 10, </claim-text><claim-text>which is connected via the hydroxy group denoted with (cl) in formula (300) respectively and in formula (CAMPTO); compound of formula (III0-I-IVa) is compound of formula (320); <!-- EPO <DP n="167"/>--> </claim-text><claim-text><img id="imgf000167_0001" he="78" wi="106" file="imgf000167_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> compound of formula (IV) is selected from the group consisting of compound of formula (40), compound of formula (41), compound of formula (42), compound of formula (43), compound of formula (44), compound of formula (45) and compound of formula (46); </claim-text><claim-text> <img id="imgf000167_0002" he="66" wi="92" file="imgf000167_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <!-- EPO <DP n="168"/>--> </claim-text><claim-text>167 <img id="imgf000168_0001" he="73" wi="112" file="imgf000168_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <img id="imgf000168_0002" he="69" wi="92" file="imgf000168_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text> <img id="imgf000168_0003" he="67" wi="92" file="imgf000168_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <!-- EPO <DP n="169"/>--> </claim-text><claim-text> <img id="imgf000169_0001" he="66" wi="110" file="imgf000169_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <img id="imgf000169_0002" he="74" wi="92" file="imgf000169_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text> <img id="imgf000169_0003" he="70" wi="105" file="imgf000169_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text>compound of formula (IVO) is compound of formula (400); <!-- EPO <DP n="170"/>--> </claim-text><claim-text><img id="imgf000170_0001" he="69" wi="94" file="imgf000170_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> wherein </claim-text><claim-text>camptothecin is the compound of formula (CAMPTO) as defined in claim 10, </claim-text><claim-text>which is connected via the hydroxy group denoted with (cl) in formula (400) respectively and in formula (CAMPTO); compound of formula (IVOa) is compound of formula (400a); </claim-text><claim-text><img id="imgf000170_0002" he="69" wi="95" file="imgf000170_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> compound of formula (V) is selected from the group consisting of compound of formula (50), compound of formula (50-1), compound of formula (51), compound of formula (51-1), compound of formula (52), compound of formula (52-1), compound of formula (53), compound of formula (53-1), compound of formula (54), compound of formula (54-1), compound of <!-- EPO <DP n="171"/>--> formula (54-2), compound of formula (54-3), compound of formula (55), compound of formula (55-1), compound of formula (56) and compound of formula (56-1);</claim-text><claim-text> <img id="imgf000171_0001" he="66" wi="99" file="imgf000171_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <img id="imgf000171_0002" he="66" wi="99" file="imgf000171_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <!-- EPO <DP n="172"/>--> </claim-text><claim-text>171 <img id="imgf000172_0001" he="73" wi="118" file="imgf000172_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <img id="imgf000172_0002" he="73" wi="119" file="imgf000172_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text><img id="imgf000172_0003" he="69" wi="99" file="imgf000172_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="173"/>--> 172 <img id="imgf000173_0001" he="69" wi="99" file="imgf000173_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text><img id="imgf000173_0002" he="67" wi="99" file="imgf000173_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><img id="imgf000173_0003" he="70" wi="99" file="imgf000173_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="174"/>--> 173 <img id="imgf000174_0001" he="66" wi="118" file="imgf000174_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text> <img id="imgf000174_0002" he="67" wi="118" file="imgf000174_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text><img id="imgf000174_0003" he="67" wi="93" file="imgf000174_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="175"/>--> 174 <img id="imgf000175_0001" he="67" wi="118" file="imgf000175_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text> <img id="imgf000175_0002" he="74" wi="99" file="imgf000175_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text><img id="imgf000175_0003" he="74" wi="99" file="imgf000175_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="176"/>--> 175 <img id="imgf000176_0001" he="69" wi="111" file="imgf000176_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text> <img id="imgf000176_0002" he="69" wi="111" file="imgf000176_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <img id="imgf000176_0003" he="70" wi="92" file="imgf000176_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <!-- EPO <DP n="177"/>--> </claim-text></claim><claim id="clm-0013" num="13"><claim-text>13. A compound of formula (VI), with compound of formula (VI) as defined in claim 5. </claim-text></claim><claim id="clm-0014" num="14"><claim-text>14. Compound of formula (VI) according to claim 13, wherein </claim-text><claim-text>compound of formula (VI) is selected from the group consisting of compound of formula (6), compound of formula (6-1), compound of formula (6-2), compound of formula (6-3), compound of formula (6-4), compound of formula (6b), compound of formula (6b- 1), compound of formula (6b-2), compound of formula (6b-3), compound of formula (6b-4), compound of formula (6c) and compound of formula (6-5). </claim-text><claim-text> <img id="imgf000177_0001" he="59" wi="92" file="imgf000177_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> <img id="imgf000177_0002" he="59" wi="87" file="imgf000177_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <!-- EPO <DP n="178"/>--> </claim-text><claim-text> <img id="imgf000178_0001" he="59" wi="87" file="imgf000178_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <img id="imgf000178_0002" he="58" wi="64" file="imgf000178_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text>BocHN </claim-text><claim-text> (6-4) <img id="imgf000178_0003" he="59" wi="46" file="imgf000178_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> <!-- EPO <DP n="179"/>--> 178 <img id="imgf000179_0001" he="65" wi="94" file="imgf000179_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text><img id="imgf000179_0002" he="60" wi="82" file="imgf000179_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><img id="imgf000179_0003" he="66" wi="87" file="imgf000179_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/><!-- EPO <DP n="180"/>--> 179 <img id="imgf000180_0001" he="66" wi="63" file="imgf000180_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> </claim-text><claim-text> <img id="imgf000180_0002" he="60" wi="69" file="imgf000180_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <img id="imgf000180_0003" he="59" wi="104" file="imgf000180_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/> <!-- EPO <DP n="181"/>--> <img id="imgf000181_0001" he="58" wi="110" file="imgf000181_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text>Use of the compound of formula (I), the compound of formula (I) as defined in claim 2, for the preparation of a pharmaceutical composition or of a drug. </claim-text><claim-text>A pharmaceutical composition or a drug, wherein the pharmaceutical composition and the drug comprise the compound of formula (I), the compound of formula (I) as defined in claim 2. </claim-text><claim-text>Compound of formula (I), a pharmaceutical composition or a drug, wherein the compound of formula (I) is as defined in claim 2, and the pharmaceutical composition and the drug are as defined in claim 16, </claim-text><claim-text>for use in treatment of a disease or an illness. </claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
